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Abstract 
The early detection of prostate cancer (CaP), the most common internal cancer in men, is 
limited by an absence of biomarkers that accurately reflect clinically significant disease. 
Currently, the prostate cancer antigen 3 (PCA3) test in combination with TMPRSS2-ERG 
fusion gene detection in urine obtained following rectal prostatic massage represent 
arguably the best standalone biomarkers for CaP but are not widely used in comparison 
with serum prostate specific antigen (PSA). Limitations in CaP diagnosis and 
characterisation may be overcome by use of naturally-produced, prostate-specific 
biofluids, such as ejaculate and post-ejaculate urethral washings (PEUW). Ejaculate is 
known to contain prostatic cells and relevant molecules in the non-cellular component, 
while PEUW may contain these as well as biomarkers reflective of systemic changes due 
to or causing CaP.  
The overall aim of this thesis was to use molecular and metabolomic nuclear magnetic 
resonance (NMR)-based detection methods to study prostatic fluid derived from ejaculate 
and PEUW to improve CaP diagnosis. Specifically, this thesis sought to optimise ejaculate 
sample processing for metabolomics studies and evaluate the diagnostic performance of 
mRNA, microRNA and metabolomic markers in ejaculate to complement serum PSA in 
detecting clinically significant CaP. Furthermore, this thesis investigated the feasibility and 
performance of PEUW-based mRNA and metabolomic biomarker performance attributable 
to the presence of ejaculate in urine to reflect local prostatic and systemic alterations in 
order to more accurately detect clinically significant CaP. Dependent clinical variables 
considered were absolute (positive/negative) and clinically significant (present/absent) 
CaP as well as risk groups (low, intermediate, high) according to the D’Amico criteria.  
Using a NMR-based metabolomics enzyme kinetics study design, the addition of tartrate 
and cooling of ejaculate samples improved the stability of choline and phosphorylcholine 
concentrations. Sample collection into a sterile urine jar containing 5 mM (on-site) or 10 
mM (off-site) tartrate in 20 ml PBS solution cooled to 277 K and cooled during transport 
until processing would result in at most a 2-3% change in choline and phosphorylcholine to 
facilitate sample collection off-site without significant effect on choline-based metabolites.  
Following prostatic cell RNA isolation, amplification and qPCR for β2-microglobulin (β2M), 
PSA, PCA3 and Hepsin in ejaculate, adequate RNA for all assays was obtained for 66 
patients and determined that a Hepsin:PCA3 ratio in ejaculate together with serum PSA 
best predicted absolute CaP (AUC= 0.724 vs 0.676) and csCaP (AUC= 0.701 vs 0.680). 
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Matched mRNA and microRNA expression was possible for a subgroup of patients (n=20), 
with miR-200c (AUC=0.788) and miR-375 (AUC=0.758) performing best on ROC curve 
analysis. Serum PSA combined with miR-200c and miR-125b improved prediction of 
absolute CaP (AUC=0.869 vs 0.672; p<0.05), improving specificity (67%) at 90% 
sensitivity compared with PSA alone (11%).  
Metabolomic analysis of ejaculate supernatants was complicated by the presence of a 
variable glucose concentration attributable to the initial buffer used and unbalanced 
metabolite (choline/phosphocholine) regulation. Following appropriate adjustment, 
multivariate analysis showed that metabolites best predicted low and intermediate risk 
CaP with grouping observed between these groups and benign and high risk samples. 
Lipids/lipoproteins dominated spectra of high grade samples. Overall CaP prediction using 
metabolites described in previous studies was not validated. However, findings suggest 
that incorporation of in vitro NMR-based metabolomics may translate to in vivo metabolite 
quantification using magnetic resonance spectroscopic imaging (MRSI) to better triage 
patients for biopsy or monitor active surveillance cohorts.  
For 38 PEUW samples, with corresponding ejaculate markers, prostatic cell RNA isolation, 
amplification and qPCR for β2M, PSA, PCA3 and Hepsin was possible. PCA3:PSA in 
ejaculate (AUC=0.668) and PEU (AUC=0.569) were comparable with serum PSA 
(AUC=0.617) in predicting absolute CaP status. PEUW markers were not predictive of 
CaP or csCaP, which may be due to predominance of normal prostatic cells over 
malignant cells and subsequently help identify patients without csCaP.  
PEUW NMR-based metabolomics analysis was feasible and demonstrated prostate-
specific biomarkers attributable to the presence of ejaculate, both in young volunteers and 
at-risk patients. As observed for ejaculate, initial metabolomic analysis of PEUW 
demonstrated best discrimination between low and intermediate risk CaP and benign 
samples. However, analysis was complicated by the presence of borate-citrate adducts, 
which has been adjusted in updated sample preparation and data acquisition.  
The presented methods may also monitor tumours in active surveillance as well as effects 
on tumorigenesis by metabolically restricting drugs, such as metformin and atorvastatin, of 
which this thesis contains a published study protocol for a phase II “window” randomised 
controlled clinical trial that commenced in March 2015 which has been designed on the 
findings of this thesis. 
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This thesis has demonstrated that ejaculate and PEUW are legitimate and valuable 
sources of CaP-specific biomarkers that require validation in larger cohorts. Prostatic fluid 
metabolomics serves to improve diagnosis and risk stratification and further investigation 
is warranted to corroborate these findings in vivo with MRSI in moving towards 
personalised medicine and improved clinical care for these patients. 
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Chapter 1 - Introduction 
Overview 
Prostate cancer (CaP) is the most common internal cancer in men and the sixth leading 
cause of cancer-related death worldwide1-3. Most CaP arises from the acinar epithelium in 
the peripheral zone (PZ) of the prostate, accounting for 70% of all CaP diagnoses. The 
incidence of CaP increases with age and has risen worldwide, with highest incidence 
observed in highest resource countries1. Early diagnosis and treatment of localised CaP, 
with radical prostatectomy (RP) or radiotherapy prior to spread outside the prostate, 
improves overall and cancer-specific survival compared with observation4. Metastatic CaP 
is predominantly treated with androgen deprivation therapy (ADT) in conjunction with or 
followed by chemotherapy to improve overall survival, but is incurable. CaP-specific 
mortality rates are highest in less developed regions and have improved among developed 
countries1, presumably due to earlier detection and treatment. Thus, biomarkers to 
accurately diagnose localised CaP are required to enable early treatment and improved 
outcomes for men.   
Biomarkers are essential in aiding medical diagnosis and treatment and are predominantly 
found in bodily fluids including blood and urine. Serum prostatic specific antigen (PSA) is 
the main biomarker used to improve diagnosis of localised CaP. However, serum PSA is 
an imperfect test due to unacceptable sensitivity and specificity in detecting aggressive, 
clinically significant CaP (csCaP). Furthermore, judicious use of serum PSA has resulted 
in over diagnosis of indolent, non-aggressive CaP leading to unnecessary morbidity 
inherent to the diagnostic and treatment process5. These limitations have reduced CaP 
detection overall, including csCaP, and driven the discovery of biomarkers in serum, such 
as the Prostate Health Index (phi)TM, and urine, such as prostate cancer antigen 3 (PCA3) 
in combination with TMPRSS2:ERG fusion gene6-9. These tests may improve diagnostic 
accuracy10, but are currently used as adjunctive tests and are potentially not cost-effective 
as standalone detection tests11.  
Prostatic fluid in ejaculate contributes up to 40% of due to physiological prostatic smooth 
muscle contraction and is a promising biofluid for biomarker discovery12. Contributed 
proteins (such as PSA and prostatic acid phosphatase; PAP) as well as metabolites (such 
as citrate, spermine and myo-inositol) and ions (such as zinc, calcium, magnesium) 
physiologically aid spermatozoa in fertilization12 but are also altered due to CaP. Indeed 
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PSA was first discovered in ejaculate, which also harbours PAP, a biomarker used prior to 
PSA13. Following discovery of malignant prostatic cells in the ejaculates of men with 
CaP14, small proof-of-concept studies undertaking analysis of genes (PCA3, Hepsin) and 
microRNAs in the cellular component of ejaculate have demonstrated superior detection to 
PSA alone15,16. Furthermore, the ability to ejaculate among donors has been shown to 
correlate with improved survival compared to age-matched controls with CaP17, 
hypothetically due to adequate erectile function, favourable cardiovascular status and long 
term survival and treatment benefit for the patient18. Thus, ejaculate is theoretically an 
ideal biofluid for sourcing biomarkers for improved detection of localised csCaP. Prostatic 
fluid can also be obtained as expressed prostatic secretions (EPS), by first performing 
prostatic massage at time of digital rectal examination (DRE) then collecting the first-catch 
(5ml) after commencing urination. A novel biofluid described in this thesis is post-ejaculate 
urethral washings (PEUW), which is hypothesised to contain prostatic fluid from remnant 
ejaculate in the urethra and be a potential physiological alternative to EPS.  
Metabolomics is a modern biomarker discovery approach that quantifies small metabolites 
in biological samples19, most commonly using nuclear magnetic resonance (NMR) or mass 
spectrometry (MS)20,21. NMR-based metabolomics analysis of ejaculate samples has been 
shown by multiple investigators to improve diagnosis compared to serum PSA22,23, and 
represents a highly sensitive and reproducible analysis method with affordable sample-to-
sample costs20. Early studies also indicate in vivo monitoring of metabolite profiles in 
tumours using MRSI to aide diagnosis and active surveillance24. 
This thesis investigated molecular and metabolomic detection methods to study prostatic 
fluid derived from ejaculate and PEUW to improve CaP diagnosis. The thesis is broadly 
structured as Introduction, Methods, Results and Discussion. 
Within Part 1 (Introduction), chapter two of this thesis contains a comprehensive literature 
review on CaP biomarkers, with particular focus on metabolomics, including the 
experimental workflow, previous studies and future directions. This literature review is 
presented as a peer-reviewed book chapter and review article, as well as a literature 
update since the included manuscripts were published. 
Part 2 (Methods) contains chapter three of this thesis, which described a NMR-based 
metabolomics study to investigate the inhibition of PAP to improve metabolite stability 
within ejaculate in order to optimise sample collection protocols for future clinical 
metabolomics studies. This study is presented as a published manuscript.  
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Part 3 (Results) of this thesis consists of three chapters. Chapter four investigated the 
utility of ejaculate for non-invasive CaP diagnosis and includes two manuscripts, with one 
accepted and one submitted for publication. The studies used different analytical platforms 
to detect CaP biomarkers, including gene detection by PCR in the ejaculate epithelial cell 
fraction as well as metabolite profiling of ejaculate using NMR spectroscopy.  
Chapter five of this thesis investigated the feasibility and performance of PEUW-based 
biomarkers and includes a published manuscript and preliminary NMR-based 
metabolomics investigation. First, the presence of prostatic RNA biomarkers and their 
diagnostic performance in the epithelial cell fraction of PEUW was investigated. Second, 
PEUW was analysed using NMR spectroscopy with three objectives. Initially, to determine 
if prostatic metabolite biomarkers are present, both in clinical samples and in a dedicated 
cohort comparing with mid-stream urine. Then the kinetic behaviour of these markers was 
characterised to determine if they behave similarly to that observed in ejaculate. Finally, 
metabolite profiles in PEUW collected from a clinical cohort were analysed to detect and 
characterise CaP.  
Chapter six contains a published clinical trial protocol to demonstrate the translational 
potential of prostatic fluid markers to characterise and monitor CaP. Specifically, prostatic 
fluid marker use, as well as magnetic resonance imaging (MRI), is described to detect and 
monitor CaP in the presence of disease modifying agents (metformin, atorvastatin). 
Part 4 (Discussion) includes chapter seven which contains a summary of the thesis 
findings and discussion regarding future directions for research into diagnosis of CaP. 
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Aims 
The overall aim of this thesis was to use molecular and metabolomic detection methods to 
study prostatic fluid to improve CaP diagnosis. The specific aims of this thesis were to: 
1. Critically appraise the available evidence on CaP biomarkers from prostatic fluid in 
vitro with particular focus on NMR-based metabolomics and imaging in vivo, as well 
as provide a basic outline of a clinical NMR-based metabolomics study. 
2. Investigate the performance of tartrate as an inhibitor of PAP, as well as an internal 
concentration standard by examining ejaculate metabolite profile variation, at 
different tartrate concentrations and temperatures and evaluate any negative effects 
on established ejaculate processing methods for molecular (mRNA) analysis. 
3. Examine the predictive ability of ejaculate biomarkers, specifically molecular (PCA3 
and Hepsin mRNA, novel microRNAs) and metabolomic analysis of ejaculate, 
together with serum PSA to predict and characterise CaP in a high-risk clinical 
cohort. 
4. Investigate the presence and diagnostic potential of CaP-specific biomarkers in 
PEUW, including molecular markers in comparison with the same markers in 
ejaculate and metabolite biomarkers. Metabolite biomarkers will be characterised 
against mid-stream urine (MSU) in young men, kinetically over time and in a “high 
risk” clinical cohort to detect and characterise CaP. 
5. Describe a phase II “window” clinical trial utilising NMR-based markers in vitro 
(prostatic fluid) and in vivo (MRSI) to investigate if atorvastatin and metformin by 
themselves and together, favourably alter selected parameters in a group of 
clinically-localized, aggressive tumours. 
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Chapter 2 – Molecular and metabolomic biomarkers for non-
invasive prostate cancer diagnosis and monitoring 
2.1 Synopsis 
The aim of this chapter is to critically appraise the available evidence on CaP biomarkers 
from prostatic fluid with particular focus on NMR-based metabolomics. The evolution of 
NMR-based metabolomics and requirements of a clinical NMR-based metabolomics study 
will be reviewed, while current approaches in elucidating tumour biology in vitro and in vivo 
to improve diagnosis and monitoring in clinical practice will be outlined.  This literature 
review is presented as a peer-reviewed book chapter (section 2.2) and review article 
(section 2.3), as well as a literature update (section 2.4) since the included manuscripts 
were published. 
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2.2 “NMR-based Metabolomics: Global Analysis of Metabolites to 
Address Problems in Prostate Cancer” (published manuscript) 
The published manuscript entitled, “NMR-based Metabolomics: Global Analysis of 
Metabolites to Address Problems in Prostate Cancer” has been published as a peer-
reviewed book chapter in Breast, Cervical and Prostate Cancer (iConcept Press. 
Tokwawan, Kowloon, Hong Kong; http://www.iconceptpress.com/books/breast-cervical-
and-prostate-cancer/).  
Since publication, this chapter is the most viewed in this book (viewed 2333 as at 
10/02/17), which is the most viewed medical book by this publisher (viewed 38895 as at 
10/02/17). This chapter has been downloaded 557 times (as at 10/02/17) from UQ 
eSpace. 
The contributions of the co-authors to this manuscript were as follows: Literature review 
and summary was performed by Matthew Roberts, the PhD candidate, under the 
supervision of Dr Horst Schirra and Prof RA “Frank” Gardiner. Prof Martin Lavin provided 
critical manuscript revisions. Preparation of the manuscript and associated figures was 
performed by Matthew Roberts, the PhD candidate. 
The manuscript text is presented as originally published by the publisher. To maintain a 
consistent style between chapters in this thesis, abbreviations, placement of figures and 
tables within the text, as well as numbering of pages, figures and tables has been 
adjusted. The references have been collated in the section, ‘Bibliography’, with others 
contained in this thesis. 
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2.2.1 Introduction 
Cancer significantly contributes to the worldwide burden of disease and premature death 
across many countries. Consequently, current oncology research focuses on discovering 
and validating new biomarkers to improve early detection. These efforts are of worldwide 
importance in detecting significant cancer while it is still localised and in lessening 
associated morbidities and death.  
Biomarkers have mostly been sourced from non- or minimally invasive biofluids, such as 
blood, urine, and biopsy tissue. Traditionally, biomarkers were limited to circulating end-
products of altered cellular function in cancer. However, technology advances and 
emergence of the –omics sciences have improved analysis of genes, gene expression, 
proteins and metabolites alike – on both an individual and system-wide scale. This field of 
research, termed “systems biology”, has allowed for molecules at all levels of the cellular 
hierarchy to be considered as biomarkers. Continuous improvements in sensitivity, 
resolution and precision of these analytical techniques produces large datasets, allowing 
for simultaneous characterisation of, ideally all, compounds in a single sample. 
Subsequent statistical analysis of these datasets and their interpretation with respect to 
cellular function is the basis of the different -omics technologies, such as genomics, 
transcriptomics, proteomics and metabolomics.  
In this chapter, we will describe principles and processes that are involved in investigating 
biological or clinical problems with NMR-based metabolomics - an approach that involves 
the global analysis of metabolites. In writing for the scope of this book, we have broken 
this chapter into three sections: (1) First we will describe and illustrate the methods 
commonly used in NMR-based metabolomics, including spectral processing, data 
treatment and subsequent statistical analysis. (2) Secondly, we will use CaP as a case 
study to illustrate how NMR-based metabolomics can be applied to a clinical problem. CaP 
is the second most common type of cancer and the sixth leading cause of cancer-related 
death worldwide1-3. The diagnosis of prostate cancer is currently problematic for a number 
of reasons that include lack of sensitive and specific tumour markers as well as limitations 
due to morbidity inherent with the biopsy diagnosis process. Furthermore, many patients 
harbour early prostate cancer with insignificant tumours that may not progress to produce 
clinical problems. (3) Lastly, we will briefly outline the future directions for the role of NMR-
based metabolomics, including personalized medicine and integration with other –omics 
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datasets, in order to create a holistic, systems biology approach to solving clinical 
problems. 
Outlining the processes, applications and potential of metabolomics will be of assistance to 
biostatisticians and bioinformaticians who may be interested in expanding into this area of 
research. Similarly, we aim to inspire scientists and clinicians who are interested in 
applying this approach to a scientific or clinical problem. 
2.2.2 Metabolomics: History and Methods 
2.2.2.1     What is Metabolomics? 
Metabolomics has been highlighted as a technique that is unique and exciting in biomarker 
discovery25-27. It is the quantification of all small molecular weight metabolites to accurately 
define the metabolite composition of a biological sample19. The term “metabolomics” is 
often used interchangeably with “metabonomics”, which is defined as ‘the quantitative 
measurement of the dynamic multiparametric metabolic response of living systems to 
pathophysiological stimuli’28. The technical approach to both metabonomics and 
metabolomics is similar, involving measurement and analysis of metabolite data for a 
given sample. Conceptually, however, the objective and application of these techniques is 
slightly different: Metabolomics seeks to describe the composition of complex biological 
samples, while metabonomics aims to map and understand the change of a biological 
system in response to external or artificial stimuli. In the current chapter, we will use the 
term “metabolomics”, while both metabolomics and metabonomics will be discussed. The 
advent and development of metabolomics/metabonomics has largely been possible due to 
advances in analytical techniques, such as NMR spectroscopy and MS, as well as 
chromatographic separation techniques. As the authors have expertise in NMR 
spectroscopy, the focus of this chapter will be on NMR-based techniques within the field of 
metabolomics. We refer the reader to several excellent reviews that detail the application 
of MS in metabolomics and systems biology29-31. 
2.2.2.2     Historical Perspective 
While “metabolomics” is a recently coined term, the analysis of metabolic end products is a 
long-practiced ancient scientific process. About 2000-1500 BCE, analysis of urine by 
human taste or animal behaviour (due to the high urinary glucose concentration) helped 
diagnose patients with diabetes mellitus32. In 1506, a “urine wheel” by Ulrich Pinder linked 
crude changes detected by human senses (colour, smell, taste) with various medical 
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conditions33,34. Although qualitative measures of metabolism have been performed for 
centuries, the origins of quantitative studies stem from the measurement of insensible 
perspiration and other hydration losses in medieval Italy35. Technological limitations in 
analytical chemistry hindered further advances until the early 20th century. At this time, the 
development of sensitive analytical methods allowed quantification of key 
compounds/metabolites in urine and other sample types36. This quantitative approach 
continued to develop with the introduction of various analytical techniques, such as MS37,38 
and NMR39-41, and with the application of these techniques to metabolic research42,43. The 
integration of medical science and analytical chemistry at this time led to a greater 
understanding of metabolic perturbations in medical conditions, e.g. kidney stones among 
many others44. Further improvements in metabolite profiling in the latter half of the 20th 
century were aided by advances in chemometrics, the foundation behind data analysis in 
analytical chemistry45. Appropriate data processing and interpretation was achieved by 
multivariate statistical methods, which will be outlined in more detail below. 
2.2.2.3     Modern Metabolomics and its Varieties/Applications  
Metabolomics continues to evolve as a field and is increasingly used in a variety of 
applications. Initially, biofluids were analysed specifically to quantify metabolic 
perturbations due to drug toxicity, disease, and other internal and external influences. For 
example, perturbations in steroid metabolism were used for anti-doping testing during the 
Los Angeles Summer Olympics in 198446. In the following section, the diverse applications 
of metabolomics are briefly described; more comprehensive accounts are available in 
other sources47-51. 
2.2.2.3.1     Biofluid and Excretion Analysis  
Metabolomics has been used to quantify endogenous metabolites in many human 
biofluids, with those most commonly analysed being urine and blood (serum, plasma). 
Analysis of urine metabolites has shown early promise in diagnosing kidney52 and bladder 
tumors53, as well as more systemic conditions such as type 2 diabetes mellitus54. Indeed, 
distinct serum metabolite patterns have been characterized for abnormal clinical states 
including breast cancer55, leukemia56, sepsis and acute lung injury57, coronary artery 
disease58 and obesity59,60. Furthermore, cardiovascular health has been assessed by 
metabolomic analysis of faeces, linking perturbations in the metabolite profiles of gut flora 
to the metabolic syndrome and dyslipidemia61. Ejaculate and EPS, have been used to 
characterize disturbed metabolism in prostate cancer22,23,62-64 and infertility 65-67.  Studies 
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on cerebrospinal fluid have associated metabolite changes with brain tumours and 
neurodegenerative disorders, such as multiple sclerosis and Alzheimer’s disease68. 
Salivary metabolomics has been used to investigate oral cancer and pre-malignant 
changes, such as leukoplakia69. Thus, this minimally invasive approach has enormous 
potential in providing valuable scientific and clinical information for medical professionals 
and researchers. 
2.2.2.3.2     NMR Spectroscopy of Tissues and in vivo Imaging Techniques  
High-resolution magic-angle spinning (HR-MAS) NMR spectroscopy can be used to 
perform non-destructive metabolite profiling of tissue or other solid samples70. That means 
that after HR-MAS NMR spectroscopy, further testing of tissue samples can be performed 
such as histopathological evaluation, the current gold standard in disease diagnosis, or 
genome and protein sequencing. As a result, HR-MAS NMR has been used to investigate 
a number of disease states71-77. 
Metabolomic analysis can also be performed directly in vivo, largely owing to advances in 
magnetic resonance spectroscopic imaging and positron emission tomography (PET). A 
standard clinical MRI scan uses similar physical concepts to NMR, but takes many scans 
across a section of living tissue. This data is processed to produce an anatomically correct 
image based on physical properties of the tissue. A magnetic resonance spectroscopy 
imaging sequence is able to produce NMR-like spectra for a targeted volume segment in 
the body, allowing for visualization of metabolite content in that anatomical location. 
Metabolic alterations measured in vivo have been shown to correlate with 
histopathology78,79. Furthermore, in vivo metabolomics is being used to monitor the 
response to various therapies, such as radiotherapy and chemotherapy80,81.  
Different MRI techniques allow the investigation of different phenomena. Dynamic 
contrast-enhanced MRI uses the uptake and elimination of contrast agents, such as 
gadolinium, to distinguish between different tissues. The use of dynamic contrast-
enhanced MRI in oncology is based on the premise that cancer cells have a higher 
metabolism, and thus a higher uptake and elimination of gadolinium contrast82. Diffusion 
weighted imaging, initially used to investigate connectivity between different brain 
regions83, uses slower water diffusion in cancerous tissues compared with surrounding 
healthy cells due to a higher nuclear content and cellular density coupled with extracellular 
changes84. Recently, these MRI techniques have been combined into multiparametric MRI, 
which has been shown to increase accuracy in cancer detection85. The value of these in 
13 
 
vivo applications and their role in oncology is commonly described and reviewed in 
radiology literature85-88. 
Further understanding of altered metabolism in cancer and identification of abnormal 
pathways facilitates imaging using PET in combination with computed tomography (CT) 
via PET/CT89,90. After identifying metabolites, that are either preferentially used or 
upregulated within particular pathways, nuclear isotopes can be chemically attached either 
to these metabolites or to metabolite analogues. The emission of positrons from these 
isotopes can then be measured as gamma rays and superimposed on a CT scan during 
PET/CT scanning. For example, most cancer cells display heightened glycolysis. Thus, 
fluoro-deoxy-glucose, containing a radiolabelled positron emitter such as 18F, can be 
administered and taken up by cancer cells, which are highlighted91. In addition, PET is 
able to distinguish specific cancers, e.g. 11C-choline PET is used to detect prostate 
cancer92,93.The application of PET in other clinical scenarios is diverse, but widespread 
use is limited by logistical and financial constraints94-96.  
Recently, a novel method has been proposed to perform in vivo metabolomics during 
surgery by using real-time MS analysis of the smoke produced from electric cautery to 
biochemically recognize malignant/diseased tissue in which macroscopic changes are not 
present97,98. Although major development is required before clinical use, the initial concept 
is intriguing in its potential to improve surgical accuracy and treatment outcomes following 
cancer surgery. 
2.2.2.4    Integration with other -Omics Sciences 
Metabolites are part of the complex and interconnected cellular hierarchy involving DNA, 
RNA, proteins and metabolites, as outlined in Figure 2.1. Consequently, providing an 
understanding of the mutual relationships between genomic, transcriptomic, proteomic and 
metabolomic data is a major aim of systems biology.  
Integration of multi-omics data sets is already providing insight into biological processes. 
This integration is enabled by the availability of new statistical methods to correlate 
information contained in multiple large datasets99. Furthermore, ever increasing genome-
wide association studies (GWAS) are identifying multiple risk loci associated with various 
disease states. However, the penetrance of these loci, and therefore their relevance, 
remains unclear. By integrating metabolomics and other –omics sciences with GWAS, it is 
expected that identification of loci with a high penetrance or phenotypic manifestations will  
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Figure 2.1: Major targets for exploratory analysis in systems biology. The flow of information 
and biochemical processes between various levels in cellular organisation illustrates the 
progression from genotype to phenotype (solid arrows). The individual levels of cellular 
organisation are also regulated by complex intrinsic feedback mechanisms (dashed arrows). 
Adapted from20. 
be unveiled100,101. Integration of –omics data sets has major potential in oncology102 and 
some studies have used a targeted approach in relating datasets obtained by different 
analytical methods99. A recently published study related metabolomic changes to genomic 
disturbances in CaP tissue to demonstrate alterations in m-aconitase and acetyl citrate 
lyase. Phospholipase A2 group VII and choline kinase α were responsible for altered 
citrate and choline levels, respectively103. Other integrative works investigated colorectal 
cancer104, heart failure105 and other diseases106,107. These studies show impressive proof 
of concept of this new approach. As a result, multivariate statistical analysis and 
integration of large and multi-omics data sets are a valuable strategy for further 
investigation. 
Another key frontier in systems biology is the creation of genome-wide in silico models of 
cellular metabolism that are able to incorporate and integrate multi-omic data108. Such 
reconstructed metabolic networks have already suggested improvements for targeted 
treatment strategies of cholesterol homeostasis in human cellular models109.  
The first genome-scale model of human metabolism published in 2007 was a promising 
milestone110. The next step in metabolic modelling in oncology will be to construct cancer-
specific metabolic models that will incorporate –omics data. This daunting task requires 
improved curation and annotation of genome databases, as well as integration of high 
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quality –omics datasets from studies of specific cancer types, or of other disease states to 
create disease-specific reconstructions. Public accessibility and maintenance of data from 
publicly funded research is critical to these efforts111, as is data management112 and 
interpretation113. 
2.2.2.5    Analytical Techniques 
Of the many analytical techniques that are used in metabolomics to investigate 
physiological and pathological states, NMR spectroscopy and gas chromatography (GC) 
or liquid chromatography (LC) combined with MS are the two most commonly used 
methods. Both have low running costs, are diverse in sample type and allow for accurate 
metabolite identification. Other techniques in use are ultra-performance LC-MS, inductively 
coupled plasma MS, Fourier-transform MS, Fourier-transform infrared spectrometry and 
thin layer chromatography114. We will briefly describe the processes involved in MS-based 
metabolomics, with more extensive reviews available elsewhere29-31,115-117. Subsequently, 
we will focus on NMR-based metabolomics, describing the basic principles and statistical 
approaches that are currently in use. 
2.2.2.5.1    GC-/LC-MS 
Mass spectrometry detects ionized compounds in biological samples according to their 
mass/charge (m/z) ratio following chromatographic (e.g. GC or LC) separation and 
metabolites can be identified in the resulting mass spectrum with reference to internal 
standards118. LC- and GC-MS are well used techniques in metabolite analysis and have 
similar sensitivity, with the major difference being that GC requires more sample 
preparation (derivatization) and higher analysis temperatures, thus LC may be preferred 
for this reason117,119. We will briefly outline the basic processes in MS-based 
metabolomics, which are sample preparation, separation (via liquid-/gas-chromatography), 
ionization, mass analysis and detection, and finally, data processing.  
Sample preparation for MS is dependent on the type of sample. Simple biofluid 
preparation often involves removing macromolecules through protein precipitation and 
centrifugation or filtration. Similarly, sampling of the exometabolome (metabolites secreted 
by cells or organisms into the growth medium) is straightforward. In contrast, to obtain 
intracellular metabolites, tissues or cells need to be extracted in an appropriate solvent 
system117). As different solvent systems are biased towards particular classes of 
metabolites (e.g. polar extraction systems yielding predominantly polar metabolites), the 
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exact choice of solvent depends upon the metabolites of interest. To achieve consistency 
between samples, internal standards are typically added during/after extraction117.  
In GC-MS, derivatization is a further necessary preparation step, which is applied to non-
volatile metabolite classes, such as amino and organic acids, sugars, amines and lipids, to 
render them volatile and thermally stable for GC115-117. Derivatization can introduce bias 
towards individual metabolites if the derivatising agents are not provided in excess, as the 
derivatising reactions have different efficiencies with different metabolites117. In addition, 
metabolites with multiple exchangeable protons will create multiple derivatization products 
that will show up as separate peaks, thus complicating the final mass spectrum. For GC-
MS, electron impact ionization is almost exclusively used115. 
LC-MS is rapidly replacing GC-MS as method of choice in metabolomics, as both methods 
are similarly sensitive, but sample preparation for LC-MS is simpler, because derivatization 
is not required120. LC typically runs as reverse-phase high-performance LC (HPLC), or 
recently even as ultra-performance LC, and electrospray ionization is typically used in LC-
MS systems117. Electrospray ionization MS can run in positive or negative ionization mode, 
and because individual metabolites are generally only detected in one of those two modes, 
both ionization modes need to be run to improve coverage of the metabolome116.  
In the resulting mass spectrum, metabolites are quantified by external calibration or by 
comparison with internal standards116. GC-MS experiments may also require the use of 
deconvolution software to adequately analyse overlapping chromatographic peaks116. To 
allow comparable results between experiments, data may also undergo further pre-
treatment steps, including spectral alignment and automated picking of metabolite 
peaks121. The subsequent multivariate analysis of processed MS data is similar to data 
obtained by NMR-spectroscopy. 
2.2.2.5.2    NMR Spectroscopy 
NMR spectroscopy is a quantitative technique used to accurately determine metabolite 
concentrations in samples. Chemical compounds in biological samples are identified by 
their characteristic peak patterns and signal positions in the NMR spectrum with the aid of 
online databases122 (http://www.metabolomicssociety.org/database). More comprehensive 
accounts of NMR theory and application in metabolomics are available in dedicated 
texts123. A comparison of the strengths and limitations of NMR and MS is provided in Table 
2.1. 
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Technique Advantages Limitations 
NMR • high reproducibility 
• high resolution 
• non-destructive 
• quantitative 
• low running costs  
• minimal sample preparation/no 
derivatization 
• unbiased metabolite profile 
• analysis of tissue (HR-MAS) 
• translation to in vivo (MRI) 
• rapid analysis 
• ability for automation 
• structural identification (2D, 3D) 
• low sensitivity 
• peak overlap 
• libraries of limited use due to 
complex matrix 
• long acquisition times for 
heteronuclear techniques, e.g. 
13C 
• high initial capital cost 
• reduced availability  
GC-MS • high sensitivity 
• large linear range 
• robust 
• identification of wide range of 
metabolites  
• (wider range with LC-MS) 
• analysis of complex biofluids 
• non-targeted 
• established databases 
• widely available and 
comparably low capital cost  
• preferred for targeted analysis 
• slow 
• sample unable to be re-used 
• requires chemical 
derivatization 
• potentially multiple 
derivatization products for 
metabolites 
• many analytes thermally 
unstable 
• metabolite weight limitation 
(<1400 Da) 
LC-MS • high sensitivity 
• high reproducibility 
• large linear range 
• no chemical derivatization 
needed 
• slow 
• limited commercial libraries 
• sample unable to be re-used 
• generation of adducts 
• higher capital cost (HPLC-MS) 
Table 2.1: Comparison of the advantages and disadvantages of NMR, GC-MS and LC-MS 
114,119,124,125. 
2.2.2.6    Processing of NMR Data 
Processing of NMR data comprises four steps: Fourier transformation, phase correction, 
baseline correction and calibration. Fourier transformation transforms the raw real-time 
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data into the frequency domain, and phase correction corrects the phase of the resulting 
NMR spectrum. Baseline correction ensures a constant zero baseline across an NMR 
spectrum, and calibration is needed to ensure a consistent chemical shift scale/axis across 
all spectra. Inadequate processing introduces artefacts that confound statistical analysis 
and jeopardize data integrity (see Figure 2.2).  Minimum standards for reporting and 
processing have been outlined126, and continue to be a good guide for authors publishing 
metabolomics research. 
 
Figure 2.2: Sequential steps of processing NMR spectra. Shown is a spectrum of human 
ejaculate in the region of citrate (2.45 – 2.65 ppm) as example. Correct baseline position is 
illustrated with dotted lines. a - Spectrum after Fourier transformation. The phases of the NMR 
signals are partly dispersive and in need of phase correction. b - Spectrum after phase 
correction. Globally reduced metabolite peak intensities and negative values for the baseline 
occur across the entire spectrum. c - Spectrum after baseline correction, but requiring 
calibration to a chemical shift standard. Chemical shift values are incorrect across the entire 
spectrum, resulting in incorrect metabolite identification. d - Correctly processed spectrum 
suitable for data reduction. 
Usually, NMR spectra require a phase correction following Fourier transformation in order 
to achieve pure absorptive line shapes for all peaks in a NMR spectrum. Where possible, 
phasing should be performed automatically or by the same operator across all samples to 
ensure consistency. Incorrect phasing can distort peak integrals and thus, the subsequent 
multivariate statistical analysis (MVSA; see Figure 2.2A/2.2B).  
Baseline correction is the third critical processing step in producing consistent, comparable 
and reliable data in NMR spectroscopy. At a minimum, the y-offset of the entire spectrum 
is corrected to be zero. However, baseline corrections are often more complex, using 
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spline, polynomial or other mathematical functions to accomplish a zero baseline over the 
whole spectrum. 
As signal intensities are calculated with reference to zero, inadequate baseline correction 
will distort spectral peak intensities (Figure 2.2B/2.2C), and compromise the subsequent 
MVSA.     
Importantly, the chemical shift axis of each NMR spectrum must be adequately calibrated 
using a chemical shift standard, such as (deuterated) 4,4-dimethyl-4-silapentane-1-sulfonic 
acid (DSS). In samples containing a high protein content (such as plasma), DSS cannot be 
used as internal standard. Thus, other endogenous metabolites that are present across all 
samples, such as lactate, glucose or formate, are used as internal reference. The 
alternative is to use DSS as an external standard by either inserting a capillary with DSS in 
deuterium oxide (D2O) into the NMR tube, or inserting the sample in a capillary into a tube 
containing DSS in D2O. The use of 4,4-dimethyl-4-silapentane-1-ammonium 
trifluoroacetate has also been suggested as chemical shift standard that is not affected by 
protein binding127. Chemical shift calibration ensures consistent global alignment of 
spectra in a metabolomics data set which is critical for statistical analysis. In addition, 
correct spectral alignment is required for reliable metabolite identification. However, even 
in correctly calibrated spectra, individual peaks can still exhibit differences in chemical shift 
between individual spectra due to differences in sample pH and ionic strength. These can 
be corrected post-processing by various automatic peak alignment procedures128-133. 
2.2.2.7    Statistical Pre-processing 
2.2.2.7.1     Data Reduction  
After processing of raw NMR data, further processing steps are needed to prepare data for 
MVSA, which are usually termed “statistical pre-processing”. Reducing the full resolution 
data into small segments of equal width, called bins, or “buckets” (Figure 2.3), is the most 
widespread method of data reduction in chemometrics134. Compared with analysis at full 
resolution, this method considerably reduces the size of the data matrix in MVSA, and is 
particularly helpful when peak positions or widths vary slightly due to changes in pH, ionic 
strength or other factors. However, due to decreasing data resolution, bucketing can 
complicate metabolite identification following data analysis. Other pre-processing methods 
that can be used, particularly in targeted metabolomics, include deconvolution, peak-
picking, and weighting factors126. 
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Figure 2.3: Illustration of data reduction by “bucketing”. a - NMR spectrum of human ejaculate 
with suitable pre-processing (segment shown). b – Same spectrum segmented/data reduced 
into buckets of 0.04 ppm width across the region 8 – 0 ppm. The region around the water signal 
from 5.08 – 4.52 ppm was excluded due to artefacts from imperfect water suppression. Note 
that the area in each individual bucket is integrated across the spectral width of 0.04 ppm and 
then normalized, yielding intensities similar to a histogram.  
2.2.2.7.2     Normalization  
After data reduction, data need to be normalized to produce data that are comparable 
between samples135. Normalization is a row operation in the data matrix, and different 
normalization methods are used to obtain the best representation of the data. In total 
integral normalization, or normalizing to total intensity, the spectral intensity in each bucket 
is divided by the total intensity of each spectrum. This procedure normalizes differences 
between spectra due to sample concentration/dilution, e.g. due to different water content 
between samples. However, total integral normalization is vulnerable to distortions when 
one or a few intense signals change considerably between spectra. 
Another method involves normalization to an internal reference compound. For 
metabolomics analysis of urine, normalization to creatinine has been widely used136,137. 
For physiological reasons, urine creatinine is believed to be a suitable indicator of urine 
concentration as creatinine excretion is constant. However, creatinine normalization has 
limitations because it will be confounded by any background pathophysiology that alters 
serum creatinine concentration or creatinine excretion, such as in kidney disease. In these 
cases, creatinine normalization is not suitable. Furthermore, variations in chemical 
properties within the sample can distort creatinine alignment, so that other metabolites, 
especially creatine, will overlap with the creatinine signal and thus impede the proper 
measurement of creatinine concentration123.  
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Probabilistic quotient normalization (PQN) is a method that reduces variation caused by 
large changes in the intensity of one or a few signals across samples, as shown in Figure 
2.4. Thus, PQN can overcome the main weakness of total integral normalization. In PQN, 
which is usually performed after total integral normalization, each variable (bucket) in a 
spectrum is first divided by the intensity of the same variable in a reference spectrum. 
Afterwards the full spectrum is divided by the median of these quotients. This procedure is 
repeated for all spectra in a data set, using the same reference spectrum138.    
 
Figure 2.4: Schematic depiction of spectra containing four NMR signals A-D, following two 
different normalization methods. a – raw spectra with marked intensity variation present in the 
first peak A and identical intensities of remaining peaks between all spectra. b - Integral 
normalization (normalization to total intensity) reduces variation, and therefore influence of the 
dominant signal A, but also alters relative intensities of the smaller, previously identical signals.  
c - Probabilistic quotient normalization partially reduces variation and influence of the larger 
signal A, while maintaining the original relationships between smaller peaks to allow optimal 
comparison during MVSA.  
Recently, Kohl et al. compared many normalization methods, with some derived from 
genomic data analysis, and recommended more advanced methods, such as quantile 
normalization for datasets of n ≥ 50, as well as Cubic Spline Normalization and Variance 
Stabilisation Normalization139.  
2.2.2.7.3     Scaling Effects  
Following normalization, metabolomic data must be appropriately scaled, or transformed in 
a column operation in a way that changes how much signals of large and small intensity, 
respectively, influence the data analysis126,135. The objective is to reduce noise and 
maximize information content in the data. Inappropriate scaling may lead to results that 
highlight parts of the data unrelated to a biological factor, thus compromising the analysis 
and biological interpretation of the data. In metabolomics statistical analysis, three scaling 
methods are largely used.  
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Centre scaling, or mean centering, subtracts the mean value of each variable/bucket from 
the original data of that bucket135. This method is the least manipulative, and is also best at 
minimizing background noise, but large relative variations in small signals may not be 
detected. Mean centering is usually performed mandatorily. Thus, this method is also 
sometimes referred to as “no scaling”, as no further scaling is performed after mean 
centering.  
Univariate, or unit variance, scaling divides the raw data obtained after mean centering by 
the standard deviation of each variable. Univariate scaling gives each variable equal 
weighting, such that variables with small absolute but large relative variation are 
highlighted, but this also means that background noise and other unrelated data variation 
may be overemphasized and thus confound the analysis135.  
Pareto scaling is performed by dividing each variable by the square root of its standard 
deviation140. This is the recommended scaling method for NMR-based metabolomic data, 
as it is able to increase the weighting on metabolites with smaller amplitudes, but does not 
overemphasize the influence of background noise.  
2.2.2.8    Statistical Analysis 
Statistical analysis of metabolomic data depends on the biological question studied and 
the design of the particular project, thus, the choice of data analysis methods varies 
between different projects. In addition, the methods for data analysis are continually 
evolving. Nevertheless, there is a core set of methods of univariate and multivariate 
statistical analysis that is in use for metabolomics, and minimum reporting standards for 
data analysis have been established126,141,142.  
2.2.2.8.1     Univariate Statistical Analysis  
The role of univariate analysis in metabolomics is largely of a targeted nature. An example 
would be where metabolites of interest have been identified by MVSA, and detailed 
analysis of statistical significance of the individual metabolites is desired. Basic univariate 
methods can be used to analyse whether or not individual metabolites are significantly 
different between two classes. However, as with any statistical analysis, the distribution of 
the data determines the type of analysis used. If the data are normally distributed, t-tests, 
z-tests, and analysis of variance (ANOVA) may be used. In cases where the distribution is 
not normal, non-parametric methods such as the Kruskal-Wallis test are used126. However, 
given the high number of variables within a metabolomics dataset, use of multiple 
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hypothesis testing corrections, such as Bonferroni correction or false discovery 
rate/Benjamini-Hochberg are absolutely imperative143. This means that, to be significant, 
p-values need to be much smaller (e.g. p ≤ 5 × 10-5) after correcting for multiple hypothesis 
testing compared to standard univariate statistical analysis144.  
2.2.2.8.2     Multivariate Statistical Analysis (MVSA)  
Modern day metabolomics is largely based on data sets incorporating many variables, 
between several hundred in the case of bucketed data and up to 65,536 if 1D-NMR 
spectra are used at full resolution.  Thus, MVSA methods which simultaneously analyse all 
these variables are preferred144. MVSA determines whether there are inherent patterns or 
groupings within the data that correspond to biological states and also which variables are 
important in discriminating between the different groupings. Thus, this approach is well 
suited to analysing metabolomics datasets, where the aim is to correlate multiple 
metabolite changes with alterations in biology.  
There are two general classes of MVSA methods: unsupervised methods, which 
analyse patterns within a data matrix X, and supervised methods in which the patterns in X 
are correlated with other external data (e.g. clinical data) contained in a Y matrix or Y table. 
The advantages and disadvantages of the most common MVSA methods are summarized 
in Table 2.2, and will be discussed in the following sections.  
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Approach Method Advantages Disadvantages 
Unsupervised Principal 
components 
analysis 
(PCA) 
• Simplifies data 
• Describes variation in original 
data without bias 
• Groups samples with similar 
metabolite profiles 
• Variation may be 
unrelated to 
biological 
question  
• Influenced by any 
confounders  
Supervised Partial least 
squares 
(PLS) 
• Simplifies data  
• Groups samples with similar 
metabolite profiles  
• Extracts variation that is 
correlated with external 
data/identifiers  
• More directed to the biological 
question 
• Possibility of 
introducing bias  
• Require rigorous 
validation 
Orthogonal 
projections to 
latent 
structures 
(OPLS) 
• As PLS 
• Removes orthogonal (unrelated) 
variation 
• Improved knowledge extraction 
2-way OPLS 
(O2PLS) 
• As OPLS 
• Two-way data correlation 
between X and Y 
• Potential for unsupervised 
analysis (when analysing two 
large datasets without external Y 
table) 
Kernel OPLS • As OPLS 
• Improved model prediction 
OnPLS • As O2PLS 
• Simultaneous data correlation 
from multiple (n) matrices 
• Possibility of 
introducing bias  
• Require rigorous 
validation 
• Not widely 
available 
(commercial/open 
source) 
Bi-modal 
OnPLS 
• As OnPLS 
• Data correlation between 
variables (columns) and samples 
(rows) 
OnPLS path 
modelling 
• As OnPLS 
• Linkage of matrices along 
statistically related paths  
Table 2.2: Summary of multivariate statistical analysis methods used in metabolomics for information 
recovery. The advantages and disadvantages of unsupervised and supervised methods are outlined. 
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Some examples of software programs, both commercial and free/open-source, that are 
available to perform MVSA are given in Table 2.3. 
Software Package Use in 
NMR/MS 
Reference/Source 
Commercial 
SIMCA Both http://www.umetrics.com 
MATLAB Both http://www.mathworks.com 
MarkerLynx/MassLynx MS http://www.waters.com 
STATISTICA Data Miner Both http://www.statsoft.com 
Analysis of Mixtures (AMIX) Both http://www.bruker.com 
Agilent Mass Profiler 
Professional 
MS http://metabolomics.chem.agilent.com 
Progenesis CoMet MS http://www.nonlinear.com 
Free/Open Source 
R Both http://www.r-project.org 
Metaboanalyst Both http://www.metaboanalyst.ca 145 
MAVEN MS http://maven.princeton.edu 146 
MZmine MS http:// mzmine.sourceforge.net 147 
MeltDB MS https://meltdb.cebitec.uni-bielefeld.de/ 148 
MetabolomeExpress MS https://www.metabolome-express.org 149 
Table 2.3: Examples of software packages used to perform multivariate statistical analysis in 
metabolomics. 
2.2.2.8.3     Unsupervised Methods in Multivariate Statistical Analysis  
Often, unsupervised analysis methods are initially used in MVSA as they are excellent 
data exploration tools that can be either used to simplify the data (dimensionality reduction 
– principal- or independent-components analysis) or to group samples with similar 
metabolite patterns (clustering – hierarchal, partitional). Although many different methods 
exist, principal components analysis (PCA) is the most commonly used method of 
unsupervised analysis in metabolomics. 
PCA simplifies the original multivariate data which form a swarm of data points in a high-
dimensional statistical space, by projecting them down into a new space with 
comparatively few dimensions called principal components (PCs). These PCs are latent 
variables that describe the variation in the original data. The first PC indicates the direction 
in which most variation occurs in the data. Subsequent PCs are all orthogonal to each 
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other and sorted in order of descending amount of variation. This arrangement describes 
the majority of variation in the data within the first few PCs. PCA is visualized by two types 
of plots, the scores and loadings plots (Figure 2.5).  
 
Figure 2.5: Visualization of a typical multivariate analysis (e.g. PCA, PLS etc.). Sheep urine 
samples before and after road transport of 12 and 48 hours are shown as an example150. a – 
Scores plot – shows any relationships between samples, such as the presence of separate 
groups or outliers. This scores plot shows similarity of the pre-transport groups for both 
transport durations (open inverted triangle = 12 h, black squares = 48 h), and differences 
between both post-transport groups (48 hours = black diamonds, 12 hours = open triangles). b 
– Loadings plot – displays the relationship of influential variables that are responsible for the 
position of outliers or groups seen in the scores plot. Note that the positions/directions of 
groupings/outliers in the scores plot and responsible variables in the loadings plot correspond to 
each other151. 
The scores plot illustrates the relationship and similarity of samples to each other, and 
allows for inspection of groupings and outliers. Outliers can be visually identified on the 
scores plot, or statistically defined as being outside the Hotelling’s 95% confidence range 
across all components. Further statistical validation can be obtained using the residual 
variance of the model, known as distance to model plot140,151.  The variables (buckets, 
ultimately metabolites) attributable to each component in the model are illustrated in the 
loadings plot (see Figure 2.5)152,153. 
The inherent advantage of unsupervised methods is that they are unbiased, i.e. they 
detect any statistical variation in the data, whether or not it is related to the underlying 
biological effect (e.g. differences between cancer and non-cancer samples). This property 
is also their most noticeable limitation, because when confounding effects are larger than 
the biological effect, unsupervised analyses will predominantly show the effects of these 
confounding factors. Distorting variation may also come from uncorrelated background 
variation, or from noise. For this reason, robust experimental design that limits 
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confounding factors and appropriate pre-processing prior to data analysis are vitally 
important to ensure meaningful results. 
2.2.2.8.4     Supervised Methods in MVSA 
MVSA can be improved by including external data, such as clinical data, in a Y table or Y 
matrix. This data inclusion then makes it possible to use a different class of MVSA 
methods, which are called supervised analysis methods. The biggest advantage of 
supervised methods is that they can identify the variation (and associated variables) in the 
biological data that is correlated (or co-varies) with the external data, i.e. they improve 
information recovery and thus interpretation of the biological data. The main supervised 
methods used in metabolomics-based biomedical research are partial least squares (PLS) 
and orthogonal projections to latent structures (OPLS)153-155.  
PLS is a method that seeks to identify correlation between the dataset matrix (X) and one 
or multiple variables (contained in Y). Y data may be categorical (class identities, e.g. 
healthy vs. disease) or continuous (blood pressure, height etc.). If the external variable(s) 
are qualitative, then the method will discriminate between the corresponding classes and 
is known as PLS discriminant analysis (PLS-DA)151.  Figure 2.6 illustrates this distinction. 
Supervised analyses in metabolomics can be affected by systematic variation that is 
unrelated to the class, as this affects any correlation found by the analysis method.  
OPLS is an improvement on PLS that separates variation in the data into two parts: one 
that is correlated with the biological factor(s) and one that is unrelated/orthogonal, i.e. 
OPLS separates X into variation that is predictive of Y and variation that is orthogonal to 
Y58,151,156-158. A further development of OPLS is 2-way OPLS (O2PLS). While OPLS only 
correlates data in X with Y, O2PLS is able to correlate X and Y with each other in both 
directions156. In addition, individual variables from an O2PLS analysis can be visualized as 
a bivariate 1D loadings plot facilitating identification of potential metabolites159. Both, OPLS 
and O2PLS have recently been preferred to PLS, as separation and correlation of 
predictive variation to the Y table has been shown to optimize discriminant analysis, 
improving overall knowledge extraction160-162.This is because both predictive and 
orthogonal variation can be examined, which may provide more detailed insight into the 
factors influencing the biological system163. Furthermore, O2PLS can be used to correlate 
two different data sets with each other, e.g. metabolomic and proteomic datasets in an 
animal model of prostate cancer99. If applied in this way, O2PLS is essentially an 
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unsupervised analysis that is able to correlate variables of different datasets, providing 
further insight into related structures and pathways in altered metabolic states164.  
                  
Figure 2.6: Data included in a PLS analysis. The X table/matrix comprises the metabolomic 
data following pre-processing. Depending on the objective of the analysis, the Y table/matrix 
can include continuous (PLS) or categorical (PLS-DA) data to which the X data are correlated. 
Different extensions of OPLS or O2PLS have been published, including kernel-OPLS, 
which improves model prediction165.  OnPLS is an extension of O2PLS which determines 
correlation not only between two, but multiple (n) matrices, allowing for integration of any 
number of datasets for a given study166. Bi-modal OnPLS is an extension to OnPLS that is 
not only able to analyse orthogonal variation in variables (columns), but also in samples 
(rows)167. This bi-modal approach should provide more informed data analysis, of both, the 
variables associated to the biological question, and of confounding factors associated to 
particular samples. Finally, OnPLS path modelling is a method of linking multiple matrices 
along a set of paths that flow between data blocks. These paths are assumed to be due to 
a specific causative mechanism, e.g. changes over time, and are able to extract the 
minimum number of predictive components that have maximum covariance and 
correlation168. Use of these recent extensions of O2PLS is not yet widespread, but highly 
promising in improving metabolomic data analysis. 
One inherent problem of any supervised MVSA method is that, because they attempt to 
correlate the experimental data (X) with external data (Y), they are prone to introducing 
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bias in the analysis. This can happen due to overemphasis of spurious correlations in the 
data that are only coincidental and not caused by biology. As a result, MVSA models have 
to be rigorously validated when compared to unsupervised analysis methods. The value of 
a validated supervised model may be higher than that of a model originating from 
unsupervised methods because supervised methods are more directed toward the 
biological question. There are several methods of validation. The gold standard is the use 
of an independent set of data to test the predictive power of the original (training) set of 
data, combined with external cross-validation of the training data set. An established 
alternative is permutation analysis in which the data in the Y table are repeatedly permuted 
at random and the model recalculated with the permuted Y data169. If the model is stable 
and correlations to Y are only of biological origin, randomization and permutation of Y data 
will reduce the fit and predictability of the model (see Figure 2.7A). Weak models in which 
correlations to Y are due to chance, rather than biology, will produce permuted models that 
may provide similar or superior prediction than the original model and are thus invalid (see 
Figure 2.7B).  
 
Figure 2.7: Validation by permutation analysis. a – Example of a valid model (original R2 and Q2 
plotted on right side of panel), with permutations resulting in models that are less predictive 
(plotted on left side of panel). The x-axis indicates the distance of the permuted model to the 
original model, and the y-axis indicates R2 and Q2. b – Example of an invalid model, with 
permutations resulting in models with similar or improved predictability. 
Measures of validity in this context are the R2 value, which measures goodness of fit, and 
Q2, which measures model prediction ability. However – similar to cross-validation – 
permutation analysis becomes less trustworthy the lower the ratio between number of 
samples (n) and variables (k) is. The turning point may be near a ratio of n/k of < 0.02 – 
0.04, although this is not applicable for all data sets, and each study has to be evaluated 
on its own merits170. In situations where validation via permutation analysis is not easily 
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accessible, cross-validated ANOVA can be used which uses cross-validated predictive 
residuals using two degrees of freedom for each component, and is more reliable than 
ANOVA which uses fitted residuals171.  
2.2.3 Current Evidence: Metabolomics in Prostate Cancer 
2.2.3.1.1    Prostate Cancer Pathophysiology 
CaP is the most common internal cancer in men worldwide and is more prevalent and 
lethal in Western countries3. Continually evolving methods for early CaP detection have 
improved outcomes due to earlier treatment and a better prognosis for patients. Current 
methods of detection (serum PSA and/or digital rectal examination) leading to diagnosis 
(via trans-rectal ultrasound guided biopsy [TRUSBx]) require improvement due to limited 
diagnostic sensitivity and specificity. Improved methods will help to avoid morbidity in men 
for whom a diagnosis of CaP remains elusive due to limitations and problems associated 
with TRUSBx, as is the current situation. Thus, CaP pathogenesis has been extensively 
studied to facilitate the discovery of new methods for determining the presence of CaP. 
The prostate gland sits in the pelvis below the bladder and in front of the rectum. It is a 
secretory gland that contributes to the seminal plasma component of ejaculate/semen to 
facilitate sperm motility and egg fertilization in utero. The secretory portion of the gland is 
the PZ, and constitutes 70% of the gland volume. The epithelium within the PZ secretes 
prostatic fluid, which contains proteins, such as prostatic acid phosphatase and PSA, and 
metabolites, such as citrate and polyamines (e.g. spermine)172. Furthermore, prostatic 
cells have been shown to be present in EPS and ejaculate, which makes both biofluids 
suitable media for molecular analysis14.  
Citrate production, after sequestration, by PZ epithelium results in a higher citrate 
concentration in EPS when compared with blood plasma172. This process is facilitated by 
zinc-dependent truncation of the tricarboxylic acid cycle by inhibiting the enzyme m-
aconitase, as shown in Figure 2.8.   
ZIP1 is the primary transporter for zinc ions in PZ epithelium, and is expressed by the ZIP1 
gene, which has consequently been described as a tumour suppressor gene in CaP173. 
The expression of ZIP1 and other zinc transporters recently has been described as being 
regulated by the micro-RNA cluster miR-183-96-182174. Zinc ions inhibit m-aconitase, 
which converts citrate to isocitrate, the first step of the citric acid cycle. As a result, the  
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Figure 2.8: Pertinent physiology of the healthy PZ epithelium. Biochemical reactions are shown 
by solid/open arrows and regulatory interactions by dashed arrows. When healthy, ZIP1 
mediated uptake of zinc inhibits isomerization of citrate to isocitrate by m-aconitase. The result 
is high intracellular concentrations of zinc ions and citrate, which are secreted to aid in 
fertilization. Adapted from20,172.   
preferential sequestration of zinc ions in the PZ epithelium causes citric acid cycle 
truncation, producing an increased glucose requirement within the PZ epithelium. 
The resulting high citrate and Zn2+ concentrations in PZ epithelium are reflected in EPS. 
Citrate is important in ejaculate ion homeostasis, and is the predominant regulator of 
calcium ions, which are important in the motility, metabolism and fertilization functions of 
sperm175. Levels of zinc ions are correlated with those of other cations, such as calcium 
and magnesium, but are considerably higher in concentration. In semen, these cations are 
largely redistributed in binding to negatively charged seminal vesicle proteins, such as 
seminogelins, which are vital in regulating sperm function176. In ejaculate, zinc ions are 
bound mostly to metallothionein, with changes in levels of zinc being paralleled by those of 
this protein which is mostly derived from the prostate itself177.  
2.2.3.1.2    The Malignant Prostate 
Malignant transformation of cells is the result of irreversible genetic alterations, most 
commonly due to mutations. Specific to CaP, malignant transformation impairs Zn2+ 
accumulation, removing zinc-mediated inhibition of m-aconitase. The result is completion 
of the citric acid cycle and increased ATP production via oxidative phosphorylation. This is 
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reflected by low zinc and citrate concentrations present in PZ epithelium and prostatic 
fluid, which have been investigated as potential biomarkers172. Further alterations in gene 
expression impair normal mitochondrial functioning. Coupled with the relatively rapid 
division and increased basal metabolic rate in cancer cells, increased glycolysis and 
lactate fermentation in the presence of oxygen occurring in the malignant state increases 
glucose uptake, as well as proteolysis and subsequent alanine production. Pyruvate is 
produced in excess of what can be processed by the tricarboxylic acid cycle, and is 
converted to lactate. This is known as the Warburg effect, and is seen as a marker of 
advanced disease in prostate and other cancers178,179. This process is outlined in Figure 
2.9.  
 
Figure 2.9: Pathophysiology of the PZ epithelium after malignant transformation. Impaired zinc 
uptake reduces inhibition of m-aconitase, resulting in citrate isomerization and completion of the 
TCA cycle. Alanine is produced secondary to proteolysis and lactate as a consequence of the 
Warburg effect.  Adapted from20,172,180. 
Furthermore, increased membraneogenesis accompanying increased cellular proliferation 
adds to the changes in the metabolite profile with malignant transformation, and requires 
synthesis of choline and creatine, which have been shown to be elevated in malignant 
prostate tissues181. 
2.2.3.2    Individual Biomarkers 
A single biomarker that is able to confirm the presence of an altered biological process or 
indicates progression of a disease is a valuable asset in prompting appropriate 
management for any medical condition to improve the outcome for a particular patient. For 
instance, extremely high serum concentrations of the human hormone β-chorionic 
gonadotropin (β-hCG; a marker normally used in pregnancy) in a male patient with a small 
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testicular mass strongly indicate the presence of choriocarcinoma. While this is an 
example of an ideal biomarker, such biomarkers do not currently exist for most scenarios 
in oncology, particularly in CaP182.  
2.2.3.2.1    Serum 
The most widely used biomarker for CaP is serum human kallikrein 3, also known as PSA. 
PSA is a serine protease that is normally secreted in ejaculate to catalyse proteolysis of 
seminal proteins, such as seminogelin183. PSA is elevated in blood in the presence of CaP 
as well as with other prostatic conditions, such as bacterial prostatitis and benign prostatic 
hyperplasia (BPH). Despite not being specific for cancer, PSA is clinically valued and 
widely used21.  
The normal range of serum PSA, based on population studies, is defined as <1.0 ng/ml. 
Serum PSA is not only frequently elevated in other disease states, but can also change in 
the absence of pathology due to other confounders, such as racial and environmental 
variables184-186. In biomarker research, often a cut-off point is derived from studies to 
determine the optimal sensitivity (i.e. the ability of the test to accurately predict true 
negative patients) and specificity (i.e. the ability of the test to predict accurate true positive 
patients). A vast body of evidence has shown that a safe cut-off value for PSA does not 
exist187,188. Safety in this context refers to a level that is low enough to detect the majority 
of men with cancer, but not so low as to cause extensive and unnecessary investigation of 
men without cancer. This finding of the absence of a safe cut-off value for PSA has been 
used as one of the major arguments against population screening for CaP using PSA8,189.  
Serum PSA is a clinically valued test when used with discrimination, and various 
adaptations have been discovered and trialled with varying success, though none has 
been considered superior to total serum PSA itself190,191. Examples include free to total 
PSA levels, PSA velocity and doubling time (time course of an increase by a factor of two), 
PSA density (serum PSA in relation to the prostate volume determined during TRUSBx) 
and, most recently, the prostate health index which incorporates serum PSA, pro-PSA and 
percentage free PSA192-194.  
Other serum biomarkers in CaP diagnosis vary in type and size, from circulating tumour 
cells195,196, to microRNAs197,198, with small molecules and ions, such as sarcosine and 
zinc, having yielded inconsistent results as markers199-202. 
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2.2.3.2.2    Urine 
Ideally, the perfect marker of CaP is sourced from a non-invasive sample/procedure and 
indicates both the presence and nature of the disease. Currently, the best urinary marker 
for CaP is PCA3, formerly known as differential display clone 3203. The PCA3 test relies on 
a patient having had a firm digital rectal examination or prostatic massage just before 
micturition with the flow of urine flushing dislodged prostatic cells in the prostatic urethra to 
beyond the external meatus with the void for collection, so there is some licence involved 
in calling this a urine test. PCA3 is a non-coding RNA which has been shown to be highly 
expressed in and specific for prostatic tissue204-206. PCA3 in urine is expressed as a ratio 
to PSA RNA, and improves detection compared with serum PSA. Use of recently 
described PCA3 isoforms may further improve results207-209. PCA3 also contributes to and 
has been recommended for clinical decision making for men with previous negative 
biopsies but in whom clinical suspicion is high210, however its role in CaP detection has yet 
to be established clinically. Inclusion of the TMPRSS2: ERG fusion gene also has been 
reported to improve detection of CaP with reference to biopsy211.  
2.2.3.2.3    Ejaculate 
The main concern with tests using EPS is that both firm DRE / prostatic massage and 
TRUSBx target the posterior part of the prostate, and neglect anterior and anterolateral 
aspects of the gland in which up to 30% of tumours are sited212,213. In contrast, ejaculate 
contains a prostatic component, which is the result of global smooth muscle contraction, 
and thus theoretically reflects the pathological status of the whole gland. Furthermore, the 
ability to produce ejaculate among donors has been shown to correlate with improved 
survival compared to age-matched controls with CaP17, hypothetically due to adequate 
erectile function and favourable cardiovascular status18,214. Thus, men who produce 
ejaculate are expected to have a more favourable mortality outcome following intervention 
with curative intent for CaP than men who are impotent since cardiovascular disease is the 
commonest cause of patient demise in this population. Prostatic tissue and prostatic fluid 
show similar levels of citrate and Zn2+, further suggesting that prostatic fluid reflects 
intraprostatic pathophysiological status215. 
2.2.3.2.4    Metabolite Changes in Ejaculate 
Historically, changes in citrate and Zn2+ in CaP have been the most pronounced and easily 
detectable in prostatic and ejaculate216. Metabolite profiling and recent metabolomic 
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analysis of ejaculate and EPS have discovered alterations in other metabolites, 
summarized in Table 2.4. Disturbed zinc homeostasis removes the inhibition of m-
aconitase, resulting in citrate oxidation in the citric acid cycle. This causes luminal Zn2+ 
and citrate depletion. Zinc depletion only occurs in CaP, and has been shown to be a 
stable indicator of CaP status and progression215.  
Although citrate levels are altered in other pathophysiological states, such as BPH and 
prostatitis217, reduced citrate concentrations in histologically benign prostatic tissue is 
considered to precede microscopic evidence of CaP72. In poorly differentiated tumours, 
these normally abundant metabolites are present in very low concentrations218. This 
metabolite relationship in CaP has also been correlated with the Gleason histological 
scoring system and is more accurate than serum PSA22. Such biochemical changes reflect 
early neoplastic processes that may not be histologically identifiable, a concept familiar in 
oncology as the “field effect”172. This further supports the role of metabolomics in 
identifying significant metabolic alterations in pre-malignant tissue.  
Other metabolite changes seen in oncology that are not prostate-specific are also present 
in ejaculate. Disturbed synthesis and intracellular depletion of polyamines, such as 
spermine, are reflected in prostatic fluid22,23,219,220. The prostate contains the highest levels 
of spermine in the body, and disturbances in ornithine-decarboxylase in polyamine 
metabolism have been a hypothesized mechanism for spermine depletion220 221,222. A role 
of increased reactive oxygen species production by increased expression of spermine 
oxidase in CaP has linked inflammation with CaP carcinogenesis223. Levels of myo-
inositol, a molecule involved in membrane biosynthesis, have also been shown to be 
reduced in prostatic fluid23,64. Some changes in metabolite levels in prostatic tissue are not 
reflected in prostatic fluid. Choline is upregulated in CaP tissue, both in vitro and in vivo, 
being hypothesized as another metabolite involved in membrane biosynthesis. The use of 
choline as a marker in prostatic fluid is compromised by the endogenous conversion of 
phosphocholine (from the seminal vesicles) to choline catalysed by prostatic acid 
phosphatase (from the prostate) shortly following ejaculation. This produces a biological 
artefact in choline concentration.  Lactate and alanine are also increased in CaP tissue as 
part of the Warburg effect. However, spermatozoa utilize fructose from the seminal 
vesicles and glucose via glycolysis to produce ATP to fuel flagellal movement in utero to 
aid fertilization, resulting in varying levels of lactate and alanine as metabolic by-products. 
This illustrates a confounding factor between external cellular components and 
intraprostatic metabolites. 
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CaP-induced 
change 
Metabolite Role (normal) Alteration  
hypothesis 
Reference 
Increase Choline Membrane 
phospholipid precursor 
Increased  
membraneogenesis 
224-227 
Lactate End product of 
anaerobic glycolysis 
Warburg effect 224 227,228 
Alanine End product of 
anaerobic glycolysis 
Warburg effect 224 227,228 
Omega-6  
fatty acids 
Cell membrane 
biosynthesis, fatty acid 
oxidation 
Altered gene  
Expression 
229 
Cholesterol Membrane 
biosynthesis,  
androgen regulated 
Increased cell  
Turnover 
230 
Sarcosine Glycine metabolism, 
purine synthesis 
Cell invasion 231 
(Choline + 
creatine) / citrate 
Metabolite ratio Increased ratio 232,233 
Choline / citrate Metabolite ratio Increased ratio 233 
Choline / creatine Metabolite ratio Increased ratio 233 
Decrease Citrate Ion homeostasis,  
pH buffer 
m-aconitase  
activation 
23 
Spermine Polyamine synthesis Oxidative stress, 
enzyme alteration 
23,220 
Myo-inositol Membrane 
biosynthesis 
 23 
Citrate / spermine Metabolite ratio Decreased ratio 64 
Citrate / creatine Metabolite ratio Decreased ratio 233 
Table 2.4: Summary of metabolite changes in prostate cancer. Changes generic to cancer, 
such as lactate and alanine, are listed together with changes specific to prostate physiology, 
such as citrate, sarcosine and spermine. Adapted from20. 
2.2.3.3    Metabolomics in Prostate Cancer Diagnosis: Finding the Best Combination 
Metabolite concentrations and ratios have aided in distinguishing CaP from benign 
prostates225,226,228,233. Yet, despite promising preliminary results, there is currently no test 
available that is accepted as an accurate, stand-alone diagnostic or screening test. With 
improved data acquisition and processing technology, the concept of using entire 
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metabolic profiles as a large-scale combination of biomarkers has become feasible. 
Furthermore, metabolite profiles have been shown to be more sensitive as predictors of 
CaP, and in predicting metastatic potential234-237. This concept has been demonstrated by 
metabolomic imaging, in which multivoxel MR spectra of intact prostates were analysed 
with MVSA. This was able to detect highly significant changes between the global 
metabolite profiles of benign and malignant prostate tissue without the need to identify 
specific metabolites237. Similar relationships were demonstrated using freshly frozen CaP 
tissue when microarray gene expression data and metabolomic data were combined using 
PLS, providing further insight into mechanisms of metabolite alterations in CaP103. In 
another study, metabolomic profiling provided an accurate prediction of biochemical 
recurrence of CaP, that is a rise in serum PSA, following intervention75. This illustrates the 
potential of metabolomics as a suitable method for monitoring CaP behaviour following 
clinical interventions20. 
The concept of multiple markers in cancer diagnosis has been examined for some time. 
Specific to CaP, panels of molecular and protein-based markers have been used to 
improve serum PSA-based CaP detection238-240. The most widely publicized and promising 
appear to be the combination of PCA3 and TMPRSS2-ERG fusion transcripts in post-
massage urine as previously described. Multiple studies have shown improved sensitivity 
when combining PCA3 and TMPRSS2-ERG compared with PCA3 or serum PSA 
alone208,211 . Multiple mRNA markers (GalNAc-T3, prostate specific membrane antigen; 
PSMA, Hepsin and PCA3) in malignant prostate tissue have been able to provide optimal 
detection rates21,206,241. Other researchers have attempted to combine single markers of 
different origins to improve CaP diagnosis. For example, a multiplex model utilizing gene-, 
protein- and metabolite-based targets for CaP outperformed any single biomarker238. 
However, although these studies are promising in improving CaP diagnosis, many are 
impractical for use in a clinical setting, mostly due to financial and logistical constraints. 
Thus, in addition to improved accuracy, a further potential benefit of using metabolomics in 
CaP diagnosis is a reduction in cost and logistical requirements for each sample, although 
a high initial capital equipment financial outlay is required. Further limitations of this 
approach are outlined below. 
2.2.3.4    Limiting/Confounding Factors 
As previously discussed, detecting early CaP non-invasively is difficult. This is due to 
many confounding factors relating to the pathophysiology of CaP, but also due to 
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concomitant prostatic disease mimicking CaP. In the majority of studies to date, the 
greatest interference arises from concomitant pathophysiology of the prostate, such as 
BPH and prostatitis. Serum PSA is known to be elevated in BPH: androgens contributing 
to BPH development drive PSA synthesis which is mirrored in serum levels. Prostatitis 
associated with inflammation and prostatic cell lysis, results in increased release of 
intracellular PSA into the bloodstream, elevating serum PSA. It is for these reasons that 
serum PSA lacks sensitivity (detecting many false positives) and that there is sustained 
criticism directed toward serum PSA testing.  
Tissue and prostatic fluid levels of citrate were reported to be initially promising in CaP 
diagnosis compared with serum PSA, but were observed in the past to be depleted in 
prostatitis22,62,242. Notwithstanding similar potential dilemmas as those experienced with 
serum PSA, diminished levels of both zinc and citrate in these samples may provide 
improved sensitivity in CaP detection, although conclusive evidence in conjunction with 
PSA elevations is lacking to date199,215,242. The relationship of citrate depletion in tissues 
following radiotherapy or hormonal therapy also relates to biochemical recurrence, defined 
as a rising serum PSA following intervention with curative intent243,244. Furthermore, 
reduced specificity of serum PSA when compared with metabolite diagnosis may be due to 
pre-malignant disturbances in metabolic homeostasis that are not histologically visible 172. 
The underlying issue of biochemical characterisation preceding histopathology creates 
ongoing uncertainty, as tissue histopathology is the current gold standard for CaP 
diagnosis. 
Intra- and extracellular citrate levels are also known to increase in BPH, thus citrate 
estimation in biopsy tissue may be unreliable. In these circumstances, prostatic fluid may 
be a more appropriate sample to use since prostatic fluid is produced mostly in the 
peripheral zone, which is also where most CaP is located172, whereas BPH develops in the 
transition (central) zone of the prostate. A small proportion of transition zone tumours may 
be missed, but in the large majority of cases these are less aggressive and therefore of 
less significance245.  
2.2.4 Future Directions 
2.2.4.1    Pharmacometabolomics and Theranosis: Towards Personalized Medicine 
Pharmacometabolomics seeks to predict the metabolic response to exogenous therapeutic 
agents prior to or during drug administration, and theranosis is the identification and 
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monitoring of optimal treatments for patients as guided by diagnostic tests246-248. Both are 
important aspects, given the recently emerging evidence of inter-individual differences in 
drug pharmacokinetics, being the ability of an individual to absorb, distribute, metabolize 
and excrete an administered drug100. The result is reduced therapeutic efficacy, but may 
also be responsible for toxicity and adverse drug effects. The aetiology of these 
differences in drug metabolism is diverse and is well understood in only a limited number 
of circumstances (e. g. Cytochrome p450 enzyme family249. Gender, age, race and 
concomitant diseases have been suggested as inherent factors, but have yet to be 
substantiated250. External factors such as dietary and lifestyle habits, as well as toxin 
exposure, may also have a large influence on therapeutic efficacy. Furthermore, less 
obvious but important factors may contribute, such as altered gut flora in various 
circumstances251-253. As such, metabolic phenotypes are diverse and complex due to 
these many influencing factors254. Although genetic profiling across different disorders is 
important, metabolite profiling promises to better reflect the phenotype of disease states, 
and advanced analysis between both methods may help to identify genes with significant 
penetrance. 
As has been illustrated, the carcinogenic changes in various cancers will cause common 
changes to individual metabolic profiles that can be investigated with metabolomics. In 
contrast, each individual patient will exhibit inherently different metabolic profiles, while 
also responding differently to therapeutic interventions255. Thus, the concept of 
personalized medicine, where treatments are tailored to an individual’s personal metabolic 
or genetic phenotype, is one that is exciting, and important in advancing medical 
treatments256. Using metabolite profiles as a representation of metabolic phenotype 
promises to enable theranosis by providing the most useful information for predicting inter-
individual variation that will guide and assess efficacy of treatment outcomes. 
Early research focused on genetic predisposition to cancer or alterations in drug-
metabolizing enzymes257. Recent research has focused on identifying varying metabolic 
profiles that indicate significantly affected drug metabolism, with links to altered gut flora 
homeostasis246,258. This research related individual background urinary metabolic 
phenotype to biological and therapeutic outcomes of drug metabolism. Other research has 
identified alterations in metabolite profiles to illustrate pharmacokinetics and early toxicity, 
important in preventing adverse outcomes from drug toxicity259. Recently, this approach 
has been applied to surgery, and allows for personalized pre-, intra- and post-operative 
care to improve patient outcomes98,260. The concept of pharmacometabolomics can also 
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be applied to outcome prediction, similar to that used in GWAS, with evidence of serum 
metabolite levels to be predictive of body mass following chemotherapy for breast 
cancer261.  
Theoretically, pharmacometabolomics has advantages over pharmacogenomics in 
representing the phenotype resulting from multiple genetic effects. However, it is believed 
that a combination of approaches will provide best prediction and outcomes262. Given 
current variations in efficacy, toxicity and adverse outcomes of treatments, developing 
personalized medicine is imperative to provide better medical care to patients while also 
reducing health budget costs. Thus, the pharmacometabolomic approach is one that has 
potential to change the therapeutic landscape not only in oncology, but across all fields of 
medicine. 
2.2.4.2    Metabolomics to Elucidate Biological Mechanisms 
As outlined, metabolomics has been useful in displaying changes in metabolites in various 
healthy and pathological states. The analysis of metabolites illustrates the end product of 
normally functioning or disturbed cellular processes and mechanisms. Thus, analysis of 
changes in metabolite profiles can lead to insights about the underlying biochemical or 
biological mechanisms. This has been demonstrated in different areas, including but not 
limited to, drug toxicity, cancer and plant studies99,164,263.  
For example, metabolomics could explain how altered STAT5 signalling as a result of 
truncated intracellular domains of growth hormone receptor in liver tissue leads to late-
onset obesity, as systemic metabolite changes were consistent with globally altered 
metabolism contributing to obesity264. A similar approach was used for data obtained from 
a human prostate cancer xenograft model in mice measured by NMR-based 
metabonomics and proteomics (two dimensional difference gel electrophoresis). Pathway 
analysis was used to link altered protein expression to changes in amino acids, which 
contributed to the metabolic phenotype99. 
2.2.4.3    Integration with other –omics  
As previously outlined, the –omics approach to sample analysis provides data sets that 
require complex statistical analysis to extract meaningful information. In isolation, each –
omics field provides insight into that particular level of cell function, and interactions and 
influences causing the results are hypothesized based on previous research or logical 
thinking. Thus, appropriate integration of –omics datasets has become an important step 
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in providing meaningful information in systems biology265,266. This approach was e.g. used 
in insulin resistant mice using NMR-based metabonomics and genomics (quantitative trait 
locus mapping), and showed altered gut metabolites that were linked with genomic 
alterations 267. In both studies, large datasets were used to determine which metabolites 
were similarly affected by alterations in precursor compounds.  
A suggested method that uses O2PLS for integration of large datasets for optimal 
information recovery is outlined in Figure 2.10266, using the example of a study that has 
data from transcriptomics, proteomics and metabolomics experiments. As O2PLS is able 
to extract information from two datasets at a time, the method for correlating multiple 
datasets is naturally a multi-step procedure. In the first step the joint variation between two 
of the three datasets (e.g. transcript and metabolite data) is extracted by O2PLS. This 
means using one of the datasets as X matrix in O2PLS and the other one as Y matrix. 
Note that in this case, O2PLS is effectively run as unsupervised analysis, because only 
two experimental datasets are correlated against each other, without including a set of 
external metadata. In the second step, the joint variation between transcript and metabolite 
data obtained in step 1 is then correlated with the third dataset (proteomics) in a second 
O2PLS, which will yield the variation common to all three datasets. In the final step, the 
joint variation that is common to all three datasets is deflated from the original datasets in 
a series of three parallel O2PLS analyses, to produce variation specific to each dataset.  
 
Figure 2.10: Graphic representation of stepwise data integration of multiple –omics datasets 
with O2PLS. In the first step, joint variation between two –omics datasets (e.g. transcript and 
metabolite data) is determined. Using O2PLS in a second step, this joint variation is then 
correlated with the third –omics dataset (e.g. protein data) to determine variation that is common 
to all three sets of data. The third step removes the joint variation between all three individual 
datasets to produce variation that is specific to each dataset. This dataset-specific variation may 
be important in helping to address the biological question. Adapted from 266. 
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It is trivial to extend this scheme to more than three datasets by adding on further O2PLS 
steps between steps 2 and 3 that each time introduce a further set of experimental data 
into the analysis. It should also be noted that it is prudent to repeat the first two steps with 
different orders of combining the three datasets – e.g. transcript and metabolite data first, 
then including protein data, versus metabolite and protein data first, then including 
transcript data, etc. – in order to rule out that potential slight imperfections in the symmetry 
behaviour of O2PLS might cause secondary effects on the data analysis.   
2.2.4.4    Use of Computational Modelling 
As is widely highlighted, the current approach to metabolomics including valid statistical 
analysis, metabolite identification, and biological interpretation is highly time-consuming. 
As such, the quest to develop computerized methods of metabolite analysis and 
identification is underway268,269. Following metabolite identification, the next step is to 
determine the relationship and similarities, if any, of the identified metabolites to metabolic 
pathways, of which some preliminary programming applications have been released to 
address this issue 113,270,271. 
Even more promising is the development of genome-scale computer models of metabolic 
networks. Extensive work has been completed on bacteria such as Escherichia coli, with in 
silico simulation reported to mimic experimental changes272. Application of these 
reconstructed networks is more complicated in eukaryotes, such as human cells, due to 
the complex cellular and organismic organisation, including intra- and extra-cellular 
regulation and interactions. Despite these, an initial model human cell was constructed to 
provide a general baseline in expression and response to biological variables108,109. 
Furthermore, a reconstruction of healthy liver cells was combined with whole-body 
pharmacokinetics to investigate multiple levels in biological organisation and provide 
mechanistic insights into for various drug-induced scenarios273. Alterations to such models 
to accurately reflect cancer and other pathophysiological states by incorporating known 
and emerging evidence will better describe the response of these cells274.  Depending on 
the type of model, spatiotemporal processes and interactions within cells that may be 
undefinable or difficult to quantify are currently difficult to incorporate and apply to an 
artificial model275. Further development of these reconstructed networks may occur via 
integration of –omics data sets, and research in this field is continuing276. Computational 
modelling by incorporating multiple data sets represents a logical and informative, yet 
challenging, approach to oncology research to guide pharmaceutical development 
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strategies. The result will be better informed treatment approaches and improved 
treatment outcomes for these patients.  
2.2.5 Conclusions 
Metabolomics is a novel, modern and robust scientific approach that has shown great 
advances across many fields in biomedical research. The application of metabolomics to 
differing fields in medical science, including pathophysiology insight, drug development 
and in vivo imaging make it unique from all other approaches. Further research and 
collaboration to develop reconstructed networks, via integration of many terabytes of –
omics data, is the next frontier in providing valuable insights to advance medical research 
and treatments in various human disease states.  
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2.3 Recent developments in prostate cancer metabolomics 
Contemporary CaP metabolomics studies have expanded from biomarker discovery to 
elucidation of tumour aetiology and therapeutic targets. While most mechanistic 
investigations have occurred using malignant and benign human tissues, as well as cell 
lines, systemic metabolite disturbances detected in serum have furthered biomarker 
discovery as well as provided insight into metastatic mechanisms.  
Localised metabolite changes 
A recent key advancement has shown metabolic aberrations to be most pronounced in 
early malignant transformation, a notion hypothesised for some time20. Giskeødegård and 
colleagues used HR-MAS 1H NMR spectroscopy to analyse 158 prostate tissue samples 
from 48 patients277. CaP diagnosis was accurate (sensitivity 86.9% and specificity 85.2%) 
due to reduced spermine and citrate and an increased metabolite combination ratio (total 
choline+creatine+polyamines)/citrate) differentiation of low from high Gleason grade 
tumours and were correlated to progressing Gleason score. Other significant metabolites 
included putrescine, phosphoethanolamine, lactate, alanine, glucose, succinate, 
glutamate, glutamine, glycine, isoleucine, leucine and valine 
(glycerophosphoethanolamine, ethanolamine, creatine, taurine, myo-inositol and scyllo-
inositol were not significant). A metabolomics approach was also used to characterise 
advanced CaP using GC/LC-MS in RP tissues, McDunn and colleagues demonstrated that 
citrate and polyamines, among other amino acid, energetic and lipid metabolites, were 
altered in CaP278. Aggressive prostate tumours were further subdivided by abundance 
profiles of metabolites including nicotinamide adenine dinucleotide (NAD) and kynurenine, 
while metabolites such as ADP, laurate and mannose were able to stratify between organ 
confinement and extracapsular extension. When added to multiparametric nomograms, 
metabolites improved prediction of organ confinement (area under the curve [AUC] from 
0.53 to 0.62) and 5-year recurrence (AUC from 0.53 to 0.64). These studies further 
support the role of metabolomics in detecting CaP and determining tumour 
aggressiveness based on grade and extent of disease. 
Two landmark studies from independent investigators used prostate tissue metabolomics 
with other methods (transcriptomics, immunohistochemistry, histopathology) to investigate 
the relationship of the TMPRSS2:ERG fusion gene, a clinically used biomarker of 
aggressive CaP with tumour metabolism279,280. Using HR-MAS 1H NMR spectroscopy in 
129 samples from 41 patients, Hansen and colleagues demonstrated that the presence of 
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ERG (36% of samples) was associated with lower citrate and spermine and reciprocally 
altered gene expression of enzymes involved in citrate and polyamine metabolism. Meller 
and colleagues found similar metabolite alterations (reduced citrate, cis-aconitate, 
spermine and putrescine) using GC-/LC-MS in matched (benign/CaP) samples from 106 
patients undergoing RP280.  When CaP grade was considered in conjunction with ERG 
status, ERG-positive tumours displaying a lower Gleason grade demonstrated more 
pronounced differences in metabolites and their reciprocal enzymes, including reduced 
citrate, glycerophosphoethanolamine, putrescine and spermine among increased 
glutamine and glycine levels, of which citrate and spermine were only observed in higher 
Gleason grade tumours. Similar relationships were confirmed in vivo using MRSI against 
21 samples among 9 patients, with citrate, choline and spermine levels shown to be 
altered according to ERG status. High grade tumours are associated with altered 
cholesterol metabolism, potentially improving energy storage280. Aspartate, isoleucine, 
tyrosine and tryptophan were correlated with ERG status, while reduced maltotriose and 
gluconic acid were seen in ERG positive samples280, a relationship also reported for earlier 
biochemical recurrence281. Gene enrichment meta-analysis considering metabolic 
pathways related to ERG status demonstrated glutathione, polyamine and glycolysis as 
well as purine and pyrimidine metabolism to be deranged, which was more pronounced in 
lower Gleason grade tumours279. These important studies linked well-described and 
clinically used genetic changes to metabolic aberrations to improve understanding of 
metabolic pathways in early CaP development and potentially demonstrate the initiation of 
tumorigenesis.  
Altered prostatic metabolic pathways 
Further insights into mechanisms of altered metabolic pathways and their consequences 
on tumour behaviour have been elucidated. Specifically, reduced cellular citrate levels are 
due to reduced aconitase 2 expression coupled with increased expression of lipogenic 
enzymes (acetyl-CoA carboxylase alpha and fatty acid synthase)279,280. These expression 
patterns suggest citrate mobilisation to the cytosol for de novo fatty acid synthesis, which 
may indicate an aggressive phenotype, given association with tumour progression and 
reduced survival282. Concomitantly elevated ATP citrate lyase may also implicate 
carbohydrate metabolism in malignant transformation280. Reduced cellular spermine in 
CaP is well described, however changes in spermidine are conflicting. Reduced 
spermidine may be due to increased spermidine synthase and spermidine N(1)-
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acetyltransferase279, while elevated spermidine and glutathione has been observed in CaP 
samples280.  
In matched prostate tissues analysed using LC-MS, Ren and colleagues demonstrated 
multiple altered metabolic pathways283. Dysregulated cysteine and methionine metabolism 
manifested by elevated choline, S-adenosylhomoserine, S-adenosylmethionine and 5-
methylthioadensine with reciprocally altered methyl transferase gene expression mapped 
previously reported alterations in sarcosine, glycine and methionine. Upregulation of NAD 
metabolism, presumedly related to oxidative stress, and elevated hexosamine 
biosynthesis pathway metabolites were also observed. The metabolites carnitine C4-OH, 
citicoline, choline, GPCho, pantothenic acid, NAD, and sphingosine were significantly 
increased on MVSA. Sphingosine was determined to be most diagnostic (AUC > 0.8), 
while also implicated in sphingolipid metabolism due to altered sphingosine-1-phosphate 
receptor (S1PR1-5) expression, specifically impaired S1PR2 signalling and loss of tumor 
suppressor gene function. The mechanisms for metabolic changes described in these 
studies reinforce underlying rationales for current clinical practices, such as 11-choline 
PET imaging, while also describing potential future imaging and drug targets. 
Hormonal and metastatic metabolite changes 
Metabolomics studies have also helped describe relationships between intracellular 
processes and tumour progression. Metastatic CaP cell lines demonstrate elevated 
phosphatidylcholines, phosphatidylethanolamines, glycerophosphoinositols and other 
metabolites when analysed with MS-based metabolomic and lipidomic profiling284. Choline 
kinase alpha, involved in lipid metabolism, was upregulated in metastatic cells compared 
with benign and localised CaP cells, indicating de novo lipogenesis in aggressive, 
metastatic CaP. While both MYC and AKT1 oncogenes induce FASN expression in 
immortalized human prostate epithelial cells, dysregulated lipid metabolism with negative 
enrichment of glycolysis and expression of GLUT1 transporter was present with MYC 
oncogene overexpression285. In contrast, AKT1 activation results in accumulated aerobic 
glycolysis metabolites. AKT1/MYC status was not associated with Gleason grade and 
pathologic staging, indicating difference between architectural and molecular or metabolic 
phenotypes and potential role of the baseline metabolic state in oncogene-mediated 
metabolic reprogramming.  
Androgen regulation is a key factor in CaP pathogenesis and hallmark of treatment of 
advanced and metastatic CaP with ADT. Circulating testosterone promotes prostatic 
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growth and alters cell metabolism following activation of the androgen receptor (AR), of 
which a splice variant, AR-V7, has been implicated in poor response to ADT in clinical 
studies. Using an LNCaP model, Shafi and colleagues286 demonstrated that inducing AR 
increased citrate levels, in contrast to AR-V7 which reduced citrate and mirrored metabolic 
shifts observed in patients resistant to ADT (castrate resistance). Flux analyses suggested 
that reduced citrate is due to increased utilisation, while AR-V7 produced some citric acid 
cycle metabolites due to increased dependence on glutaminolysis and reductive 
carboxylation. In a clinical study, absolute metabolite, lipid and macromolecule 
concentrations in 23 RP samples including some after receiving ADT (degarelix) were 
analysed using HR-MAS 1H NMR spectroscopy24. Lactate, alanine and total choline 
concentrations were significantly elevated in CaP tissue compared to BPH, however 
lactate and total choline were reduced in samples subject to ADT24. While small sample 
size limited detection of other statistically significant compounds such as citrate, lipids and 
macromolecules, these are likely to be altered in the high risk, ADT-treated samples. Thus, 
metabolomics may provide an avenue for in vivo characterisation of metastatic disease 
and monitoring of treatment response.  
Systemic biomarkers 
Analysis of serum in metastatic CaP has demonstrated serum biomarkers related to 
cholesterol metabolism (deoxycholic acid, glycochenodeoxycholate, docosapentaenoic 
acid) among others (l-tryptophan, arachidonic acid, deoxycytidine triphosphate, and 
pyridinoline) to delineate patients with CaP from healthy controls287. When patients were 
monitored during ADT, these markers remained abnormal in patients who developed 
hormone resistance in 1 year, yet reverted toward normal levels in those without hormone 
resistance after 2 years.  Similarly dysregulated lipid metabolism is commonly reported 
among studies investigating circulating markers of localised CaP in urine and serum. 
Mondul and colleagues showed circulating 1-stearoylglycerol was inversely associated 
with overall and aggressive CaP, potentially related to overexpression of monoacylglycerol 
lipase288. Energy/citric acid cycle metabolites, glycerophospholipids and fatty acids have 
also been shown to be altered in sera collected 1-20 years prior to clinical CaP diagnosis, 
where serum PSA is significant between subjects289. Metabolite changes in serum 
acyclcarnitines, related to fatty acid synthesis have also been reported, as well as choline 
and amino acid metabolites to improve diagnostic accuracy290,291. Serum metabolite 
biomarker panels improve sensitivity and specificity beyond 85%291,292, with glycine, 
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sarcosine, alanine, creatine, xanthine, hypoxanthine, and citrate delineated in very high 
risk CaP (median PSA 31 ± 37 ng/ml) from BPH291.  
Analysis of urine has reported to improve diagnosis (sensitivity 88.4%, specificity 93%) 
and showed many dysregulated metabolic pathways293. Using MetaboAnalyst, 
upregulation of purine and pyramidine metabolism as well as downregulation of multiple 
pathways (histidine, arginine, tyrosine, tryptophan, taurine, alanine, aspartate, glutamate) 
was observed293. Other investigators have observed implicated deranged pathways 
including the urea and tricarboxylic acid cycle as well as amino acid and purine 
metabolism in urine samples294. 
While metabolomics analyses of systemic markers in serum and urine have yielded initially 
promising results, these appear to be conflicting between studies with no reliable validation 
of their performance described. As such, these continue to be refined until an acceptable, 
reproducible diagnostic performance is confirmed. 
Disease monitoring in vivo with MRI 
In contemporary clinical practice, multiparametric MRI (mpMRI) has emerged as an 
important adjunct to serum PSA for improved detection and localisation of CaP tumour foci 
as well as providing information on tumour extension and metastasis6. While NMR-based 
tissue studies have demonstrated metabolite disturbances to discern CaP from BPH, in 
vivo NMR as 1H MRSI is minimally used due to a reported lack of additional benefit at the 
expense of increased acquisition time compared with standard mpMRI295. Commonly used 
MRI hardware and acquisition parameters result in suboptimal MRSI spectra for use in 
metabolite quantification and ratio calculation. High quality shimming and adjustment for 
field inhomogeneity296 help improve spectral acquisition, while peak overlap between 
choline, creatine and spermine complicates reproducible quantitation297.  
Indeed, Hansen and colleagues corroborated in vitro 1H HR-MAS NMR findings with in 
vivo 1H MRSI, suggesting that MRSI may provide an avenue to stratify patients prior to 
biopsy or monitor metabolite profiles in vivo in active surveillance programs, potentially in 
place of repeat biopsy279. Furthermore, metabolite profile changes due to ADT could be 
monitored using 1H MRSI, shown in vitro using 1H HR-MAS NMR24. Multiple clinical 
studies have combined MRSI with mpMRI to improve diagnostic accuracy and correlation 
with Gleason score298. MRSI has also been shown to predict extracapsular extension and 
post-RP treatment failure based on number of voxels with undetectable polyamines299. 
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Furthermore, voxel resolution is reported to improve tumour localisation compared to 
expert observer image interpretation300. Increasing utilisation of higher field strength 
magnets and ongoing refinements in acquisition techniques hopes to reduce signal-to-
noise ratio and lipid artefacts to improve metabolic data acquisition and use in clinical 
studies301. Improved metabolic data acquisition may allow easier incorporation of MRSI 
into mpMRI protocols to further describe biochemical characteristics of the imaged 
tumours to guide treatment recommendations or monitoring during active surveillance. 
These data could also be incorporated into in vitro metabolomics biofluid and biopsy 
diagnostics studies, as well as be correlated with surgical pathology specimens using non-
destructive, NMR-based methods. 
Current status and opportunities 
A major limitation in CaP metabolomics studies to date has been inconsistent 
reproducibility and validation. As discussed in Section 2.2.3.4, underlying prostatic biology 
related to BPH can cause localised metabolite changes similar to those seen in CaP, while 
many serum and urine studies have mostly recruited groups of men with disparate 
pathology unlike the populations seen in clinical practice. Table 2.5 contains a summary of 
validated, unverified, putative and unreliable metabolites described in CaP studies. 
While verified metabolites are those with consistently reported changes, such as reduced 
citrate or increased choline and lactate, some metabolites that have been reported by 
separate studies require further verification, such as sarcosine. Putative markers that 
appear promising but require further replication include 2-hydroxybehenic acid and 
sphingosine. Inconsistently reported markers that are currently unreliable include myo-
inositol and alanine, which for some, relate to the sample used (e.g. glycine increased in 
tissue and serum but decreased in urine). Despite reproducible relationships observed in 
prostate tissue studies, there is a grave lack of reliable prostate-derived biomarkers in 
prostate-specifc biofluids, such as ejaculate or EPS, that can be used for early diagnosis 
of localised CaP. Further investigation is required to determine accurate biomarkers in 
prostate-specific biofluids, first confirming validated markers observed in tissue, while 
exploring unverified markers in need urgent replication and verification and others 
currently undescribed. 
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Metabolite Change Reference 
Validated in multiple studies 
Citrate Decrease (EPS, tissue, urine) 23,277-280,294 
Spermine Decrease (EPS, tissue) 23,220,277-280  
Choline Increase (tissue in vitro/in vivo) 24,224-227,277-279,283 
Lactate Increase (tissue in vitro/in vivo) 24,224 227,228,277  
Observed in multiple studies (unverified) 
Sarcosine Increase (tissue, serum) 231,280,291 
Glutamate Increase (tissue) 277,278,280 
Putrescine Decrease (tissue) 277-280 
Infrequently observed (putative, not replicated, unverified) 
2-hydroxybehenic acid Increase (tissue) 280,281 
cis-Aconitate Decrease (tissue) 280 
Glucose Decrease (Tissue) 279,280 
Sphingosine Increase (tissue) 283 
Unreliable based on multiple studies 
Myo-inositol Decrease (EPS, tissue) 
Increase (tissue) 
23,280 
277 
Cholesterol / Fatty acids Increase (tissue in vitro/in vivo) 
Decrease (tissue in vitro) 
229,230 
280 
Creatine Unchanged (tissue) 
Reduced (tissue) 
277 
280 
Alanine Increase (tissue in vitro/in vivo, serum) 
Variable (serum) 
Reduced (urine) 
24,224,227,228,277,278 
291 
293 
Glycine Increase (tissue, serum) 
Decrease (urine) 
279,280,291 
293 
Table 2.5: Localised and systemic metabolite changes in prostate cancer based on 
metabolomics studies. Described metabolite changes are grouped according to whether they 
are validated, observed and require verification, infrequently observed and require replication or 
unreliable (inconsistent). 
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2.4 Conclusions on molecular and metabolomic biomarkers for non-
invasive prostate cancer diagnosis and monitoring 
Prostatic fluid-based biomarker discovery has improved understanding of metabolic 
changes during CaP initiation and progression. Accurate characterisation of underlying 
metabolic abnormalities in clinical populations using prostatic tissue in vitro and MRI in 
vivo provide an ideal target for a mechanistic approach to biomarker discovery.  Given 
known genetic and phenotypic heterogeneity among CaP, it is likely that biomarker panels 
in combination with selective imaging may provide highest diagnostic accuracy. While 
prostatic fluid presents an ideal non-invasive biomarker platform, the feasibility and 
accuracy of a prostatic fluid-based biomarker panel is yet to be investigated within a “high 
risk”, clinical cohort.  
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Part 2 – Methods  
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Chapter 3 – Optimisation of prostatic fluid for metabolomic 
biomarker discovery  
3.1 Synopsis 
The aim of this chapter was to optimise biofluid sample collection and processing 
techniques for future clinical metabolomics studies. PAP activity results in variable 
ejaculate choline/phosphocholine levels which influence metabolomics analysis so the 
performance of tartrate as an inhibitor of PAP at different concentrations and temperatures 
and as an internal concentration standard was investigated to improve ejaculate 
metabolite stability and quantification. Subsequent effects of tartrate on established 
ejaculate processing methods for molecular (mRNA) analysis were also analysed. This 
investigation is presented as a peer-reviewed manuscript (section 3.2). 
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3.2 “Tartrate inhibition of prostatic acid phosphatase improves seminal 
fluid metabolite stability.”  (published manuscript) 
The manuscript entitled, “Tartrate inhibition of prostatic acid phosphatase improves 
seminal fluid metabolite stability” has been published by Metabolomics (2016; 12(11):162). 
The contributions of the co-authors to this manuscript were as follows: Experiment design, 
sample collection, experiment execution, data processing and statistical analysis were 
performed by Matthew Roberts, the PhD candidate, under the supervision of Dr Horst 
Schirra and Prof RA “Frank” Gardiner. Jake Hattwell and Clement Chow assisted with 
sample collection, experiment execution, data processing and statistical analysis. Dr 
Gregory Pierens advised on experimental design and set-up, data acquisition and 
interpretation of results. Prof Martin Lavin provided critical manuscript revisions. 
Preparation of the manuscript and associated figures was performed by Matthew Roberts, 
the PhD candidate.  
The manuscript text is presented as originally published by the journal. To maintain a 
consistent style between chapters in this thesis, abbreviations, placement of figures and 
tables within the text, as well as numbering of pages, figures and tables has been 
adjusted. The references have been collated in the section, ‘Bibliography’, with others 
contained in this thesis. 
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3.2.1 Abstract 
Introduction: Ejaculate has been suggested as a biofluid suitable to characterise male 
reproductive organ pathology with metabolomics. However, various enzymatic processes, 
including phosphorylcholine hydrolysis mediated by prostatic acid phosphatase, cause 
unwanted metabolite variation that may complicate metabolomic analysis of fresh 
ejaculate samples. The aim of this study was to investigate the effects of PAP inhibition 
with tartrate.  
Methods: Using NMR spectroscopy, the kinetics of phosphorylcholine to choline 
hydrolysis was characterized in ejaculate samples from three subjects at different 
temperatures and tartrate concentrations. Principal components analysis was used to 
characterise the effects of tartrate and temperature on personal differences in metabolite 
profiles. Potential effects of tartrate on RNA quantification were also determined. 
Results: Metabolite profiles and the kinetics of phosphorylcholine degradation are 
reproducible in independent samples from three ostensibly normal subjects. Increasing 
concentrations of tartrate and refrigerated sample storage (279 K) resulted in greatly 
reduced reaction rates as judged by apparent rate constants. Multivariate statistical 
analysis showed that personal differences in metabolite profiles are not overshadowed by 
tartrate addition, which stabilises phosphorylcholine and choline concentrations. The 
tartrate signal also served as an internal concentration standard in the samples, allowing 
the determination of absolute metabolite concentrations in ejaculate. Furthermore, the 
presence of tartrate did not affect RNA expression analysis by qPCR.  
Conclusion: Based on these results we recommend as standard protocol for the 
collection of ejaculate samples, that 10 mM tartrate are added immediately to samples, 
followed by sample storage/handling at 277 K until clinical processing within 6 hours to 
remove/inactivate enzymes and isolate metabolite supernatant and other cellular fractions.  
 
Keywords: Prostatic acid phosphatase, Nuclear Magnetic Resonance, enzyme inhibition, 
metabolomics, seminal fluid, prostate cancer  
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3.2.2 Introduction 
Biomarkers are an essential component of modern medicine in aiding diagnosis and 
treatment of various medical conditions and are predominantly found in bodily fluids 
including blood, urine and ejaculate. Metabolite changes in ejaculate have been shown to 
reflect tissue changes172, thus metabolite quantification may allow ejaculate to indicate 
male reproductive organ pathology. For example, citrate, myo-inositol and spermine have 
been suggested to assist with prostate cancer diagnosis20, while 
glycerylphosphorylcholine, glycerylphosphorylethanolamine, citrate, lactate and 
metabolites associated with oxidative stress have been implicated in other cancers and 
male infertility65,302. 
However, investigation of metabolites or proteins as biomarkers in ejaculate has been 
limited in comparison with other biofluids, because metabolite profiles in ejaculate exhibit 
temporal variation as a result of various enzymatic processes. These include small peptide 
and amino acid changes due to seminogelin proteolysis catalyzed by PSA, a commonly 
used marker for prostate cancer183. More important for metabolomics studies, hydrolysis of 
phosphorylcholine to choline increases inorganic phosphate production within minutes and 
is mediated by PAP, a previously used prostate cancer biomarker303,304. Both of these 
enzymes enhance function and protection of spermatozoa via improved zinc shuttling and 
hyaluronidase action, among other mechanisms176,305,306.  
The rapid and dynamic changes in ejaculate metabolites over time may complicate reliable 
quantification, as any single measurement is likely to capture an indeterminable point 
within the hydrolysis reaction in progress. In practical terms, a varied and unavoidable time 
delay from sample production to processing and storage may cause unwanted variation in 
metabolites such as phosphorylcholine and choline, given their known rapid changes after 
sample collection, to result in analysis not reflecting underlying pathology. Choline-based 
metabolites have been implicated with prostate cancer in vivo307, and choline-based PET 
imaging is an emerging diagnostic aide clinically308. However, accurate in vitro 
characterization to help predict if these imaging modalities are clinically useful remains 
unexplored.  
Current sample preparation approaches to improve metabolite stability for ejaculate 
metabolomics studies are varied, including incubation at 37°C304,309 and snap freezing with 
subsequent thawing at 4°C or 37°C23,62, which may jeopardise analysis of other ejaculate 
components, such as RNA310. 
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Because of PAP’s rapid effect in hydrolysing phosphorylcholine, immediate PAP inhibition 
of ejaculate may permit better characterization of choline-based metabolites compared 
with other described sample preparation methods. Various compounds that are potentially 
suitable PAP inhibitors are known, including tartrate, vanadate and molybdate311,312. Ions 
such as vanadate and molybdate are less attractive for NMR profiling because of 
paramagnetic line broadening leading to reduced peak signal-to-noise ratio and analytical 
sensitivity313. In contrast, tartrate has been used previously as a competitive inhibitor of 
PAP in clinical assays312 and is present as a single NMR peak, largely removed in peak 
position from other metabolites. Furthermore, tartrate quantification during NMR 
spectroscopy may also serve as an internal concentration standard for metabolomics 
studies, and allow for determination of absolute metabolite concentrations in ejaculate. 
Here we demonstrate the performance of tartrate as an inhibitor of PAP, as well as an 
internal concentration standard by examining ejaculate metabolite profile variation, at 
different tartrate concentrations and temperatures. Furthermore, we quantify ejaculate-
based mRNA species in vitro in the presence of tartrate to evaluate any negative effects of 
tartrate on established ejaculate processing methods for molecular (mRNA) analysis. 
3.2.3 Materials and Methods 
3.2.3.1 – Experimental Design 
3.2.3.1.1 – Reproducibility of kinetic curves and influence of tartrate 
The reproducibility of kinetic curves in ejaculate were investigated using a two-factor 
design comprising the addition/absence of 1 mM tartrate (Tar) and temperature (298 K = 
room temperature; and 277 K = refrigerator temperature) as outlined in Figure 3.1a. 
Duplicate experiments were conducted on ejaculate samples collected on separate days 
from different subjects for each experimental condition. Samples were collected, as 
outlined in Section 2.1.3, and measured using NMR spectroscopy, as described in Section 
2.2. 
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Figure 3.1: Experimental workflow of sample preparation and spectral acquisition using two-
factor design a: Reproducibility of ejaculate kinetic profiles was determined by measuring 
ejaculate kinetic profiles from three healthy subjects on two separate occasions each as well as 
with and without 1 mM tartrate (Tar). b: The influence of tartrate concentration and temperature 
on ejaculate kinetic profiles was investigated using cyclically interleaved measurement of 
ejaculate samples with added tartrate at different concentrations and at separate spectrometers 
(AV900/AV700) set to different temperatures (298 K; 279 K). The temperature change from 277 
K to 279 K was required because the SampleJet refrigerating system, is set to a fixed 
temperature of 279 K.  
3.2.3.1.2 – Kinetic curves with varied tartrate concentration and temperature 
The efficacy of tartrate as a PAP inhibitor was investigated using a two-factor design with 
different temperatures (279 K and 298 K) and tartrate concentrations (0 mM, 1 mM, 3 mM, 
5 mM, 10 mM, 20 mM). To save time and increase throughput, the experiments were 
interleaved by cycling samples and measurements at regular intervals, as outlined in 
Figure 3.1b. Furthermore, throughput was further increased by measuring the kinetic 
curves at these two different temperatures simultaneously using two different NMR 
spectrometers. 
Serial aliquots from samples were collected and combined with L(+) – tartrate-phosphate 
buffered saline (PBS) buffer solutions to produce specific final tartrate concentrations 
within each sample solution. Aliquots were then measured, interleaved, and 
simultaneously at 298 K at an AV900 spectrometer and at 279 K at an AV700 MHz 
spectrometer. The lower temperature of 279 K was chosen, as that is the temperature at 
which samples are stored in a Sample Jet sample changer, and it is close enough to 
temperatures in a laboratory refrigerator (277 K). Thus, any changes seen at 279 K and 
any consequent recommendations would, if anything, be under-estimating the expected 
effects. For the first two subjects, measurements were taken in triplicate every 12 h after 
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the first 24 h in order to maintain sample temperature at 279 K for as large a fraction of 
time as possible, so that measured kinetic profiles accurately reflected conditions at lower 
temperatures over a prolonged period. For the third subject, measurements at 279 K were 
taken at regular 30 minute intervals similar to that seen for 298 K, as each sample spent 
the majority of time in storage at 279 K for each measurement cycle, with a mandatory 
drying time of ~4-5 min at 293 K in the pre-heater before insertion into the magnet. The net 
effect of this was an overall slightly faster kinetics than for subjects 1 and 2, which was 
deemed to be inconsequential if sufficient inhibition was able to be demonstrated. The 
tartrate concentrations were selected on the basis of prior reports of 70, 90 and 95% PAP 
inhibition at tartrate concentrations of 1, 5 and 20 mM, respectively314.  
3.2.3.1.3 – Subjects/samples 
Ethical approval for this study was obtained from the University of Queensland Medical 
Research Ethics Committee (Project no. 2006000262) and the Royal Brisbane and 
Women’s Hospital (RBWH) Human Research Ethics Committee (HREC/09/QRBW/320, 
HREC/09/QRBW/305 together with 1995/088B). The study was conducted in accordance 
with the ethical standards outlined in the 1964 Declaration of Helsinki. 
Following informed consent, three healthy Caucasian subjects of different ages [26, 29 
and 45 (no familial history, PSA=0.96 µg/L)] were recruited and provided serial ejaculate 
samples into sterile micro-urine jars containing 20 ml Phosphate Buffered Saline (PBS – in 
house preparation). Samples were vigorously mixed with the buffer solution and 100 µl 
aliquots were distributed among Eppendorf tubes containing 80 µl of sodium potassium 
L(+)-tartrate (Sigma Chemical Company, Saint Louis, MO, USA) in PBS solution at 
concentrations  according to experimental design (see Figure 3.1). Samples were 
prepared to a total volume of 200 µL with 20 µL D2O as lock substance that 
contained DSS as internal chemical shift standard and 1,1-difluoro-1-trimethylsilanyl 
methylphosphonic acid (DFTMP) as internal pH indicator to yield a final concentration of 
100 µM for both. 
3.2.3.2 – NMR Spectroscopy 
NMR spectroscopy of ejaculate samples was performed on Bruker Avance 900 (AV900) 
and Avance 700 (AV700) spectrometers operating at 1H frequencies of 900.13 and 700.47 
MHz, respectively, (Bruker Biospin, Rheinstetten, Germany), both equipped with a 5 mm 
self-shielded z-gradient triple resonance cryoprobe and a SampleJet® sample changer, 
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chilled to 279 K. Spectra were measured at temperatures of 277 K, 279 K and 298 K 
according to experimental design (Figure 3.1).  
One-dimensional (1D) nuclear Overhauser effect spectroscopy (NOESY) proton (1H) 
spectra were acquired in high-throughput automation mode via the ICON-NMR interface of 
Bruker Biospin with the “noesypr1d” pulse sequence ((RD) – 90° - t1 – 90° – τm – 90° – 
acq,  Bruker Biospin pulse program library) in “baseopt” digitization mode with 32 scans 
(following 8 dummy scans) at 32k resolution and a spectral width of 14 ppm150. The 
transmitter frequency was set to the frequency of the water signal, and water suppression 
was achieved by continuous wave irradiation during both the NOESY mixing time (τm) of 
0.1 s and the relaxation delay of 3.0 s. Automatic tuning and matching was performed, as 
well as automatic shimming on the z and z2 shims during spectral acquisition.   
Pseudo-2D spectra were acquired manually as 1D NOESY spectra increments acquired 
every 162.4 s (AV900) and 180 s (AV700) using similar parameters as above with an in-
house adaptation of the pulse programs noesygppr1d (AV900) and noesypr1d (AV700).  
3.2.3.3 - Spectral Processing 
1D NMR spectra were processed with TopSpin Version 3.2 (Bruker BioSpin GmbH, 
Rheinstetten, Germany). The free induction decays (FIDs) were baseline corrected by a 
Gaussian function of 0.1 ppm filter width for post-acquisitional water deconvolution 
according to315 and multiplied by an exponential window function with 0.1 Hz line 
broadening factor, before Fourier transformation to a size of 32,768 (AV900) and 65,536 
(AV700) data points.  The chemical shift of spectra was calibrated on the DSS peak at 
0.0 ppm after exponential multiplication, Fourier transformation and manual phasing, 
followed by manual baseline correction.  
3.2.3.4 – Non-linear curve fitting 
For 1D NOESY spectra, peak integrals for phosphorylcholine (3.205 - 3.215 ppm) and 
choline (3.188 – 3.198 ppm) were calculated with user defined integrals and peak epsilon 
radius, to allow for variation in peak positions in F2 of 30 data points between experiments, 
and exported using Dynamics Center Version 2.1.8 (Bruker BioSpin GmbH, Rheinstetten, 
Germany). For experiments where triplicates were measured, the average integral was 
calculated. 
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The averaged integrals (y-var) were imported into SigmaPlot 13.0 (Systat Software, San 
Jose, CA), coupled with the time (in h) since first acquisition (x-var, extracted from the 
timestamps of creation for each FID file) for non-linear curve fitting. 
For pseudo-2D-NOESY spectra, the visible region of 3.18 – 3.24 ppm was exported from 
TopSpin into MATLAB 2012b (The Mathworks Inc., Natick, Massachusetts, United States) 
and peak integrals for phosphorylcholine (3.205 - 3.21 ppm) and choline (3.188 – 
3.198 ppm) were calculated. Time periods between integral peak values were 162.4 s 
(AV900) and 180 s (AV700). 
To characterise the decay of phosphorylcholine in initial pseudo-2D NOESY and serial 1D 
NOESY spectra, integral values at time t were fitted to the following exponential equation 
in SigmaPlot: 
𝑓 (𝑡) = 𝑎 ∙ 𝑒(−𝑏∙𝑡) + 𝑐 
The resulting fit parameters are listed in Table A1.1. Where poor fits were obtained, as 
determined by a low r2 value or large standard errors for fitted parameters, a two-
parameter fit omitting c was used. If that yielded a poor fit as well, the corresponding fit 
was denoted in Table A1.1e. Similarly, to characterise the kinetics of choline production, 
peak integral values at time t in initial pseudo-2D NOESY and serial 1D NOESY spectra 
were fitted in SigmaPlot to the exponential equation  
𝑓 (𝑡) = 𝑎 ∙  (1 − 𝑒(−𝑏∙𝑡)) + 𝑐 
and then displayed as intensity ratio (f(t)/f(t=∞), i.e. scaled by the fitted peak integral at 
t=∞, the highest value of the curve. Each combination of volunteer and temperature was 
scaled using the curve with the highest final intensity at t=∞ (usually the uninhibited 
kinetics). The rationale for this was that all samples were aliquots from the same ejaculate 
sample and should thus increase to the same final choline concentration. For most 
inhibited samples the reaction speed is so slow that this point is never reached. The 
resulting exponential fit parameters are also listed in Table A1.1.  
3.2.3.5 – Multivariate analysis 
1D NOESY spectra corresponding to samples containing 0 mM and 10 mM tartrate 
acquired at different temperatures and time points were automatically data-reduced with 
AMIX (version 3.6.6, Bruker Biospin, Rheinsetten, Germany) into spectral integral regions 
(“buckets”) of 0.001 ppm width over the range δ = 10.0 – 0.25 ppm (with exclusion of  the 
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water region from 5.08 – 4.52 ppm), and metabolite peaks were then aligned with the 
spectral alignment algorithm “icoshift ”131, first by initial automatic alignment based on the 
lactate doublet at 1.32 ppm, then by a combination of alignment on the choline singlet at 
3.19 ppm and subsequent manual alignment of metabolite peaks corresponding to user-
defined intervals representing approximate peak widths. The resulting dataset was 
manually data-reduced to buckets of 0.01 ppm width (in the range 9.996 – 0.256 
ppm).  Quantile normalization was performed in order to correct for improper influence of 
large signals across the dataset139. A second data matrix was constructed in a similar way, 
but excluding the tartrate signal from δ = 4.4334 – 4.24 ppm after peak alignments, but 
before quantile normalisation. Both data matrices were imported into SIMCA P+ 12.0 
(Umetrics, Umeå, Sweden) for MVSA. 
Both metabolite data matrices (X-matrix) underwent Pareto-scaled Principal Components 
Analysis (PCA) as an unsupervised analysis151. The multivariate models were optimized 
using cross-validation, with model quality assessed using the R2X and Q2 figures of merit. 
R2X measures the variance of the X variables, expressed as the sum of squares fraction 
for the selected component, to quantify “goodness of fit”. Q2 uses cross validation to 
quantify the predictive accuracy, or “goodness of prediction” of the model. 
3.2.3.6 – Univariate statistical analysis 
To demonstrate the usefulness of tartrate as internal concentration standard, absolute 
concentrations of significant metabolites in the PCA were calculated based on their signal 
intensity and corresponding proton ratios relative to that of tartrate. The equation used to 
determine the relative molar concentration of each metabolite was: 
[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒] = [𝑇𝑎𝑟𝑡𝑟𝑎𝑡𝑒] ∙
𝑏𝑢𝑐𝑘𝑒𝑡_𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦(𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝑠𝑖𝑔𝑛𝑎𝑙)
𝑏𝑢𝑐𝑘𝑒𝑡_𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦(𝑡𝑎𝑟𝑡𝑟𝑎𝑡𝑒 𝑠𝑖𝑔𝑛𝑎𝑙)
∙
𝑛𝑢𝑚𝑝𝑟𝑜𝑡𝑜𝑛𝑠(𝑡𝑎𝑟𝑡𝑟𝑎𝑡𝑒 𝑠𝑖𝑔𝑛𝑎𝑙)
𝑛𝑢𝑚𝑝𝑟𝑜𝑡𝑜𝑛𝑠(𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒 𝑠𝑖𝑔𝑛𝑎𝑙)
 
with bucket intensities taken from the icoshifted but not normalized bucket table with 
0.01 ppm bucket width. This formula was applied to each metabolite identified in the 
MVSA for each tartrate-containing spectrum in the dataset where the tartrate peak was 
excluded (n = 66). As the citrate signal exhibited sample dependent shifts, the full chemical 
shift range of the citrate signal of δ = 2.486 – 2.706 ppm was used to quantify citrate.  
3.2.3.7 – Application to mRNA extraction and processing 
Various groups are exploring the use of RNA (PSA, PCA3 and Hepsin) and microRNA 
markers in ejaculate as biomarkers for prostate cancer15,16, while also investigating 
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metabolomic profiles in this context (using sodium azide [NaN3] as our preservative of 
choice). The influence of tartrate on ejaculate-derived mRNA expression and processing 
was investigated in vitro using LNCaP cell culture. Cells were grown to 90% confluence in 
T175 flasks with RPMI media (In-house) supplemented with 10% Fetal Calf Serum (Invitro 
Technologies) and 0.01% Penicillin/Streptomycin (Gibco). Cells were harvested in 20 ml 
PBS with a cell scraper and split evenly into 4 separate tubes. The tubes were spun down 
at 1200 rpm (290×g) for 300 s and the supernatant was decanted. The resulting cell 
pellets were subsequently re-suspended in PBS solution with additional 20 mM sodium 
potassium tartrate (Sigma-Aldrich), 0.05% NaN3 (Sigma-Aldrich), both 0.05% NaN3 and 
20 mM sodium potassium tartrate and no additives. The cells were then incubated in the 
respective solutions for 600 s to simulate the maximum time taken for specimens to be 
processed after collection from an on-site clinic.  
In 4 fresh tubes, 10 ml of isopynic gradient (1.08 g/ml Percoll (GE Healthcare)/PBS buffer) 
was added to each of them and the cells in the respective different buffers was layered 
gently on top. The tubes were then spun down for 0.5 h at 2200 rpm (974×g) at 277 K. 
Following centrifugation, a layer of cells should be seen at the sample/Percoll interface. 
The cell layer which is at the sample/Percoll interface was removed into fresh tubes and 
re-suspended in 25 ml of cold PBS. The cells underwent two cycles of centrifugation 
(2500 rpm; 1258×g) at 277 K for 600 s and the supernatant was removed. The cell pellet 
was then re-suspended in 1 ml Trizol (Life Technologies)/ 200 mg of pellet. RNA was 
isolated with Trizol reagent and synthesized according to first strand cDNA synthesis 
protocol.  
All qRT-PCR were performed using the Corbett Rotorgene-6000 (Corbett Research, 
Australia), Rotorgene-6000 Series Software Version 1.7 (Corbett Research, Australia) and 
Quantitect® SYBR® Green PCR Kit (Cat. No. 204143, Qiagen). qRT-PCR reaction were 
prepared in triplicates and each contained 7.5 µl of qPCR master mix, 0.5 µl of each 
10 µM forward and reverse primer and 5 µl of diluted cDNA (1:10 dilution). Cycling 
condition for PCA3, PSA, Hepsin and beta-2 microglobulin (β2M) primers were as follows: 
368 K for 900 s, followed by 45 cycles of 368 K for 20 s, 331 K for 20 s and 345 K for 20 s. 
Data were generated with the Rotorgene-6000 Series Software and relative gene 
expression levels were calculated as described by Pfaffl et al.316, with β2M used as the 
reference gene (RG), and plotted using Excel. 
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3.2.3.8 Data Deposition 
All primary NMR spectra and categorical metadata were deposited in the MetaboLights 
database (http://www.ebi.ac.uk/metabolights)317 with the accession number MTBLS285.  
3.2.4 Results  
3.2.4.1 – NMR spectroscopy of human ejaculate over time  
3.2.4.1.1 – Establishing reproducibility of kinetic curves  
Because NMR spectrometers can only measure one sample continuously at a time, we 
performed initial 1D NOESY (example in Appendix 1 – Figure A1.1a) and pseudo-2D 
experiments (example in Figure A1.2b) to establish whether metabolite profiles and the 
kinetics of phosphorylcholine degradation are reproducible in independent samples (Figure 
3.1a). The pseudo-2D spectra showed time dependent changes in the signal intensities of 
phosphorylcholine and choline (Figure A1.2a, b) which were plotted as time-dependent 
decay/growth curves in Figure 3.2 (plotted as intensity ratios, which were calculated as 
peak integral at time t : peak integral at t=0 for phosphorylcholine, and as peak integral at 
time t : fitted peak integral at t=∞  for choline), together with exponential fits to the raw 
data. The decay/growth curves for the phosphorylcholine and choline peak integrals, 
respectively, were reproducible when separate samples were measured at different 
temperatures (277 K/ 298 K) or with/without 1 mM tartrate using a simple two-factor 
experiment (Figure 3.2). The spectral profiles for ejaculate samples in our dataset were 
comparable to those reported previously in NMR studies of this biofluid304, and an NMR 
spectrum for a representative ejaculate sample is shown in Figure A1.1a. 
3.2.4.1.2 – Kinetic curves with varied tartrate concentration and temperature  
After establishing in the initial experiments that kinetic parameters were reproducible in 
independent samples, we used a more detailed two-factor experimental design with 
different temperatures and tartrate concentrations to explore the influence of both 
parameters (Figure 3.1b). To save time and increase throughput, experiments were 
interleaved by using the sample changer to cycle samples and measurements at regular 
intervals. In addition, measurements at 279 K and 298 K were performed on two separate 
NMR spectrometers in parallel. Initial choline concentration (t=0) differed between samples 
at the same temperature, as without the addition of tartrate, a different amount of 
phosphorylcholine has already been hydrolysed to choline when each NMR measurement 
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starts. This resulted in the kinetic curves for choline starting at different amounts of 
choline. Similar kinetic curve patterns were observed for each subject (Figure 3.3) when 
compared to the curves obtained in the preliminary experiments (Figure 3.2). Increasing 
concentrations of tartrate and reduced storage temperature (279 K) resulted in a slower 
reaction, reflected by the kinetic curves (Figure 3.3), by the fitted apparent first-order rate 
constants (Figure 3.4), and by the ratio of change in signal after 24 h at a given tartrate 
concentration compared to the uninhibited sample (Appendix 1 – A1.3b). Overall the 
change from initial concentration of choline or phosphorylcholine was lowest at a tartrate 
concentration of 20 mM and the reduced storage temperature of 279 K (Figure 3.3 right 
half, Figure 3.4), signifying maximal inhibition of PAP.  
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Figure 3.2: Kinetic profiles of phosphorylcholine hydrolysis to choline mediated by prostatic acid phosphatase. The raw data points and calculated 
exponential fit curves are shown. First and third column of panels: The intensity of phosphorylcholine (PCho) is for samples in Figure 3.1a displayed as 
peak integral at time t : peak integral at t=0) and at varying temperatures (298 K and 277 K) and in the absence (left panels) or presence (right panels) 
of 1 mM tartrate (Tar). Second and fourth columns: Time-dependent intensity ratios of choline (Cho), displayed as measured peak integral at time t : 
peak integral at t=∞, for samples in Figure 3.1a. Starting values for choline differ because the measurement of the first spectrum of each curve occurs at 
different times after the reaction was initiated by sample donation, and so a different amount of PCho has been converted to Cho before the first 
measurement.  Kinetic curves at 298 K (faster kinetics) were followed for a shorter amount of time than curves at 279 K (slower kinetics) to minimize 
NMR measurement time.  Black curves: First sample, grey curves: second sample.  
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Figure 3.3: Kinetic profiles of phosphorylcholine hydrolysis to choline mediated by prostatic acid phosphatase under varying tartrate concentration. The 
raw data points and calculated exponential fit curves are shown. First and third column of panels: The intensity of phosphorylcholine (PCho) is for 
samples in Figure 3.1b displayed as peak integral at time t : peak integral at t=0 and at varying temperatures (298 K; 279 K) and in the absence (left 
panels) or presence (right panels) of tartrate (Tar) at varying concentrations as indicated (mM). Second and fourth columns: Time-dependent intensity 
ratios of choline (Cho), displayed as measured peak integral at time t : peak integral at t=∞, for samples in Figure 3.1b. As in Figure 3.2, sreaction time 
elapsed before spectra acquisition. Kinetic curves for subject 1 and 2 at 298 K (faster kinetics) were followed for a shorter amount of time than curves at 
279 K (slower kinetics) to minimize NMR measurement time.  Different tartrate concentrations are denoted by different symbols: Black circles: no 
tartrate, open circles: 1 mM, black triangles: 3mM, open triangles: 5mM, black squares: 10mM and open squares: 20mM. The discrepancy between 
using a low temperature of 277 K in Figure 3.2 and 279 K in this Figure is due to 279 K being the fixed temperature at which samples are stored in a 
Sample Jet sample changer.
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Apparent rate constants (kapp) were fitted to each exponential curve and are presented in 
Figure 3.4 and Table A1.1. The apparent rate constants for the hydrolysis of 
phosphorylcholine and the appearance of choline were reduced at 279 K compared with 
298 K, as well as with increasing tartrate concentration (Figure 3.4; Table A1.1). 
 
Figure 3.4: Apparent first-order rate constants (kapp) obtained from exponential fits of 
phosphorylcholine hydrolysis and choline production from the three subjects for reactions at 
298 K (left panel) and 279 K (right panel). The kapp decreases with increasing tartrate 
concentration. Lower kapp were observed for samples measured at 279 K compared to 298 K.  
3.2.4.1.3 – Influence of tartrate concentration and temperature on metabolomic analysis of 
ejaculate 
After establishing that addition of tartrate to ejaculate samples inhibits the 
phosphorylcholine to choline hydrolysis by PAP, we characterized what effects the addition 
of tartrate had on the subsequent multivariate analysis of ejaculate metabolite profiles. 1D 
NOESY spectra of samples with 0 mM and 10 mM tartrate measured at 279 K and 298 K 
at 0 and 24 hours after sample preparation were spectrally aligned, Quantile normalized 
and analyzed with Pareto-scaled PCA.  
PCA modelling of the data resulted in a model with 12 principal components (n=66, k=982, 
R2X = 0.915; Q2 = 0.764). The samples were observed to cluster into groups 
corresponding to the presence/absence of tartrate (principal component 1) and inter-
individual differences (principal component 2 – Figure 3.5a). The presence of tartrate 
(principal component 1, Figure 3.5a, b) expectedly displayed an inverse relationship with 
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choline (3.19, 3.20 ppm). Clustering in principal component 2 as a result of inter-individual 
differences, was caused by different concentrations of glycerophosphorylcholine, 
phosphorylcholine and citrate between subjects (Figure 3.5a, b).  Changes in metabolite 
peaks due to time and temperature were responsible for cluster separation in principal 
components 3 and 5, respectively (Figure 3.5c, e). Changes due to time were due to 
elevated phosphorylcholine in contrast to choline and lactate at 0 and 24 h, and with 
tartrate loadings associated to be inversely associated with early (t=0) uninhibited samples 
(Figure 3.5d).  Temperature changes were predominantly as a result of temperature-
dependent differences in peak integrals of fructose and glycerophosphorylcholine inversely 
associated with lactate and phosphorylcholine as well as peak widths of tartrate, citrate 
and spermine (Figure 3.5f). Figure 3.5c also shows the effect of tartrate inhibition 
strikingly: In the scores plot the distance between samples at 0 h and 24 h is 
systematically larger for samples without tartrate than for samples containing 10 mM 
tartrate. 
Given that 10 mM tartrate was added to more than half of the ejaculate samples in this 
PCA, it is trivial that the presence/absence of tartrate is the dominant factor seen in this 
multivariate model. However, as the tartrate signal does not overlap with any other major 
metabolite signals it can be easily excluded from the analysis to reveal the underlying 
biological effects without direct interference from tartrate. Indeed, PCA modelling of the 
same data with exclusion of the tartrate signal resulted in a statistical model with 9 
components (n=66, k=982, R2X = 0.871; Q2 = 0.772). As before, samples were observed 
to cluster in distinct groups in principal components 1-3 (Figure 3.6a, c), with principal 
components 1 and 3 corresponding with inter-individual metabolite differences (Figure 
3.6a, c), such as glycerophosphorylcholine, choline, citrate, and spermine (Figure 3.6b, d), 
previously observed in principal component 2 (Figure 3.5a, b). Sample separation in 
principal component 2 was caused by an inverse relationship between choline and 
phosphorylcholine due to the PAP-inhibiting effects tartrate and sample measurement 
time, with tartrate containing samples measured at 24 h similar to uninhibited samples at 
0 h, in general (Figure 3.6a, b). Clustering in principal component 4 was due to 
temperature differences (Figure 3.6e, f), with broader peaks observed at lower 
temperature, seen in principal component 5 of the previous analysis (Figure 3.5f).    
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Figure 3.5: Principal Components Analysis of human ejaculate NMR spectra acquired at 0 h 
(circles/triangles) and 24 h (squares/inverted triangles) following donation from three subjects 
(subject1: red, subject 2: blue, subject 3: gold), measured at different temperatures (298 K – 
squares/circles; 279 K – triangles/inverted triangles), and with (filled symbols) or without (open 
symbols) the addition of 10 mM tartrate. Panels a, c: scores plots; panels b,d: loadings plots.  
Sample clustering is observed due to the presence of tartrate and subsequent inhibition of 
phophosphorylcholine hydrolysis to choline (principal component 1) and inter-individual 
differences in metabolite (glycerophosphorylcholine, phosphorylcholine and citrate) variation 
(principal component 2, panels a – b). Metabolite peak changes as a result of time 
(phosphorylcholine, choline and lactate) and temperature (Lactate, spermine, citrate, fructose, 
glycerophosphocholine and phosphorylcholine) and caused clustering in principal components 3 
(panels c, d) and 4 (panels e, f). Metabolite abbreviations: Cho = choline; PCho = 
phosphorylcholine; G-P-Cho = glycerophosphorylcholine; Tar = tartrate; Cit = citrate.  
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3.2.4.1.1 – Univariate statistical analysis  
The presence of the 10 mM tartrate signal does not just inhibit PAP, it also acts effectively 
as a concentration standard, and thus its presence enables us to calculate the absolute 
molar concentrations of other metabolites of interest. Comparing these concentrations 
directly is able to overcome the well-established shortcomings of most data normalisation 
methods, specifically that in the presence of unbalanced regulation (= a small number of 
high-concentration metabolites whose levels are systematically changing) the normalised 
levels of other minor metabolites can appear to increase when their absolute 
concentrations are actually decreasing and vice versa318. To evaluate whether this is the 
case in ejaculate, we calculated the mean molar concentrations of the key metabolites 
identified in the MVSA models in Figure 3.6 for the six experimental groups comprising the 
tartrate-containing spectra in this analysis (three subjects, two temperatures) (Appendix 1 - 
Table A1.2). The mean absolute concentrations confirm that there are individual 
differences in glycerophosphorylcholine, citrate, lactate, spermine, phosphorylcholine and 
fructose between the subjects. However the interpersonal differences were opposite in the 
univariate analysis to what would be expected from the MVSA when comparing subjects. 
The univariate analysis also confirms that there are changes in the levels of 
phosphorylcholine, choline, citrate, spermine, fructose and lactate associated with 
temperature. These changes are similar in the multi- and univariate analysis except for 
fructose.  These results demonstrate that there are multiple cases of unbalanced 
regulation present in the ejaculate data that can be detected by the use of tartrate as 
internal concentration standard. Interestingly, phosphorylcholine is – next to choline – one 
of the two major metabolites who dominate the NMR spectra and who are thus prime 
candidates for causing unbalanced regulation. 
3.2.4.1.1 – Application to mRNA extraction and processing  
As several groups are investigating the potential of RNA and microRNA biomarkers in 
ejaculate12,15,16,319,320 and ejaculate-related fluids321, we sought to assess if the addition of 
tartrate, as well as sodium azide, a sample preservative, may change RNA expression and 
impact on subsequent interpretation of the results. We determined the expression of PSA, 
PCA3 and Hepsin in an in vitro LNCaP cell culture model in the presence of tartrate and/or 
sodium azide. Following qPCR and relative RNA quantitation normalized to β2M, PCA3, 
PSA and Hepsin expression was observed to be identical in the presence tartrate, sodium 
azide or a combination of both (Figure A1.4). This gene expression  
73 
 
 
Figure 3.6: Principal Components Analysis of ejaculate NMR spectra after exclusion of the 
tartrate signal from the dataset. Panels a, c, e: scores plots; panels b,d, f: loadings plots. 
Sample clustering is due to inter-individual variation in principal components 1 and 3 (panels a, 
c), both absence/presence of tartrate and time in principal component 2 (panel a), and altered 
peak alignment due to temperature differences, as well as tartrate inhibition of 
phophosphorylcholine hydrolysis to choline in principal component 4 (panels e, f). Symbols and 
metabolite abbreviations are as in Figure 3.5.  
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consistency in the presence of tartrate and sodium azide supports these agents being 
used as experimental adjuncts without jeopardizing the diagnostic accuracy of RNA-based 
tests. 
3.2.5 Discussion 
In this paper we established a method for reliably and reproducibly inhibiting PAP in 
samples of ejaculate by adding sodium tartrate to a concentration of 20 mM. This has 
many benefits for the use of ejaculate for clinical investigation, most notably in the early 
detection and surveillance of prostate cancer. This method maintained the inherent 
biological variation between samples despite tartrate adding an additional signal to the 
NMR spectrum (Figures 3.5a, b; 3.6a, b). In fact, the position of the tartrate singlet at 4.32 
ppm does not significantly overlap with NMR signals of other metabolites, and can easily 
be excluded from the MVSA. However, the presence of the tartrate signal offers the 
opportunity of acting as internal concentration standard in each spectrum, allowing 
determination of absolute metabolite concentrations as demonstrated in Appendix 1 - 
Table A1.2 and detection of unbalanced regulation as shown above. While absolute 
metabolite concentrations in the NMR sample can also be calculated from other internal 
standards such as DSS and DFTMP, the presence of tartrate allows for the back 
calculation of metabolite concentration in the original ejaculate. Usually that calculation is 
imprecise as an unknown and variable amount of ejaculate is added to 20 ml of PBS at 
time of sample collection. If the PBS contains a known tartrate concentration, then the final 
tartrate concentration in the NMR sample allows calculation of the dilution factor between 
ejaculate and NMR sample and thus enables calculation of ejaculate sample volume and 
absolute metabolite concentrations in ejaculate. 
Tartrate is a competitive inhibitor of PAP. This has two consequences: Firstly, the amount 
of inhibition is dependent on the tartrate concentration; secondly it is impossible to fully 
inhibit PAP with tartrate. One consequence of this is that there is residual PAP activity, 
observed even in samples with 20 mM tartrate at 279K, resulting in time dependent 
changes in choline and phosphorylcholine concentrations of 3-5% over 24 h. Furthermore, 
the time delay from sample production to data measurement was a factor in obtaining 
consistent initial (time=0) measurements for un- or weakly inhibited samples, shown by a 
lower relative final choline concentration compared to inhibited samples (Figures 3.2, 3.3) 
and increased final relative phosphorylcholine concentration at 24 h with 3 mM tartrate 
(Figure A1.3). This variation was unavoidable and would require exact sample preparation 
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and spectrometer calibration times across multiple spectrometers which is logistically not 
possible. However, at a tartrate concentration of 10 mM and with storage of samples at 
279 K, levels of choline/phosphorylcholine changed by less than 8% over 24 h (Figure 
3.3b), so that this effect has in practice been negated during typical clinical sample 
preparation procedures which are more likely to occur within 6 h rather than the 
pessimistically assumed 24 h here, allowing these metabolites to become more useful in 
metabolite profiling of ejaculate. For example, being able to accurately quantify choline-
based metabolites may allow ejaculate to be used to indicate men who may be most 
suitable for prostate cancer detection or surveillance using choline-based PET imaging. 
When used as a marker for CaP, PAP is elevated in the serum of men with advanced 
disease322. If a comparable elevation were also present in ejaculate due to a large 
intraprostatic tumour burden, this could lead to a less efficient inhibition of PAP by tartrate 
in CaP patients. However, this is unlikely to be an issue in early disease detection when 
cancer burden is small and clinically unapparent. In the absence of available data, if an 
over-estimated 2-fold increase in ejaculate PAP in early prostate cancer were considered, 
a resulting 4-6% change may be seen in choline and phosphorylcholine concentrations 
over 6 h, the expected maximum time period for clinically collected samples, compared to 
the 2-3% change over 6 h observed above in healthy subjects.  
Our results were obtained from three volunteers. In principle one could argue that this is a 
small number of study participants. However, the requirement for a large number of 
subjects in a human study is usually based on the need to reduce statistical uncertainty 
and statistical trends unrelated to biological effect when testing a hypothesis based on a 
cause-effect relationship in the face of biological diversity. In contrast, the objective of our 
study was to investigate the effects of inhibiting the ubiquitous enzyme PAP. This objective 
is more similar to determining the optimal or best intervention for an individual subject, 
similar to a N-of-1 study commonly used in clinical research. Secondly, it should be noted 
that the analysis of each subject included multiple repeats that all showed consistent 
results. Indeed, we showed that the kinetic behaviour was reliably reproducible and 
consistent within and across the three subjects. Thus, we were able to use multiple 
replicate samples to determine the effects of tartrate and temperature on the ejaculate 
metabolome of both volunteers. Scientifically, this is equivalent to validating experimental 
effects in three different cell culture methods or animal models in which the underlying 
biological principle is the same. Indeed, the effects of tartrate and temperature on PAP 
enzyme activity were consistent across all three subjects, as would be expected when 
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effectively performing a kinetic assay of the same enzyme in three subjects, and are thus 
expected to translate to samples from other patients. Finally, our study design and 
methods were based on a landmark study304, which used 3 patients, each providing 2 
samples, to characterise the biochemical processes in human ejaculate. Our study used 
13 samples and yielded equivalent results, whilst we also explored the role of tartrate and 
temperature inhibition of PAP in detail.  
The measurement of kinetic rate constants at three different temperatures and with varying 
inhibitor concentrations opens the door to several analysis methods of classical enzyme 
kinetics, including the calculation of the activation energy for the PAP-catalysed 
phophorylcholine hydrolysis. However, such an analysis needs to be interpreted cautiously 
as the kinetic curves did not exactly follow first-order kinetics and the calculated rate 
constants are thus only apparent first-order rate constants that illustrate successful PAP 
inhibition. In addition, it is known that individuals might possess multiple isoforms of 
PAP303, which contributes to this deviation from classical first-order kinetics, and prevents 
subsequent thermodynamic calculations based on the presence of a single catalytic 
enzyme. While testing for these multiple enzyme isoforms is beyond the scope of this 
manuscript, we have nevertheless undertaken an estimation of the activation energy of 
PAP for the three volunteers. The rationale is that if different people have different PAP 
isoforms (or isoform compositions) with different catalytic properties, then that should be 
reflected in different apparent activation energies.  However, our estimation shows that the 
apparent activation energy of PAP is highly similar for all three volunteers (Figure A1.5), 
meaning that if there are different isoforms they must have similar catalytic capabilities, as 
has indeed been observed in the similar behaviour of the kinetic curves and rate constants 
under inhibition between the three volunteers (Figures 3.2-3.4). This analysis supports the 
above argument that our findings from these volunteers are biochemically generalizable. 
3.2.6 Conclusion 
In summary, we found that the addition of tartrate and cooling of ejaculate samples 
improves the stability of choline and phosphorylcholine levels. Although definitely not a 
substitute for immediate processing, for samples collected off-site with a delay to 
processing, sample collection in a sterile urine jar containing 10 mM tartrate in 20 ml PBS 
solution cooled to 277 K and cooled during transport until processing may suffice, as it 
would result in at most a 2-3% change in choline and phosphorylcholine concentrations 
over 6 h, the expected maximum time period for clinically collected samples. These 
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metabolite changes were characterised at 279 K and, if anything, under-estimate the 
expected effects. Where samples are collected on-site with near-immediate processing 
available, collection in a jar containing 5 mM tartrate in 20 ml PBS solution cooled to 277 K 
is also appropriate. This reduced tartrate concentration would be expected to result in a 3-
4% change in choline and phosphorylcholine levels over 6 h. The further addition of 0.05% 
(w/v) sodium azide as antimicrobial preservative should be considered. This method 
should be implemented for ejaculate samples collected for use in multiple scientific 
experiments where sample integrity across multiple biomarker types is of utmost 
importance. Furthermore, this method may improve the clinical application of ejaculate 
NMR metabolomics and metabolite quantitation in biomarker discovery.   
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Part 3 – Results   
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Chapter 4 – Investigating the utility of ejaculate for non-
invasive prostate cancer diagnosis 
4.1 Synopsis 
The aim of this chapter was to determine the feasibility and diagnostic accuracy of 
ejaculate as a vehicle for non-invasive CaP detection and characterisation. First, PCA3 
and Hepsin mRNA and microRNAs (miRNAs) contained in the epithelial cell fraction of 
ejaculate were examined together with serum PSA (section 4.2). Second, metabolite 
profiling of ejaculate was performed using NMR-spectroscopy (section 4.3). Both studies 
examined the accuracy of acquired biomarkers to detect and characterise CaP and are 
presented as accepted (section 4.2) and submitted (section 4.3) peer-reviewed 
manuscripts. The preceding analyses for ejaculate metabolomics experiments are outlined 
in section 4.4.  
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4.2 “Diagnostic performance of expression of PCA3, Hepsin and miR 
biomarkers in ejaculate in combination with serum PSA for the 
detection of prostate cancer.”  (published manuscript) 
The manuscript entitled, “Diagnostic performance of expression of PCA3, Hepsin and miR 
biomarkers in ejaculate in combination with serum PSA for the detection of prostate 
cancer” has been published by The Prostate (2015; 75(5):539-49) 
Since publication, the manuscript has been received 8, 11 and 14 citations for Web of 
Science, Scopus and Google Scholar, respectively (as at 10/02/17).  
The contributions of the co-authors to this manuscript were as follows: Experiment design, 
patient recruitment, experiment execution, data processing, statistical analysis and clinical 
interpretation were performed by Matthew Roberts, the PhD candidate, under the 
supervision of Dr Horst Schirra and Prof RA “Frank” Gardiner. Renee Richards, Clement 
Chow and Marion Buck assisted with sample collection and biobank curation, experiment 
execution, data processing and data analysis. Suhail Doi provided guidance for statistical 
analysis and data interpretation. Hema Samaratunga, Joanna Perry-Keene, Diane Payton 
and John Yaxley provided advice on histological and clinical interpretation. Prof Martin 
Lavin provided critical manuscript revisions. Preparation of the manuscript and associated 
figures was performed by Matthew Roberts, the PhD candidate.  
The manuscript text is presented as originally published by the journal. To maintain a 
consistent style between chapters in this thesis, abbreviations, placement of figures and 
tables within the text, as well as numbering of pages, figures and tables has been 
adjusted. The references have been collated in the section, ‘Bibliography’, with others 
contained in this thesis. 
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4.2.1 Abstract 
Background and Methods: Here, we report on the evaluation of the diagnostic 
performance of ejaculate-derived PCA3, Hepsin and miRNAs to complement serum PSA 
to detect prostate cancer. cDNA was prepared from 152 candidate specimens following 
RNA isolation and amplification for PSA, PCA3 and Hepsin qPCR, with 66 having 
adequate RNA for all 3 assays. Small RNA sequencing and examination of CaP-
associated miRNAs miR-200b, miR-200c. miR-375 and miR-125b was performed on 20 
specimens. We compared findings from prostate biopsies using D’Amico and PRIAS 
classifications and in relation to whole gland histopathology following RP.  Multivariate 
logistic regression modeling and clinical risk (incorporating standard clinicopathological 
variables) were performed for all ejaculate-based markers. 
Results: While Hepsin alone was not of predictive value, the Hepsin:PCA3 ratio together 
with serum PSA, expressed as a univariate composite score based on multivariate logistic 
regression, was shown to be a better predictor than PSA alone of prostate cancer status 
(AUC  0.724 vs 0.676) and risk, using D’Amico (AUC  0.701 vs 0.680) and PRIAS (AUC  
0.679  vs 0.659) risk stratification criteria as classified using prostate biopsies. It was also 
possible to analyse a subgroup of patients for miRNA expression with miR-200c (AUC 
0.788) and miR-375 (AUC 0.758) showing best single marker performance, while a 
combination of serum PSA, miR-200c and miR-125b further improved prediction for 
prostate cancer status when compared to PSA alone determined by biopsy (AUC 0.869 vs 
0.672; p < 0.05), and risk (D’Amico/PRIAS) as well as by RP histology (AUC 0.809 vs 
0.690). For prostate cancer status by biopsy, at a sensitivity of 90%, the specificity of the 
test increased from 11% for PSA alone to 67% for a combination of PSA, miR-200c and 
miR-125b.  
Conclusion: These results show that use of a combination of different types of genetic 
markers in ejaculate together with serum PSA are at least as sensitive as those reported in 
DRE urine. Furthermore a combination of serum PSA and selected miRNAs improved 
prediction of prostate cancer status. This approach may be helpful in triaging patients for 
MRI and biopsy, when confirmed by larger studies.  
 
Keywords: prostate cancer: PCA3, Hepsin and PSA: mRNA and microRNA: ejaculate  
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4.2.2 Introduction 
The two-step process (PSA and biopsy) of early detection of CaP is fraught with 
imprecision. Initial limitations relate to deficiencies of the standard first-line test, serum 
PSA, which lacks a lowermost cut-point and has a continuum of CaP risk with increasing 
values323. However, despite its deficiencies, published evidence has indicated that total 
serum PSA concentration remains the single most significant clinically-used predictive 
factor for identifying men at increased risk for CaP191 and is the parameter on which 
adaptations such as free:total PSA, PSA velocity, PSA density and phi are based193. 
An abnormal serum PSA level and/or an abnormal DRE lead to the second step in 
detecting CaP, namely prostatic biopsy. Since histological evidence of tumour is required 
for diagnosis and the majority of tumours arise posteriorly in the peripheral zone, TRUSBx 
has become entrenched as the standard method for obtaining prostatic tissue for 
diagnosis, with >10 cores now generally recommended324. However, TRUSbx targets the 
anterior prostate poorly so that up to approximately one third of CaPs may be missed by 
this approach213, particularly in large glands212.  Transperineal biopsy (TPbx) is 
theoretically a more accurate technique but is used less often due to time and logistical 
constraints325. Consequently, TRUS directed biopsy remains the standard approach, at 
least in the first instance. These limitations become even more significant when it is 
appreciated that the majority of men undergoing TRUSbxs for suspected CaP do not have 
CaP detected and may have further biopsies, as do men with low-risk CaP who elect to be 
managed by an active surveillance regimen213. 
Of the non-PSA based first line tests, the PCA3 urine test is most widely used326 and 
involves analyzing the first part of a specimen of voided urine after milking the prostate by 
firm DRE or prostatic massage to provide prostatic fluid from the posterior part of the 
gland. This approach is required if voided urine is to be used since there are otherwise too 
few cells present in a freely voided specimen. Although the PCA3 test has been reported 
to improve detection of CaP compared with PSA in a pre-screened population, its role in 
initial assessment of patients suspected of having CaP has yet to be established as a first-
line, stand-alone investigation327.  Addition of other RNA markers to the ‘PCA3 urine test’, 
such as the TMPRSS2:ERG fusion gene, has been reported in some, but not all cases, to 
improve cancer prediction10,211,328,329.  
Increasingly, mpMRI is being employed for CaP detection, although it is yet to be 
approved for routine clinical use330. An attraction is that MRI permits avoidance of many 
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unnecessary biopsies and facilitates targeted rather than multiple ‘blind’ biopsies to locate 
significant malignant lesions331. However, mpMR imaging misses up to 30% of CaPs and 
up to 10% of significant tumours330 so, together with logistical and cost implications, its 
acceptability as a further investigation for every man suspected of harbouring CaP is 
limited. Consequently, the need for an inexpensive, non-invasive test to determine whether 
or not CaP is present and, better still, if a lesion is significant, remains an imperative.  
Approximately 40% of ejaculate is derived from prostatic epithelia so that its contents are 
most likely to contain disease-specific biomarkers. Following our observation that 
abnormal prostatic cells in ejaculate correlated with and predated biopsy diagnosis of CaP, 
in some cases by years14, we identified 4 mRNA markers that detected 100% of CaPs in 
tissues206,241. PCA3 and Hepsin have proven to be the most predictive332. In preliminary 
analyses, a combination of PCA3 and Hepsin with serum PSA consistently provided a 
combined sensitivity and specificity >75%332. Our results with ejaculate paralleled those of 
other investigators who examined a range of markers, mostly in urine, so we have 
continued to evaluate ejaculate, with respect to other marker expression to complement 
PCA3 and Hepsin expression and improve sensitivity and specificity. We recently profiled 
and compared ejaculate miRNAs from men with subsequently proven CaP by biopsy and 
men suspected of having CaP but biopsy results were negative16. Using deep small RNA 
sequencing followed by quantitative RT-PCR validation, we showed that 5 miRNAs were 
significantly elevated in ejaculate from CaP patients and that each of these miRNAs 
outperformed PSA as a diagnostic tool16. These observations are in keeping with pooled 
results from different studies which suggest that miRNA analysis can significantly improve 
the overall accuracy of CaP diagnosis333. Our focusing on ejaculate as relevant for 
prostate cancer research has been supported by others who have also recognized its 
diagnostic potential334,335.  
The aim of this study was to examine the predictive ability of PCA3 and Hepsin mRNA  
from ejaculate together with serum PSA to identify those patients who presented for 
prostatic biopsy but who, with the benefit of hindsight, may have been spared this 
procedure and treatment with curative intent had discriminating test(s) been available 
clinically. We also determined the potential of miRNA, previously identified by this group as 
elevated in CaP, in combination with the other markers to improve diagnosis. In order to 
maximise accuracy, we updated information from repeated biopsies to exclude those 
patients whose initial TRUSbxs had missed their tumours. In addition, we included more 
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accurate RP findings from a subgroup of patients, none of the men in this study having 
had mpMRI examinations to aid in locating dominant lesions. 
4.2.3 Materials and Methods 
4.2.3.1 – Patients  
Men (n = 152) suspected of having CaP on the basis of an elevated serum PSA and/or an 
abnormal DRE provided specimens of ejaculate collected immediately in sterile micro-
urine jars containing 20 ml Hanks Balanced Salt Solution (HBSS) (Gibco), subsequently 
replaced by PBS for the last 35 patients (due to glucose content in HBSS affecting other 
biomarker discovery techniques) between January 2007 and February 2013. All 
participants have been followed closely to monitor initial biopsy findings, in particular to 
identify false negative findings subsequently corrected by further biopsy results, and to 
relate biopsy histopathology findings to those from RP for men who proceeded to surgery 
(n = 61). Ejaculate specimens were collected prior to TRUSbx or over one month following 
TRUSbx or TPbx.  All specimens were brought without cooling to the hospital by the 
patients and transferred to the laboratory and processed within 2 h of production. 
Ethics approval was obtained from the University of Queensland Medical Research Ethics 
Committee (Project no. 2006000262) and the RBWH Human Research Ethics Committee 
(HREC/09/QRBW/320, HREC/09/QRBW/305 together with 1995/088B). 
4.2.3.2 – Clinical data 
Clinical details for each patient, including serum PSA, were obtained through Queensland 
Health pathology software, AUSLAB, supplemented by reports outside the hospital from 
the private pathology firms Queensland Medical Laboratories (Siemens Centaur ® assay) 
and Sullivan Nicolaides Pathology (Abbott Architect ® assay).  
All TRUSbx and TPBx histology specimens were reported and reviewed by DP, JP-K and 
MLTHS using the 2005 International Society of Urological Pathology (ISUP) 
classification336 with standard biopsy (number of cores, number of positive cores, 
percentage, Gleason score) and RP (Gleason score, pathological stage, gland size, 
margin status, extracapsular status and pathological stage) parameters recorded. Risk 
stratification for biopsies were those recommended in the American Urological Association 
Guidelines  based on D’Amico et al.337 for biopsies, and the Prostate Cancer Research 
International: Active Surveillance (PRIAS) inclusion criteria (low-risk category)338, and 
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those outlined in Table 4.1. Our analyses of the PCR findings were based on histology that 
was most representative of tumour grade both TRUSbx and TPBx, as well as RP 
histopathology because of the well-known disparity between many TRUSbx and RP 
histopathology findings.  
Patients were classified into two clinical groups according to the three different 
classification schemes outlined in Table 4.1. They cover either: 
1. a distinction between any presence of CaP and no evidence of malignancy 
(noCaP), (Scheme 1) based on pathological evidence of CaP on either initial biopsy 
histology, or on updated histology for those men who had further biopsies or tissue 
sampling (e.g. via transurethral resection) as indicated clinically, or  
2. a distinction between high/intermediate-risk CaP and low-risk CaP combined with 
noCaP based on D’Amico (Scheme 2) or PRIAS (Scheme 3). Schemes 2 and 3 
thus distinguish between the types of CaP requiring medical intervention (scheme 
2: D’Amico high/intermediate risk; scheme 3: PRIAS high/intermediate risk) and 
those prostatic conditions that do not warrant definitive cancer treatment (scheme 2: 
D’Amico negative/low risk; scheme 3: PRIAS negative/low risk).  
Classification         
Scheme                    
Classification    
categories 
Serum PSA Biopsy RP 
1. Cancer status 
based on biopsy 
noCaP Serum PSA 
not used for 
classification 
Absence of CaP  
CaP Presence of CaP  
2. Risk status 
based on 
D’Amico 
Negative/ 
Low risk 
Any Serum PSA AND absence of CaP on Biopsy 
< 10 ng/ml Gleason ≤ 3+3 
High risk > 10 ng/ml Gleason ≥ 3+4 
3. Risk status 
based on 
PRIAS 
Negative/  
Low risk 
Any Serum PSA AND absence of CaP on Biopsy 
< 10 ng/ml Gleason ≤3+3 in <50% 
of no more than 2 
cores and cT1c/cT2 
stage 
As in biopsy + < 
1cm3 no extra 
prostatic extension; 
pT1c/ pT2 
High risk a > 10 ng/ml All other CaP All other CaP 
Table 4.1: Patient classification schemes, including both CaP status (positive/negative) and 
clinical risk (as determined by D’Amico or PRIAS criteria). noCaP = no evidence of 
malignancy; High risk = requires immediate treatment; Negative/Low risk = no immediate 
treatment is required. a The latter group is ineligible for Active Surveillance and deferred 
active treatment or further investigation is advised. The table includes two stratifications for 
serum PSA together with biopsy and RP findings. 
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4.2.3.3 – Radical Prostatectomy 
Because there are often disparities between biopsy and RP histopathology (with the latter 
considered to be the ‘gold standard’), we also analysed our data using RP histopathology 
as the benchmark as opposed to biopsy. 
4.2.3.4 – Specimen processing 
Ejaculate reconstituted in either 20 ml Hanks, subsequently changed to PBS to avoid 
confounding effects of glucose in parallel metabolomics studies, was layered over 10 ml 
isotonic Percoll (GE Healthcare-Pharmacia) and centrifuged at 974×g for 30-60 min at 4oC 
and samples were collected in 1 ml aliquots, snap-frozen on dry ice and stored at -80oC. 
The epithelial cell layer at the Percoll interface (which appeared as a discrete band in the 
middle of the test tube with supernatant above and with sperm and non-cellular 
components at the bottom was then pipetted, washed with 25 ml PBS or Hanks and 
centrifuged at 1258×g for 10 min at 4oC. Cells were subsequently subjected to total RNA 
isolation.  
4.2.3.5 – RNA isolation and amplification 
Total RNA was isolated using TRIzol reagent (Invitrogen) followed by a clean-up inclusive 
DNase treatment with the RNeasy kit (Qiagen). Amplification was performed with the 
SenseAmp kit (Gensisphere). For the cDNA synthesis, Superscript III (Invitrogen) and 
random hexamer primers were used. 
4.2.3.6 – cDNA synthesis and qPCR 
qPCR was performed using the QIAGEN Quantitect SYBR green qPCR Mastermix 
(QIAGEN, Germany) on a Corbett Rotorgene machine 3000/6000 (Corbett Research, 
Australia). 200-500 ng of total RNA were reverse transcribed into cDNA using Superscript 
III (Invitrogen) in the presence of random primers (Promega). The synthesized cDNA was 
diluted 10-fold and 5 µl was used for the assay in the presence of 7.5 µl Quantitect SYBR 
green mastermix (Qiagen) and 5 pmol gene specific forward and reverse primers. Each 
reaction was carried out in triplicates for both patient samples and calibrator. Reaction 
conditions were 95°C for 15 min followed by 45 cycles of 20 s at 95°C, 20 s at 58°C and 
20 s at 72°C. Data for each cycle was acquired at the 72°C for 20 s step. 
The primers (Sigma-Aldrich, Australia) for qPCR were: PCA3 (Fwd: 5’-
GGAAGGACCTGATGATACAGAGGTGAG-3’, Rev: 5’-CACAGGGCGAGGCTCATCG-3’; 
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Hepsin (Fwd: 5’-TGTACCCAGTGCAGGTCAGC-3’, Rev: 5’-
CGTCCCTTCCGTCTTGTCAA-3') and PSA (Fwd: 5’-GCATCAGGAACAAAAGCGTG-3’, 
Rev:5’-CCTGAGGAATCGATTCTTCA-3’). 
All runs underwent standardized processing (including standard curve fitting, dynamic 
tube, slope correct, using Rotor-Gene 6000 Series Software Version 1.7 (Corbett 
Research, Australia). Samples with atypical melt curves as well as quantitation curves that 
did not pass the threshold value for any single target (but had normal melt curves) were 
excluded (n = 55), as were samples with only one technical replicate yielding results (n = 
8), or samples that yielded insufficient RNA for cDNA synthesis (n = 11). A single threshold 
value was manually set for each individual gene across all samples and subsequently 
calculated cycle threshold (Ct) values were exported to Excel (Microsoft Corporation, 
Redmond, CA). Based on average Ct (CtAv) and standard deviation (CtSD) values 
observed across all tests (see Appendix 2 – Figure A2.1), CtAv > 35 and CtSD > 1.5 were 
defined as the cutoff points for exclusion (n = 12) leaving 66 samples for further data 
analysis.  
A method for calculating relative gene expression, previously described by Pfaffl316, was 
applied in the analysis of the real-time PCR results. The Pfaffl equation is as follows: 
Expression (R) = EGOI∆Ct(Calibrator-sample)/ERef∆Ct(Calibrator-sample) 
“∆Ct (Calibrator - sample)” in this equation estimates the difference in amplification (Ct 
values) between the target gene transcription of the sample reaction (unknown) and the 
calibrator reaction (uniform template quantity to standardize all the runs)316. This method 
also considers the reaction efficiency (E) of the gene of interest (GOI) and the endogenous 
RG, without a requirement for use of a standard curve in every run by assuming the 
reaction efficiency between different runs was consistent and normalized by the calibrator 
used. In accordance with the well-established method for determining PCA3, the RG used 
was PSA208. 
4.2.3.7 – Inclusion of miRNAs 
Recent investigations by our group confirmed ejaculate as a source of prostate cancer 
specific miRNA biomarkers16. Small RNA-seq (TruSeq Workflow, Illumina; San Diego, CA, 
USA) was used to profile RNA collected from the non-sperm cellular fraction of ejaculate, 
processed as described above and in Selth et al16. CaP-associated miRNAs (miR-200b, 
miR-200c, miR-375, miR-125b) were examined for 48 patients, a subset for whom PCA3 
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and Hepsin were also appropriately quantified in the current study (n=20). The previously 
generated miRNA data set were thus incorporated with the new data in a stepwise logistic 
regression for multivariate predictability. 
4.2.3.8 – Data analysis 
Data were collated in Excel. Hepsin and PCA3 scores were calculated with reference to 
PSA in ejaculate. A Hepsin:PCA3 ratio was also calculated, following preliminary analysis 
that indicated the two markers (relative to PSA-PCR) to be inversely associated (see 
Results).  
The qPCR results were analysed using the three clinical classifications outlined in Table 
4.1 and are reported for their ability to distinguish: 
1. CaP versus negative biopsy/no CaP (noCaP) 
2. Based on D’Amico, those requiring treatment (D’Amico high/intermediate risk) 
versus those not requiring treatment (D’Amico negative/low risk)  
3.  Based on PRIAS, those requiring treatment (PRIAS high/intermediate risk) versus 
those eligible for active surveillance, thus not requiring treatment (PRIAS 
negative/low risk) 
First, clinical characteristics were reported based on presence or absence of CaP. Data 
was tested for normality with the Shapiro-Wilk test. Where normality was accepted, 
significance testing was performed using Student’s t-test (following F-testing indicating 
equal variance), and where normality was rejected, the non-parametric Mann-Whitney U 
test was used. The predictive ability of each clinical marker was determined and compared 
using Receiver Operating Characteristic (ROC) analysis, calculated using the DeLong 
method339 and binomial exact Confidence Interval. Stepwise logistic regression (p to enter 
0.3; p to remove 0.35) was performed to ascertain the independent predictors by the CaP 
criterion (which was expressed as categorical variables: 1 = present, 0 = missing). This 
was done separately after inclusion of PCR markers (composite 1) and after inclusion of 
both PCR and miR markers (composite 2) with the PSA. The beta coefficients of selected 
variables were used to create the composite scores for composite1 and composite2 and 
their diagnostic performance evaluated and compared to PSA alone. Since stepwise 
regression selects only independent predictors of outcome into the model, we verified that 
our final models were properly specified by using a model specification (link) test, making it 
unlikely that any correlated variables were included in the model.  All reported p-values < 
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0.05 were considered statistically significant. Statistical analysis was performed using 
MedCalc for Windows, Version 12.7 (MedCalc Software; Ostend, Belgium) 
4.2.3 Results 
4.2.3.1 – Clinical characteristics  
Of the 152 men who provided specimens between January 2007 and February 2013, 54 
had non-cancerous histology and 98 had cancer detected by biopsy. Across the six year 
follow up period, 18 patients (12%) demonstrated CaP on further biopsies (Table 4.2), 
which were performed because of a clinical suspicion that CaP had been missed. The 
median (interquartile range; IQR) time elapsed between the first and second biopsy was 
12.51 (9.27 – 21.76) months.    
Characteristic n noCaP CaP (on Bx) CaP (treated by RP) 
Age 66 64 (59 – 71) 59 (55 – 68)NS 56 (54 – 65.5) 
Serum PSA 5.8 (3.25 – 6.95) 6.5 (5.13 – 10.25)* 6.25 (4.35 – 9.8) 
PCA3 0.99 (0.38 – 1.73) 1.69 0.73 – 7.77) NS 1.95 (0.78 – 8.69) 
Hepsin 0.47 (0.14 – 1.96) 0.37 (0.11 – 1.74) NS 0.33 (0.18 – 1.40) 
Hepsin/PCA3 1.13 (0.25 – 2.53) 0.21 (0.06 – 1.52) NS 0.21 (0.02 – 1.69) 
miR-200b 20 -6.04 (-9.31 – -5.12) -4.76 (-6.28 – -2.35) NS -5.93 (-6.85 – -4.12) 
miR-200c -3.86 (-4.87 – -3.02) -2.24 (-3.36 – -1.45)* -3.16 (-4.09 – -2.34) 
miR-375 -5.32 (-6.22 – -4.36) -3.45 (-5.25 – -2.54) NS -4.94 (-5.58 – -3.72) 
miR-125b -4.90 (-5.44 – -3.71) -3.88 (-5.45 – -1.69) NS -5.20 (-6.10 – -3.25) 
D'Amico (per Bx histology) 
Negative/Low risk 21 (32%) 8 (12%) 3 (5%) 
High risk b 
 
37 (56%) 25 (38%) c 
PRIAS (per Bx histology) 
Negative/Low risk a 21 (32%) 7 (10%) 2 (3%) 
High risk b 
 
38 (58%) 26 (39%) c 
Table 4.2: Demographic information for patients undergoing prostate biopsy (Bx) based on 
different classification methods used (D’Amico, PRIAS). * p < 0.05, NS = non-significant following 
Mann-Whitney U-test (two-tailed) based on raw values for “No CaP” versus “CaP (on Bx)”; a 
This group is ineligible for Active Surveillance and deferred active treatment or further 
investigation is advised. b This group contains patients who were classified as Intermediate or 
High risk (D’Amico) or ineligible for Active Surveillance (PRIAS). c  All patients were 
subsequently classified as high risk based on RP histology (n = 28). 
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Of the 98 patients with a prostate biopsy positive for CaP, 61 underwent RP (Table 4.2). 
Of the remaining 37 patients, 17 proceeded to receive radiation based therapy (External 
Beam Radiation Therapy or brachytherapy), one commenced androgen deprivation 
therapy for metastatic disease, 7 were lost to follow up, and the remainder (n=12) are 
undertaking conservative management in the form of active surveillance (n=7) or watchful 
waiting (n=5). When patients were classified into D’Amico or PRIAS risk groups as outlined 
in the methods section, the group assignments produced identical statistical results 
reflecting comparability of these stratification schemes.  
Following relative expression calculations, inclusion of PSA, PCA3 and Hepsin was 
possible for 66 patients These were due to strict exclusion criteria (see Materials and 
Methods section and Figure A2.2), with 63 having unsatisfactory q-PCR analyses (55 with 
atypical melt or quantitation curves and 8 having only single samples), 11 having 
insufficient RNA for cDNA synthesis and 12 with Ct values (CtAv or CtSD) outside defined 
cut-offs. The relationships observed for the entire cohort with respect to age and serum 
PSA were preserved in this group. 
Demographic information on the cohort including median (IQR) age, serum PSA, PCA3, 
Hepsin, Hepsin/PCA3 and miR’s (miR-200c, miR-200b, miR-375, miR-125b) for each 
group are presented in Table 4.2. The categorization schemes outlined in Table 4.1 are 
also indicated in terms of CaP diagnosis via biopsy. Serum PSA was significantly higher in 
men with CaP on biopsy [6.5 (IQR 5.13 – 10.25) ng/ml] compared with those in the no CaP 
group [5.8 (IQR 3.25 – 6.95) ng/ml; p < 0.05]. 
4.2.3.2 – Ejaculate PCA3 and Hepsin expression performance using the biopsy criterion 
For biopsy-based CaP status and risk classification (Table 4.3), PCA3 and Hepsin/PCA3 
displayed varied performance depending on the classification method, with best 
performance observed for CaP status being AUC of 0.625 (95% CI 0.498 – 0.742) for 
PCA3 and 0.650 (95% CI 0.522 – 0.763) for Hepsin/PCA3 and both were inferior to serum 
PSA with an AUC of 0.676 (95% CI 0.550 to 0.786). Performance of Hepsin by itself was 
consistently poor across all classifications (AUC range 0.517 – 0.559), further supporting 
its use as a RG in this context. For prediction of CaP status, a logistic regression based 
composite score combining serum PSA and Hepsin:PCA3 demonstrated best 
discriminative  performance [AUC 0.724 (95% CI 0.600 – 0.827), Figure 4.1A]. Similar 
estimates were observed for predicting CaP risk using both D’Amico (Table 4.4) and 
PRIAS (Table 4.5) based risk classifications. 
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Scheme 1 – CaP based on Biopsy 
n Biomarker AUC 95% CI Sp (95% CI) a LR+ 
66 Serum PSA b,c (cut-off 
>3.45ng/ml) 
0.676 0.550 to 0.786 28.57 (4.76 - 47.62) 1.28 (91% Sn) 
Hepsin (cut-off ≤7.1428) 0.517 0.391 to 0.642 9.52 (0.00 - 28.57) 1.03 (93% Sn) 
PCA3 (cut-off >0.1827) 0.625 0.498 to 0.742 19.05 (0.00 - 33.33) 1.07 (87% Sn) 
Hepsin:PCA3 b (cut-off ≤4.296) 0.650 0.522 to 0.763 19.05 (0.00 - 38.10) 1.13 (91% Sn) 
Composite1 b (cut-off >3.0492) 0.724 0.600 to 0.827 38.10 (9.52 - 61.90) 1.47 (91% Sn) 
20 miR-125b c (cut-off >-6.3274) 0.606 0.366 to 0.813 22.22 (0.00 - 66.67) 1.17 (91% Sn) 
miR-200b (cut-off >-7.0847) 0.717 0.475 to 0.892 44.44 (0.00 - 88.89) 1.64 (91% Sn) 
miR-200c c (cut-off >-4.4428) 0.788 0.550 to 0.936 33.33 (0.00 - 55.56) 1.50 (100% Sn) 
miR-375 (cutoff >-5.7315) 0.758 0.517 to 0.918 44.44 (0.00 - 66.67) 1.80 (100% Sn) 
Composite2 c (cutoff >-2.4592) 0.869 0.705 to 1.00 66.67 (5.00 - 100.00) 2.7 (91% Sn) 
Table 4.3: ROC analysis summary for available biomarkers for CaP status based on most 
recent biopsy histology. a Sp: Specificity (95% CI – BCa bootstrap interval with 1000 iterations) 
at 90% Sensitivity;  b Composite 1 based on PSA and Hepsin/PCA3; c composite2 based on 
PSA, miR200c and miR125b. LR+ = positive likelihood ratio. 
 
Figure 4.1: Receiver Operating Characteristic curve analysis of serum PSA and Composite1 
(serum PSA, Hepsin:PCA3; panel A; p > 0.05) and Composite2 (serum PSA, miR-125b, miR-
200c; panel B; *p = 0.044) in predicting prostate cancer status (based on biopsy result). The 
area under the curve (AUC) is indicated.  
  
0 20 40 60 80 100
0
20
40
60
80
100
100-Specificity
S
e
n
s
it
iv
it
y
Composite1 (AUC 0.724)
Serum PSA (AUC 0.676)
A 
0 20 40 60 80 100
0
20
40
60
80
100
100-Specificity
S
e
n
s
it
iv
it
y
Composite2 (AUC 0.869)*
Serum PSA (AUC 0.672)
B 
93 
 
Scheme 2 – D’Amico risk based on: 
 Biopsy RP 
N Biomarker AUC 95% CI Sp (95% CI) a LR+ 
(sensitivity) 
AUC 95% CI Sp (95% CI) a LR+ 
(sensitivity) 
66 Serum PSA b,c 
(cut-off >3.57; >3.36 ng/ml) 
0.680 0.554 to 0.790 30.00 
(12.76 - 49.66) 
1.29 (89% Sn) 0.619 0.469 to 0.754 27.62 
(0.00 - 47.62) 
1.25 (89% Sn) 
Hepsin 
(cut-off >0.087; ≤5.8126) 
0.551 0.423 to 0.674 20.69 
(0.00 - 37.93) 
1.12 (89% Sn) 0.520 0.373 to 0.665 9.52 (0.00 - 28.57) 0.99 (89% Sn) 
PCA3 
(cut-off >0.1592; >0.1744) 
0.566 0.438 to 0.687 13.79 
(0.00 - 24.14) 
1.13 (97% Sn) 0.643 0.493 to 0.775 19.05 
(0.00 - 33.33) 
1.10 (89% Sn) 
Hepsin:PCA3 b 
(cut-off ≤4.0024; ≤6.0477) 
0.563 0.435 to 0.685 17.24 
(0.00 - 31.03) 
1.11 (92% Sn) 0.651 0.502 to 0.782 14.29 
(0.00 - 28.57) 
1.04 (89% Sn) 
Composite1 b 
(cut-off >3.189; >2.8446) 
0.701 0.576 to 0.807 37.93 
(15.22 - 55.17) 
1.48 (92% Sn) 0.665 0.516 to 0.793 33.33 
(0.00 - 57.14) 
1.34 (89% Sn) 
20 miR-125b c 
(cut-off >-8.6917; >-6.3274) 
0.542 0.308 to 0.763 0.00 (0.00 - 0.00) 0.88 (88% Sn) 0.606 0.366 to 0.813 22.22 (0.00 to 
66.67) 
1.17 (91% Sn) 
miR-200b 
(cut-off >-14.1977; >-7.0847) 
0.646 0.404 to 0.843 0.00 (0.00 - 0.00) 0.88 (88% Sn) 0.717 0.475 to 0.892 44.44 
(0.00 - 88.89) 
1.64 (91% Sn) 
miR-200c c 
(cut-off >-4.3471; >-4.4428) 
0.719 0.476 to 0.894 33.33 
(0.00 - 50.00) 
1.31 (88% Sn) 0.788 0.550 to 0.936 33.33 
(0.00 - 55.56) 
1.50 (100% 
Sn) 
miR-375 
(cut-off >-5.6771; >-5.7315) 
0.667 0.424 to 0.858 41.67 
(0.00 - 58.33) 
1.71 (100% 
Sn) 
0.758 0.517 to 0.918 44.44 
(0.00 - 66.67) 
1.80 (100% 
Sn) 
Composite2 c 
(cut-off >-2.2677; >-2.4592) 
0.844 0.655 to 1.00 58.33 
(22.82 - 83.33) 
2.4 (100% Sn) 0.869 0.644 to 0.976 66.67 
(5.00 - 100.00) 
2.73 (91% Sn) 
Table 4.4: ROC analysis summary for available biomarkers using D’Amico-based risk stratification as determined by biopsy and RP histology. a Sp: 
Specificity (95% CI – BCa bootstrap interval with 1000 iterations) at 90% Sensitivity;  b Composite 1 based on PSA and Hepsin/PCA3; c composite2 
based on PSA, miR200c and miR125b. LR+ = positive likelihood ratio. 
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Scheme 3 – PRIAS risk based on 
 Biopsy RP 
N Biomarker AUC 95% CI Sp (95% CI) a LR+ 
(sensitivity) 
AUC 95% CI Sp (95% CI) a LR+ 
(sensitivity) 
66 Serum PSA a,b  
(cut-off >3.48; >3.36 ng/ml) 
0.659 0.532 to 0.772 25.00 
(3.57 - 39.29) 
1.19 (89% Sn) 0.619 0.469 to 0.754 27.62 
(0.00 - 47.62) 
1.25 (89% Sn) 
Hepsin  
(cut-off >0.0871; ≤5.8126) 
0.559 0.432 to 0.681 21.43 
(0.00 - 39.29) 
1.14 (89% Sn) 0.520 0.373 to 0.665 9.52 (0.00 - 28.57) 0.99 (89% Sn) 
PCA3  
(cut-off >0.1651; >0.1744) 
0.547 0.420 to 0.670 14.29 
(0.00 - 25.00) 
1.14 (97% Sn) 0.643 0.493 to 0.775 19.05 
(0.00 - 33.33) 
1.10 (89% Sn) 
Hepsin:PCA3 a  
(cut-off ≤3.8556; ≤6.0477) 
0.542 0.415 to 0.666 17.86 
(0.00 - 28.57) 
1.12 (92% Sn) 0.651 0.502 to 0.782 14.29 
(0.00 - 28.57) 
1.04 (89% Sn) 
Composite1 a  
(cut-off  >3.0729 ; >2.8446) 
0.679 0.552 to 0.788 32.14 
(8.43 - 50.00) 
1.36 (92% Sn) 0.665 0.516 to 0.793 33.33 
(0.00 - 57.14) 
1.34 (89% Sn) 
20 miR-125b b  
(cut-off ≤-1.3024; >-6.3274) 
0.505 0.276 to 0.732 9.09 
(0.00 - 27.27) 
1.10 (100% Sn) 0.606 0.366 to 0.813 22.22 (0.00 to 
66.67) 
1.17 (91% Sn) 
miR-200b  
(cut-off >-14.1977; >-7.0847) 
0.596 0.357 to 0.806 0.00 (0.00 - 0.00) 0.89 (89% Sn) 0.717 0.475 to 0.892 44.44 
(0.00 - 88.89) 
1.64 (91% Sn) 
miR-200c b  
(cut-off >-4.4824; >-4.4428) 
0.646 0.404 to 0.844 27.27 
(0.00 - 45.45) 
1.37 (100% Sn) 0.788 0.550 to 0.936 33.33 
(0.00 - 55.56) 
1.50 (100% Sn) 
miR-375  
(cut-off >-5.7583; >-5.7315) 
0.606 0.366 to 0.813 36.36 
(0.00 - 54.55) 
1.57 (100% Sn) 0.758 0.517 to 0.918 44.44 
(0.00 - 66.67) 
1.80 (100% Sn) 
Composite2 b 
 (cut-off >-10.8483; >-2.4592) 
0.758 0.522 to 0.993 18.18 
(0.00 - 36.36) 
1.22 (100% Sn) 0.869 0.644 to 0.976 66.67 
(5.00 - 100.00) 
2.73 (91% Sn) 
Table 4.5: ROC analysis summary for available biomarkers using PRIAS-based risk stratification as determined by biopsy and RP histology. a Sp: 
Specificity (95% CI – BCa bootstrap interval with 1000 iterations) at 90% Sensitivity;  b Composite 1 based on PSA and Hepsin/PCA3; c composite2 
based on PSA, miR200c and miR125b. LR+ = positive likelihood ratio.
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4.2.3.3 – Ejaculate PCA3 and Hepsin expression performance using RP histology criterion 
Risk classification according to RP histology was possible for a subgroup of 49 patients 
(Table 4.2), in which D’Amico and PRIAS classifications were identical. Within this group, 
the composite score (Composite1) combining Hepsin:PCA3 with serum PSA [AUC 0.665 
(95% CI 0.516 – 0.793) demonstrated superior performance to serum PSA or other 
individual biomarkers (Tables 4.4 & 4.5).  
4.2.3.4 – Incorporating diagnostic potential of miRNAs in ejaculate 
Integration of serum PSA, Hepsin and PCA3 results with miRNAs previously quantified by 
our group was performed as a preliminary feasibility investigation. Small RNA for this 
investigation was only available for 20 patients with biopsy- and RP-based classifications 
(11 with CaP). For biopsy-based classification, miR-200c and miR-375 showed best single 
marker performance in this group (Tables 4.3-4.5).Serum PSA, miR-200c and miR-125b 
were most discriminatory when combined as a composite score (Composite2) derived 
from logistic regression (Table A2.1, Figure 4.1B). This discrimination was demonstrated 
for CaP status based on biopsy [AUC 0.869 (95% CI 0.705 – 1.000)] and CaP risk 
determined by RP histology [AUC 0.869 (95% CI 0.644 – 0.976)] with a specificity estimate 
of 67% at 90% sensitivity (Tables 4.3-4.5). Furthermore, a consistent positive likelihood 
ratio of ≥ 2.7 was observed for Composite2 estimates across all classification methods 
(Tables 4.3-4.5). 
4.2.4 Discussion  
A pervading concern with any CaP diagnostic study is the true status of the biopsy 
negative (no CaP) patients. This issue also extends to cases where less dominant lesions 
are biopsied with the more significant tumours missed, in what is often multifocal disease 
within the prostate. Although this problem of inaccurate pathological status is likely to 
become less of an issue in the future with MRI referencing, MRI was not available for any 
of these patients. Thus, the best that could be done in this study was to ensure that the 
number of cores was 12 or more and that an adequate period had elapsed before 
analysing the data so that any clinical suspicion of a ‘missed tumour’ could be addressed. 
For this cohort, the monitoring period was a minimum of 13 months that extended to 88 
months for the earliest donors. Forty-one patients had second and third TRUSbxs or 
TPBxs or subsequent transurethral resection of the prostate and, as a consequence, 18 
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men whose initial biopsies were negative had their tumour status changed to CaP 
following further biopsies.   
Limitations with current diagnostic tests for CaP necessitate identification of new molecular 
biomarkers for prognosis and patient follow-up340. An automated assay for PCA3, 
Progensa™ PCA3, relying on urine collection after prostate massage was shown to have 
excellent clinical value based on repeat biopsies207. Nevertheless, the detection rate was 
<50% in patients with PCA3 scores >300. In a large study of 1962 cases with PSA 
>2.5ng/ml, PCA3 (AUC 0.706) performed better than PSA (AUC 0.569) but when these 
two markers were combined AUC improved to 0.720341. As many as 50% of CaP patients 
possess a fusion between the androgen-regulated gene, TMPRSS2, and the ETS family 
member, TMPRSS2:ERG342.While a correlation between ERG expression and clinical and 
pathological parameters has not been observed, specificity and recurrence of ERG in CaP 
suggests that it may be a useful adjunct diagnostic biomarker343. In another study a strong 
link was recorded between ERG activation, young patient age and low grade cancer344. 
Although a combination of PCA3 and phi has recently been reported to only moderately 
enhance diagnostic power for CaP with first or repeated prostatic biopsies10, combining 
TMPRSS2-ERG, PCA3 and phi may be complementary, reflecting other predictors of 
cancer aggressiveness329.  
In this study we employed a combination of gene, miRNA and protein markers in an 
attempt to improve the efficiency of detection of CaP. The performance of this combined 
set of markers in ejaculate for the 66 selected patient specimens gave comparable results 
to those obtained with DRE-urine by other investigators but, unexpectedly, PCA3 alone 
was not more predictive than serum PSA for this patient cohort.  
For the combination of serum PSA, PCA3 and Hepsin markers, findings for risk of 
significant CaP were comparable for D’Amico and PRIAS-based stratifications with AUCs 
of 0.701 and 0.679, respectively, using logistic regression. Interestingly, these results were 
not bettered in the smaller RP group. There was a very strong concordance of biopsy and 
RP histology, consistent with repeated biopsying of at-risk patients, but RP patients were a 
selected subgroup with more aggressive tumour patients being directed to androgen 
deprivation therapy, most commonly in association with radiation therapy.  This was further 
reflected in the performance of serum PSA for the current cohort (68%), which better 
predicts CaP than commonly reported for screening, or targeted populations. However, the 
finding for the 20 patients’ specimens that also had miR-200c and miR-375 measurements 
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is particularly notable, with these miRNAs providing best single marker performance. 
Furthermore, combining serum PSA with miR-200c and miR-125b improved significant 
CaP prediction, providing an AUC of 0.869 (95% CI 0.705 – 1.000) for a 90% sensitivity 
and 67% specificity, which was maintained when RP histology was incorporated (AUC 
0.869; 95% CI 0.644 – 0.976) and an estimated likelihood ratio ≥ 2.7. This performance is 
non-inferior, and potentially improved, when compared to PCA3 in contemporary cohorts 
(< 34% specificity at 90% sensitivity) and on systematic review (36% specificity and 
positive likelihood ratio 1.4 at 90% sensitivity)345,346. The robust nature of miRNAs in 
comparison with mRNAs makes them an attractive quarry for further investigation since 
their integrity is more likely to be retained in the enzymate-rich milieu that is ejaculate. 
Although ideally the time interval between production and specimen processing in the 
laboratory should be only a few minutes, it was nominally up to 2 hours as there was 
reliance on patients delivering their specimens to the laboratory. This variable delay which 
had the potential for cellular and mRNA degradation may help to explain the 86 specimens 
which did not meet the stringent standards imposed for inclusion for analyses. On the 
other hand, cells present in ejaculate, a medium in which sperm cells are nurtured, are 
expected to be less susceptible to time-dependent changes in cell degradation and lysis 
than, for example, those forced into the urethra with DRE and passed in urine. In order to 
minimize potential confounding factors, such as cell lysis that may result in RNA 
degradation, and enzyme mediated changes in the metabolite and protein/peptide 
composition of the samples, a room on campus is now provided in which patients may 
produce specimens without delay, and adaptations have been made to the sample 
collection medium by adding tartrate, an inhibitor of endogenous enzymes (such as 
prostatic acid phosphatase), to the fluid in the collection jar. Once the reliability of 
diagnostic performance is established in this setting, sample collection protocols can be 
tailored for practical use as a screening test with incorporation of optimization methods 
(such as that presented in Section 3.2). 
The extremely strict criteria used for our laboratory results caused the number of 
specimens to be significantly reduced but, for those fully complying with the requirements 
selected, the results are directly comparable with those of others who have reported on an 
expanded ‘PCA3 urine test’ to include the fusion gene TMPRSS2:ERG with or without the 
phi10,211 as well as  other candidates such as EN2346.  Further, the cross-referencing of a 
subgroup of those CaP patient biopsy specimens with RP pathology illustrates the high 
level of fidelity for the findings from this study. 
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While others have focused elsewhere, we have continued to examine ejaculate in 
research into the early detection of CaP since, as the closest body fluid to the prostate 
itself, assaying is comparable with ‘in-vitro biopsying’ of the whole gland. Specifically, 
prostatic smooth muscle contracts globally with ejaculation producing liquid from all parts 
of the prostate, while DRE/prostatic massage (prior to urine voiding) is directed to the 
posterior part of the gland and so may miss anteriorly sited malignancies. Undeniably, 
there have been difficulties in obtaining specimens which may extend to the clinic, 
particularly for older men. This may not be the case for younger patients if willingness to 
provide ejaculate for subfertility management is any indication. A further factor of 
relevance in CaP diagnosis is life-expectancy, particularly in relation to cardiovascular 
disease with the onset of erectile dysfunction (potentially limiting ejaculate specimen 
production) increasingly recognized as a strong indicator of impending morbidity with 
significant mortality implications18,347. Supporting this close relationship, we have found 
that ejaculate donors for our research studies who were subsequently diagnosed with CaP 
had statistically equivalent mortality expectations to the general population17. 
4.2.5 Conclusions 
These results with ejaculate mirror those from other investigators with other body fluids in 
that they are not sufficiently discriminating to be recommended as a stand-alone test for 
identifying significant CaP or for use in triaging patients. However, they do provide a basis 
to which other markers can be added to address these requirements and contribute to the 
improved selection of patients for biopsies and treatment. We intend for this study’s 
findings to serve as a template for evaluating the addition of other candidate markers using 
the same specimens (and corresponding post-ejaculate urines) in our quest to produce the 
best selection of markers for profiling patients’ clinical status and tumours. 
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4.3 “Selection and monitoring of active surveillance candidates using 
NMR-based metabolomics of ejaculate: a preliminary investigation” 
(published manuscript) 
The manuscript entitled, “Selection and monitoring of active surveillance candidates using 
NMR-based metabolomics of ejaculate: a preliminary investigation” has been accepted for 
publication by Prostate International (in press). 
The contributions of the co-authors to this manuscript were as follows: Experiment design, 
patient recruitment, experiment execution, data processing, statistical analysis and clinical 
interpretation were performed by Matthew Roberts, the PhD candidate, under the 
supervision of Dr Horst Schirra and Prof RA “Frank” Gardiner. Renee Richards, Clement 
Chow and Marion Buck assisted with sample collection and biobank curation, experiment 
execution, data processing and data analysis. John Yaxley provided advice regarding 
clinical interpretation. Prof Martin Lavin provided critical manuscript revisions. Preparation 
of the manuscript and associated figures was performed by Matthew Roberts, the PhD 
candidate.  
The manuscript text is presented as originally published by the journal. To maintain a 
consistent style between chapters in this thesis, abbreviations, placement of figures and 
tables within the text, as well as numbering of pages, figures and tables has been 
adjusted. The references have been collated in the section, ‘Bibliography’, with others 
contained in this thesis. 
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4.3.1 Abstract 
Background: Diagnosis and monitoring of localized prostate cancer requires discovery 
and validation of non-invasive biomarkers. NMR-based metabolomics of ejaculate 
reportedly improves diagnostic accuracy, but requires validation in a high-risk clinical 
cohort. 
Methods: Ejaculate samples of 151 men being investigated for prostate cancer were 
analysed with 1H-NMR spectroscopy. After adjustment for buffer (Add-to-Subtract) and 
endogenous enzyme influence on metabolites, metabolite profiling was performed with 
multivariate statistical analysis (principal components analysis, partial least squares) and 
targeted quantitation.  
Results: Ejaculate metabolites best predicted low- and intermediate-risk prostate cancer 
with differences observed between these groups and benign samples. Lipids/lipoproteins 
dominated spectra of high grade samples with less metabolite contributions. Overall 
prostate cancer prediction using previously described metabolites was not validated.  
Conclusions: Despite being unable to validate previous reports and after validation of 
discriminatory reliability with optimized sample collection, metabolomics of ejaculate in 
vitro may assist diagnosis and monitoring of either low or intermediate grade prostate 
cancer, but offers less benefit in high-risk patients. Further investigation in active 
surveillance cohorts, and/or in combination with in vivo magnetic resonance spectroscopic 
imaging may further optimize localized prostate cancer outcomes. 
 
Keywords: biomarker, metabolomics, Nuclear Magnetic Resonance, prostate cancer, 
seminal fluid, serum PSA 
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4.3.2 Introduction 
Accurate CaP diagnosis to prolong life with minimal morbidity is a daily challenge for 
urologists. While early treatment of localized csCaP with curative intent reduces mortality 
and metastases348,349, harms associated with over detection and treatment of indolent CaP 
driven by injudicious use of serum PSA and prostate biopsy have reduced overall CaP 
detection8,9. Limitations of serum PSA have driven advancements in multiparametric 
magnetic resonance imaging and biomarkers in serum (e.g. Prostate Health Index) and 
urine (PCA3, TMPRSS2:ERG fusion gene)6,7. However, due to cost-effectiveness 
concerns, these are used as adjunctive tests rather than as standalone detection tests 
despite their improved diagnostic accuracy10,11.  
Prostatic fluid, produced as ejaculate after physiological prostatic smooth muscle 
contraction, contains the clinical biomarkers PSA and PAP12,13. Malignant prostatic cells in 
ejaculates of men with CaP have been shown to express genes (PCA3, Hepsin) and 
microRNAs that improve detection compared to serum PSA14-16. Metabolomics is a 
modern biomarker approach that quantifies small metabolites19, most commonly using 
NMR spectroscopy or mass spectrometry20,21. NMR-based metabolomics is highly 
sensitive and reproducible with affordable sample-to-sample costs20. Ejaculate metabolite 
profiles improve PSA-based diagnosis22,23, but require clinical validation. 
This study investigates the feasibility of ejaculate analysis using NMR-based 
metabolomics for the prediction of csCaP in a high-risk clinical cohort and compares 
metabolite profile CaP diagnosis against prostate biopsy and RP histology. 
4.3.3 Subjects and Methods 
Ethical approval was obtained from the University of Queensland Medical Research Ethics 
Committee (Project no. 2006000262) and the Royal Brisbane and Women’s Hospital 
Human Research Ethics Committee (HREC/09/QRBW/320, HREC/09/QRBW/305 and 
1995/088B).  
4.3.3.1 – Patients and Clinical data 
Male patients (n=154) attending either the Royal Brisbane and Women’s Hospital Urology 
outpatient department or local private consulting rooms for investigation of elevated PSA 
and/or abnormal digital rectal examination between January 2007 and February 2013 were 
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enrolled in this prospective cohort study. Following informed consent, patients provided 
ejaculate specimens on site or at home prior to or at least one month after prostate biopsy.   
Patient data collected included age, serum PSA and detailed prostate biopsy and RP 
histology records. Biopsy and RP specimens were reported by uropathologists according 
to the 2005 ISUP classification350. Patients were monitored for biopsy progression, such as 
CaP detection following initial false negative biopsy or upgraded Gleason score with 
further biopsy or RP (n=61).  
Risk stratification (low, intermediate, high risk) was performed according to the D’Amico 
criteria recommended in the American Urological Association Guidelines337 and used to 
determine csCaP presence (intermediate, high risk requiring treatment). Here, low risk 
included those not requiring treatment (negative biopsy or low D’Amico risk). Given 
established disparity between biopsy and RP histopathology, risk classification accuracy 
was optimised using whichever histopathology best described tumour characteristics.  
4.3.3.2 – Specimen processing  
Ejaculate specimens were deposited directly into sterile micro-urine jars containing 20 ml 
HBSS (Gibco) for the first 117 patients used initially for cytology and RNA analyses, which 
was thereafter replaced by PBS (in-house preparation) because glucose in HBSS (Figure 
4.2) interfered with preliminary metabolomics analysis. All specimens were provided to the 
laboratory without cooling as soon as logistically possible by the patients and were 
processed in the laboratory within 2 h of production. Specimens were combined with 20 ml 
HBSS or PBS, layered over 10 ml isotonic Percoll (GE Healthcare-Pharmacia) and 
centrifuged at 974×g for 30-60 min at 4°C. Isolated supernatants, herein referred to as 
ejaculate, were snap-frozen on dry ice in 1 ml aliquots and stored at –80°C.  
4.3.3.3 – Sample preparation 
Ejaculate samples were thawed on wet ice and distributed in 100 µl aliquots. 80 µl of PBS 
solution were added along with 20 µL D2O as lock substance that contained DSS as 
internal chemical shift standard and DFTMP as internal pH indicator leading to final 
concentrations of DSS and DFTMP of 100 µM, resulting in 200 µL total sample volume. 
Samples were transferred to sterile 3 mm NMR tubes (Bruker Biospin, Rheinstetten, 
Germany). 
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4.3.3.4 – NMR spectroscopy 
NMR spectra of ejaculate samples were measured on a Bruker Avance 900 spectrometer 
operating at a 1H frequency of 900.13 MHz (Bruker Biospin), equipped with a 5 mm self-
shielded z-gradient triple resonance cryoprobe and SampleJet sample changer. 1D 
NOESY spectra were acquired at 298 K with the “noesypr1d” pulse sequence, 
accumulating 200 transients (following 8 dummy scans) at 32k data points with a spectral 
width of 14 ppm150. The transmitter frequency was set to the water resonance, which was 
suppressed by continuous wave irradiation during the NOESY mixing time of 0.1 s and 
relaxation delay of 3.0 s. Tuning/matching, shimming, and data acquisition were performed 
automatically with the ICON-NMR interface for high-throughput automation. Samples were 
measured in one batch per sample collection buffer and ordered randomly within these 
batches.   
4.3.3.5 – Spectral Processing 
NMR spectra were processed in TopSpin 3.2 (Bruker Biospin). The free induction decays 
were baseline corrected by a Gaussian function (0.1 ppm filter width) for post-acquisition 
water deconvolution315, followed by multiplication with an exponential window function (0.1 
Hz line broadening), and Fourier transformation to 64k points. Subsequently, the spectra 
were manually phased, manually baseline corrected with a cubic spline curve, and 
referenced to DSS at 0.0 ppm. For all further data manipulation, the spectra were 
truncated to δ=10.0–0.25 ppm, exported into MATLAB 2015b (The Mathworks Inc., Natick, 
Massachusetts, United States), and scaled according to the Bruker NC_proc parameter. 
4.3.3.6 - “Add-to-Subtract” glucose exclusion  
Preliminary analysis revealed glucose at sometimes dominant levels in most samples 
(Figure 4.2). As HBSS contains 1 g/L D-glucose and ejaculate volumes were varied, the 
exogenous glucose concentration and its influence on subsequent MVSA was 
unpredictable. Thus, we used the “Add-to-Subtract” method351 to exclude glucose signals 
from the NMR spectra: First, we added 1 µl of 1 M D-glucose in PBS to each sample and 
repeated measurement with identical experimental parameters, leading to a total of 302 
spectra for 151 patients (151 original, 151 with additional glucose). Secondly, using 
Topspin’s multiple display, we determined the corresponding scaling factor between 
spectrum 2 and 1 for each sample that ensures elimination of the glucose signal upon 
subtraction. Then the exported spectra 1 and 2 for each sample were aligned using  
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Figure 4.2: Sections of 1D NOESY spectra from ejaculate measured at 900 MHz. Panel A – 1D 
NOESY spectrum of ejaculate collected in HBSS, with additional peaks due to exogenous 
glucose present. Panel B – 1D NOESY spectrum of ejaculate collected in PBS.   Metabolite 
abbreviations; Ala = alanine, Arg = arginine, Asn = asparagine, Cho = choline, Cit = citrate, 
DFTMP = 1,1-difluoro-1-trimethylsilanyl methylphosphonic acid, DSS = 4,4-dimethyl-4-
silapentane-1-sulfonic acid, Fru = fructose, Gln = glutamine, Gluc = glucose, Glu = glutamate, 
Ile = isoleucine, Lac = lactate, Leu = leucine, Lys = lysine, PCho = phosphocholine, Pyr = 
pyruvate, Spe = spermine, Val = valine. 
“icoshift”131 on the glucose peaks at 3.37–3.44 ppm and then along 10 equal segments. 
Finally, for each sample spectrum 2 was scaled with the scaling factor recorded in Topspin 
and subtracted from spectrum 1. The resulting difference spectra were stored in a 
separate matrix.  
4.3.3.7 – Spectral alignment and data reduction  
The peaks of all difference spectra were aligned at full resolution using “icoshift”, initially 
on the lactate doublet at 1.32 ppm and subsequently on manually defined segments. No 
shifting artefacts were identified. Using an in-house MATLAB script, the aligned difference 
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spectra were data reduced to buckets of 0.01 ppm width over the range 10.0–5.08 and 
4.52-0.25 ppm, excluding the water signal region. 
4.3.3.8 – Multivariate statistical analysis  
Metabolite data (X) matrices containing original and difference (Add-to-Subtract) data were 
quantile normalized with the “affy” package352 in R version 3.2.2139 and imported into 
SIMCA P+ 12.0 (Umetrics, Umeå, Sweden) for MVSA together with clinical data variables 
(Y-matrix). X-matrices were Pareto-scaled before unsupervised PCA151. To determine 
which metabolite signatures were associated with clinical data (cancer/risk status; Y-
matrix), supervised PLS was performed151. Multivariate model quality was judged by the 
R2 (“goodness of fit”) and Q2 (“goodness of prediction”) figures of merit (Table A2.2). PLS 
models were validated by 200-fold response permutation.  Traditional statistical analysis, 
including the non-parametric Mann-Whitney U test, logistic regression and Receiver 
Operating Characteristic analysis were performed in MedCalc 12.7 for Windows (MedCalc 
Software; Ostend, Belgium). 
4.3.3.9 – Targeted metabolite profiling 
Ejaculate metabolites were quantified using Chenomx NMR suite353 using DSS as internal 
concentration standard. Logistic regression on the ejaculate metabolite concentrations was 
performed in MedCalc, similar to that described in23.  
4.3.4 Results 
4.3.4.1 – Clinical cohort demographics 
From 151 patients who provided ejaculate samples, 80 were initially diagnosed with CaP 
and an additional 18 patients diagnosed during the follow-up period. Within these 98 
patients, 82 met csCaP criteria. 61 patients underwent RP for localized CaP in which 59 
were determined to be high risk per the D’Amico criteria, with 6 upgraded from 
negative/low risk. Primary Gleason pattern 4 or higher or tertiary pattern 5 was present in 
34 patients based on RP histology. The demographic information (Table 4.6) 
demonstrated that serum PSA was higher in those with high D’Amico risk. 
4.3.4.2 – Unsupervised multivariate statistical analysis  
The ejaculate samples were analysed with 1H NMR spectroscopy. 1D NOESY spectra 
were measured, aligned, and data reduced to 0.01 buckets. For initial PCA, buckets  
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  Age (years) Serum PSA (ng/ml) 
Biopsy n = 151   
Overall  61 (55 – 66)  6.5 (4.33 – 9.23)  
CaP status Positive (n = 98) 60.5 (55 – 65) 6.4 (4.5 – 11) 
Negative (n = 53) 62 (55.75 – 68.25)NS  6.5 (3.6 – 7.95)NS 
D’Amico risk High (n = 82) 61 (55 – 66) 6.75 (4.5 – 11.9) 
Negative/Low (n = 69) 61 (55 – 67)NS 6.0 (3.6 – 8.13)* 
RP n = 61   
Overall  57 (54 – 64)   6.2 (4.13 – 9.4)  
RP – 
Primary/tertiary 
pattern 
Gleason ≥ 4 (n = 34) 57.5 (55 – 64) 7.6 (4.9 – 13) 
Gleason 3 (n = 27) 57 (51.25 – 63.5)NS 5.4 (3.23 – 6.83)** 
Table 4.6: Demographic information for patients based on biopsy and radical prostatectomy 
(RP) histology. Median and interquartile range are shown for age and serum PSA. All 
comparisons were made using the Mann-Whitney U-test (two-tailed). * p < 0.05; ** p < 0.01; NS 
= not significant. 
corresponding to ethanol, resulting from sample preparation, were excluded, as were 
spectra that were outliers due to broad resonances (n=2). PCA yielded a model (Table 
A2.2 M1) with 6 PCs, in which samples clustered per the buffer solution used (PC1/PC2; 
Figure 4.3a-c), with higher glucose levels in samples prepared in HBSS. In higher PCs, 
sample variation was observed due to inter-sample differences of lipids/lipoproteins, 
phosphocholine, choline and citrate, as well as spermine (data not shown), which were 
unrelated to CaP in this analysis.  
The “Add-to-Subtract” method351 was used to remove glucose signals from NMR spectra. 
Following measurement of a “baseline spectrum” (spectrum 1), glucose was added in high 
concentration to the sample in the same NMR tube and a second spectrum was measured 
(spectrum 2). Spectrum 2 was subtracted from spectrum 1 with an appropriate scaling 
factor to remove glucose signals but preserve signals of compounds in the resulting 
difference spectrum. The method assumes that introduction of glucose does not change 
sample conditions, preserving sample matrix, line shapes and signal frequencies.   
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Figure 4.3: Principal Components Analysis of ejaculate NMR spectra from men being investigated for prostate cancer (n = 151), prepared with different 
buffer solutions (Hanks Balanced Salt Solution: filled square, phosphate buffered saline: empty square). Panels a-c: Initial sample clustering is observed 
due to the difference in buffer solutions and resulting sample glucose content (principal component 1) and inter-sample differences in metabolite 
(citrate, choline, lipids/lipoproteins and phosphocholine) variation (principal component 2). Panels d-f: After Add-to-Subtract elimination of glucose, the 
previously observed effects of different buffer solutions are no longer apparent (panel a). No clustering was present according to CaP status (blue 
squares = benign; red triangles = CaP). Panels a, b, d, e: scores plots; panels c, f: loadings plots. Metabolite abbreviations: Cho = choline; Cit = citrate; 
Gluc = glucose; Lip = lipids/lipoproteins ; PCho = phosphorylcholine.  
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PCA of the difference spectra (Figure 4.3d-f, Table A2.2 M2) showed no sample grouping 
due to differences in buffer used (Figure 4.3d). The predominant drivers of sample 
variation were lipids/lipoproteins (PC1), an inverse relationship between choline and 
phosphocholine as well as citrate. An association with csCaP was suggested by the 
presence of lipids/lipoproteins, although separation between clinical groups was not 
observed in any PC.  
Given that the inverse relationship observed between phosphocholine and choline is due 
to PAP-mediated hydrolysis, a reaction which was not inhibited in these samples354, 
choline-based metabolites (choline, phosphocholine and glycerophosphocholine) were 
excluded to remove their effect of unbalanced regulation on the MVSA. However, PCA 
(Figure 4.4, Table A2.2 M3) showed no obvious clustering, with most variation due to 
lipids/lipoproteins, citrate and serine (Figure 4.4a,b). Fructose and spermine were other 
significant sources of variation in PC3/PC4 (Figure 4.4c,d). 
4.3.4.3 – Supervised multivariate statistical analysis  
In the unsupervised PCAs, which determine sources of variation potentially independent of 
underlying biology, no sample clustering into clinical groups was seen, prompting the need 
for supervised MVSA. First, the presence of csCaP according to the D’Amico criteria 
based on biopsy was used as the predictive variable in PLS analysis (Figure 4.5, Table 
A2.2 M4) and demonstrated lipids/lipoproteins to be associated with variation for csCaP, 
which were mostly limited high-risk patients. Furthermore, there was potential subgrouping 
among the D’Amico risk groups (Figure 4.5b).  
Based on these results and reports that maximal metabolite disturbances are observed in 
low- and intermediate-risk tumours, we analysed with PLS a subgroup of 11 samples 
correlating to these grades confirmed by RP histology only (Figure 4.6a-c, Table A2.2 M5). 
The single low-risk sample was separated from the intermediate-risk samples due to 
reduced lactate, pyruvate and lipids/lipoproteins and increased citrate, myo-inositol, 
spermine and fructose (Figure 4.6a,c). Within these low/intermediate-risk samples, 
separation was seen in accordance with primary Gleason pattern 4, associated with higher 
levels of lipids/lipoproteins, lactate and pyruvate as well as lower levels of citrate, spermine 
and myo-inositol (Figure 4.6b,c). These relationships were observed when classifiers 
based on all low/intermediate-risk patients, determined by biopsy or RP, were performed 
(Figure 4.6d,e; Table A2.2 M6).  When benign samples were considered with risk group 
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Figure 4.4: Principal Components Analysis after exclusion of choline containing metabolites 
demonstrated that lipids/lipoproteins, citrate and serine were influential metabolites (panels a, b) 
as well as fructose and spermine (panels c, d). No clustering was present according to CaP 
status (blue squares = benign; red triangles = CaP). Panels a, c: scores plots; panels b, d: 
loadings plots. Metabolite abbreviations: Cit = citrate; Fru = fructose; Lip = lipids/lipoproteins Ser 
= serine; Spe = spermine.  
combinations and Primary Gleason pattern 4 presence, minimal separation was observed 
and models were weak/non-predictive (Figure A2.4, Table A2.2 M7-M10).  
Analysis of only the samples collected in PBS, unaffected by any external glucose (Figure 
A2.5, Table A2.2 M11-17), showed similar relationships to those seen for the full cohort. 
Specifically, valid models were obtained for separation between low- and intermediate-risk 
samples (Table A2.2 M12, Figure A2.5c,d; limited by sample size) and low-risk and benign 
samples (Table A2.2 M13, Figure A2.5e,f). Findings were confirmed with PCA (Table A2.2 
M15-17, Figure A2.6) and driven by lactate levels (Figure A2.7). The presence of the 
TMPRSS2:ERG fusion gene, detected in the epithelial cell fraction of ejaculate, used as Y 
variable was weakly but non-predictively associated with lipid/macromolecule resonances 
(Figure A2.8, Table A2.2 M18).   
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Figure 4.5: Supervised, partial least squares analysis of ejaculate NMR spectra in predicting csCaP (according to D’Amico criteria) following Add-to-
Subtract. Minimal separation is seen according to csCaP (blue squares = benign, red triangles = csCaP; panel a). When coloured according to risk 
subgroups (blue squares = benign; green dots = negative/low risk; yellow diamonds = intermediate risk; red triangles = high risk/cancer present; panel 
b), potential intragroup clustering was seen due to pyruvate, serine and lipids/lipoproteins (high/intermediate risk) and TMAO (negative/low risk).  
Panels a, b: scores plots; panel c: loadings plot. Metabolite abbreviations: Lip = lipids/lipoproteins; Pyr = pyruvate; Ser = serine; TMAO = trimethylamine 
N-oxide
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Figure 4.6: Supervised, partial least squares analysis of ejaculate NMR spectra in predicting CaP risk (according to D’Amico criteria) following Add-to-
Subtract. Separation between low- (green dots) and intermediate- (yellow diamonds) risk patients based on RP histology due to elevated lactate, 
lipids/lipoproteins and pyruvate and reduced citrate, fructose, myo-inositol and spermine in intermediate-risk samples (panels a,c). These relationships 
were observed when expanded to all low and intermediate risk patients (panels d, e). Discrimination within the low/intermediate group was observed 
due to primary Gleason pattern 4 (filled square = present; empty square = absent) and higher lipids/lipoproteins, lactate and pyruvate as well as 
reduced citrate, myo-inositol and spermine (panels b,c). Panels a, b, d: scores plots; panels c, e: loadings plots. Metabolite abbreviations: Cit = citrate; 
Fru = fructose; Lac = lactate; Lip = lipids/lipoproteins; Myo = myo-inositol; Pyr = pyruvate; Spe = spermine. 
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4.3.4.4 – Targeted metabolite profiling 
Ejaculate metabolite quantification with subsequent logistic regression showed that citrate 
or myo-inositol were not significant predictors of CaP status (Table A2.3). Significant 
metabolites for CaP status (choline, leucine) and csCaP (leucine, valine) did not 
significantly improve diagnosis compared with serum PSA metabolite predictability. 
4.3.5 Discussion 
In this paper, we present the largest validation study of ejaculate-based metabolite 
prediction of CaP using high resolution NMR spectroscopy, having analysed ejaculate 
metabolite profiles from 151 men being investigated for CaP. Undue influence of 
exogenous glucose contained in the HBSS buffer used for RNA analyses was successfully 
excluded by applying Add-to-Subtract and revealed inherent variation due to enzyme-
dependent changes in choline-based metabolites. Ejaculate metabolites best predicted 
low- and intermediate-risk CaP with differences observed between these groups and 
benign and high-risk samples. Metabolites previously reported to determine CaP, such as 
citrate, spermine and myo-inositol, showed minimal predictive ability in this clinically 
applicable cohort. These findings were confirmed with targeted metabolite quantification.  
Well described prostatic metabolite changes due to CaP, specifically reduced citrate and 
polyamines (e.g. myo-inositol, spermine) and increased intracellular lactate, choline and 
creatine20, were not predictive in this study due to underlying the following clinical and 
biological factors: Clinically, the study population presented here contains patients 
suspected of harbouring CaP, encountered in daily urological practice (Table 4.6). In 
earlier reports where ejaculate metabolites significantly improved CaP detection, CaP-
positive samples were compared with healthy controls or men unlikely to have CaP, 
suggested by marked discrepancies in serum PSA between groups. Our population 
contained heterogeneous disease states, inclusive of all tumour grades with predominance 
toward high-risk CaP. While group separation was observed between CaP risk groups 
(Figure 4.6, Figures A2.5, 2.6), we could not truly exclude CaP in patients with a negative 
biopsy due to limitations in biopsy-based CaP detection and known metabolic changes in 
early tumorigenesis, which may lead to confounding overlap between groups and invalid 
statistical models. Given the studied population of 151 men was almost double that 
reported by Serkova and colleagues (n=78), statistical power was considered to be 
sufficient. To exclude uncertainty among the control group, a sub-analysis of the presence 
or absence of Gleason pattern 4 on RP histology showed overlap of groups (M10, Figure 
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A2.4g,h), likely owing to reduced metabolite influence in poorly differentiated tumours. 
Similarly, limitations of biopsy-based risk stratification given known upstaging at RP in up 
to 40% of patients may confound the accuracy of risk subgroup analyses355. When 
analyses based only on RP-based diagnosis were expanded to include biopsy-based 
diagnosis to increase sample size, sample grouping was less obvious despite similar 
metabolite patterns being observed in the loadings plot (Figure 4.6). Thus, a larger low-
/intermediate-risk RP cohort would be expected to accurately “up-classify” (upstage) low-
risk samples with metabolite patterns similar to intermediate-/high-risk samples, as shown 
elsewhere279. 
Biologically, Gene expression and metabolite alterations occur early in tumorigenesis and 
are more pronounced in lower grade (Gleason≤7) compared with higher grade 
(Gleason≥8) tumours279, supported by our analysis of low- and intermediate-risk patients 
(Figure 4.6, Figures A2.5, 2.6). In addition to direct metabolic changes, the inverse 
relationship between lactate and fructose resulting in group separation between low- and 
intermediate-risk and benign samples may indicate disturbed ejaculate homeostasis of 
anions (zinc) or enzymes (PSA, PAP) known to improve sperm function305, resulting in 
impaired sperm glycolysis. Indeed, poor discrimination of metabolite profiles from high-risk 
tumours was demonstrated here and in other studies, likely due to accumulated genetic 
alterations with disease progression279,280.  Thus, patients with lower grade tumours may 
be amenable to ejaculate-mediated in vitro or MRSI-mediated in vivo assessment or 
monitoring as a potential substitute for repeat biopsy in active surveillance279,356. 
Altered metabolite homeostasis correlates with increased fatty acid synthesis, due to or in 
association with TMPRSS2-ERG fusion gene translocation associated with aggressive 
CaP, may account for the overwhelming influence of lipids/lipoproteins in high-risk patients 
in this study, similar to that reported by others24. Higher grade tumours overexpress the 
oncogene MYC, which is associated with dysregulated lipid metabolism357 and display 
altered cholesterol metabolism to increase energy storage280 . Upregulated lipid 
subclasses have been described between normal, localized and metastatic prostatic cells, 
with choline kinase α implicated in de novo lipogenesis in aggressive metastatic cells284. 
Systemically, lipid and energy metabolites in serum have been strongly associated with 
aggressive CaP289 and may improve CaP detection with 97% accuracy358.  
This study was an opportunistic analysis of ejaculate samples collected initially for cytology 
and subsequently epithelial cell RNA analyses. The exogenous glucose contained in the 
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HBSS required significant correction using Add-to-Subtract, which did not introduce further 
influence into the MVSA. Subsequently, the uninhibited changes in choline-based 
metabolites showed significant influence in the preliminary MVSA. These metabolite peaks 
were excluded because PAP-catalysed hydrolysis of phosphocholine to choline is a rapid, 
endogenous reaction to enhance spermatozoal function and protection354. Variations in 
time from sample production to processing, despite most being done within 2 hours, are 
likely to cause significant variation among these metabolites independent of underlying 
CaP due to the unknown degree of reaction completion. Given the postulated role of 
choline in tumour progression, as indicated by elevated in vivo levels, reliable 
quantification of choline-based metabolites in ejaculate is desired. Thus, a sample 
collection/storage protocol should be implemented that limits the PAP reaction to 2-3% 
progression, such as our recommendation that ejaculate samples be collected in a sterile 
urine jar containing 5 mM tartrate in 20 ml PBS solution cooled to 277 K354. While 
malignant prostatic metabolite contribution to ejaculate, considering concurrent 
contributions from multiple organs and resulting proteolysis, may intuitively be minimal or 
diluted, our findings are like those seen in tissue extracts and in vivo279,280, likely to be 
enhanced by spectral acquisition at 900 MHz. 
In conclusion, this validation study was unable to replicate previous performance of 
ejaculate-based metabolite prediction of CaP in 151 men being investigated for CaP. 
Multivariate analysis and targeted metabolite profiling were used. Corroborating other 
studies, grouping was observed when comparing low- and intermediate-risk patients, while 
lipids/lipoproteins dominated spectra of high grade samples with fewer contributions from 
other metabolites. Despite being unable to validate previous reports on univariate 
metabolite analysis for CaP discrimination, dedicated metabolomics protocols ideally in 
serial collections may maximize information recovery and allow validation of discrimination 
and reliability of ejaculate metabolomics for routine use. The value of metabolomics 
analysis of ejaculate for CaP currently appears to be in active surveillance of low- or 
intermediate-grade tumours suspicious of under-staging, in which in vivo correlation with 
MRSI and monitoring in vitro with ejaculate or in vivo with MRSI may further clinical 
practice.  
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4.4 Preceding analyses for ejaculate metabolomics experiments  
4.4.1 – Exogenous glucose adjustment in NMR spectra 
The submitted manuscript as Chapter 4.3 of this Thesis was the final product after several 
confounding variables were encountered. Initial ejaculate metabolomic analysis was 
performed for 111 samples using a AV500 500MHz Bruker NMR spectrometer with 
standard spectral processing, data reduction and integral normalisation. Outlying samples 
were detected due to the presence of glucose which, following exclusion of glucose-
containing buckets, the MVSA was mostly influenced by choline and shifting metabolite 
signals, indicated by neighbouring buckets present at either end of the loadings plot 
(buckets and dominated the MVSA, as discussed in Chapter 4.3. While correction for 
shifting peaks was overcome using icoshift, the loss of information regarding metabolites 
contained in excluded regions (e.g. myo-inositol) prompted other glucose adjustment 
methods to be trialled. 
First, the buffer solution (HBSS) was measured using the same spectrometer and 
experimental variables compared with the initial measurements. Indeed glucose was a 
dominant feature of the HBSS spectrum. After the HBSS was appropriately scaled and 
subtracted from each spectrum using the method described in Chapter 4.3 (Figure 4.7A), 
baseline distortion artefacts resulted in improper influence of glucose buckets on the 
MVSA (Figure 4.7B. Furthermore, measurement of additional samples collected in PBS 
contained exogenous ethanol, also providing influence on OPLS MVSA for CaP presence 
(Figure 4.7C-D; n=147, k=919, R2Y = 0.073; Q2Y= -0.057).  
Secondly, following review of the manuscript by Ye and colleagues, initial Add-to-Subtract 
using an average glucose spectrum across all samples was attempted but resulted in 
significant baseline disturbances, even with use of icoshift (data not shown, similar to 
Figure 4.7a-b).  
Finally, the best adjustment to be made for the exogenous glucose in samples from use of 
HBSS was remeasuring all samples (n = 151) using Add-to-Subtract, resulting in 302 
measured NMR spectra, as described in Chapter 4.3. Given the requirement for re-
measurement and availability of automated sample changing at our facility, this was 
opportunistically performed at higher field strength (900 MHz). 
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Figure 4.7: Attempted adaptations to Add-to-Subtract to improve ejaculate metabolomics 
analyses. A – 1D NOESY spectral overlay of ejaculate (orange) and HBSS (blue) spectra, 
demonstrating the high glucose content of HBSS and minor peak offsets between spectra. B – 
1D NOESY spectral overlay in the region of 3.17 – 3.27 ppm near choline-containing 
metabolites (Cho, choline; PCho, phosphocholine; GPCho, glycerophosphocholine) 
demonstrating baseline distortion artefacts near the glucose (Glu) peaks following Add-to-
Subtract due to improper spectral alignment. C – Scores plot showing minimal separation due to 
CaP (red) and benign (blue) status. D – Loadings plot showing significant influence of glucose 
(Glu) despite subtraction, as well as exogenous ethanol (Eth) and choline (Cho). 
The resulting spectra demonstrated baseline signal dispersion near the water signal, which 
required manual correction for all 302 spectra using cubic spline correction. Initial glucose 
subtraction was performed in TopSpin according to the published method, however this 
resulted in significant baseline disturbances (similar to that seen in Figure 4.7B). 
To correct for this, as described in the manuscript, individual spectra were aligned on 
glucose and then in equal segments prior to subtraction. 
4.4.2 – Unbalanced choline regulation in ejaculate samples 
As demonstrated initially and in the final ejaculate metabolomics analysis, choline-based 
metabolites were additional sources of potential CaP-independent variation within the 
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MVSA (Figure 4.3). Given the known endogenous hydrolysis of phosphocholine to choline 
mediated by PAP, these findings prompted the investigation and sample optimisation for 
metabolomics studies, as presented in Chapter 3.2. While the final analysis resulted in 
exclusion of choline-containing buckets, many adjustment methods were attempted prior 
to this.  
Initial addition of choline-based metabolite (choline, phosphocholine, 
glycerophosphocholine) buckets was overly influential on the MVSA (Appendix 2 Figure 
A2.9; Figure 4.7C-D; n=154, k=879, R2X = 0.877; Q2= 0.367). 
Given that multiple reports implicate choline in CaP in vivo using MRSI, preservation of 
choline-based metabolite information was desired. A manuscript describing data 
normalisation in the presence of unbalance regulation provided a potential solution, where 
the spectra are scaled based on metabolites with least variance (based on Shapiro-Wilk 
testing). The Add-to-Subtract 0.01 ppm bucket width matrix was not normally distributed 
(Shapiro-Wilk p<0.0001). When the matrix was subject to resamp_mswsd(y), there was no 
progression away towards normal distribution with varying percentage of features used. 
The resulting graphs varied from that in the manuscript, with “features used” in the 
manuscript different to “percentage of features” in the output script (Figure 4.8).  
 
Figure 4.8: Feature-mswsd box plots demonstrating data spread with variable feature use. 
When this method was tried with ejaculate data (left panel), the outcome was uninterpretable 
compared with published results (right panel).  
Following scaling, various normalisation methods were available, including Variance 
Stabilisation Normalisation and PQN. The leading author was contacted regarding this 
discrepancy in the published manuscript and alterations are pending.  
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Chapter 5 – Post-ejaculate urethral washings as a novel 
biofluid for prostate cancer biomarkers 
5.1 Synopsis 
The aim of this chapter is to investigate if a novel prostatic biofluid, PEUW contains CaP 
biomarkers and their diagnostic performance and feasibility for clinical utilisation.  
The presence of prostatic RNA biomarkers and their diagnostic performance in the 
epithelial cell fraction of PEUW was investigated and presented as a peer-reviewed 
manuscript (section 5.2) 
PEUW was then analysed using NMR spectroscopy with three objectives. Initially, to 
determine if prostatic metabolite biomarkers are present, both in clinical samples and in a 
dedicated cohort comparing with mid-stream urine. Secondly, to describe the kinetic 
behaviour of these markers and if they behave similarly to that observed in ejaculate. 
Finally, metabolite profiles in PEUW collected from a clinical cohort were analysed to 
detect and characterise CaP. The preliminary findings of these NMR-based metabolomics 
experiments are presented in section 5.3. 
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5.2 “Prostate-based biofluids for the detection of prostate cancer: a 
comparative study of the diagnostic performance of cell-sourced RNA 
biomarkers.”  (published manuscript) 
The manuscript entitled, “Prostate-based biofluids for the detection of prostate cancer: a 
comparative study of the diagnostic performance of cell-sourced RNA biomarkers” has 
been published by Prostate International (2016; 4(3):97-102). 
Since publication, the manuscript has been received 1 and 2 citations for Scopus and 
Google Scholar, respectively (as at 10/02/17).  
The contributions of the co-authors to this manuscript were as follows: Experiment design, 
data processing and statistical analysis drafting was performed by Matthew Roberts, the 
PhD candidate, under the supervision of Dr Horst Schirra and Prof RA “Frank” Gardiner. 
Renee Richards, Clement Chow, Marion Buck and Luke Selth assisted with sample 
collection, experiment execution and data processing. Suhail Doi provided guidance for 
statistical analysis and data interpretation. Hema Samaratunga, Joanna Perry-Keene, 
Diane Payton and John Yaxley provided advice on histological and clinical interpretation. 
Prof Martin Lavin provided critical manuscript revisions. Preparation of the manuscript and 
associated figures was performed by Matthew Roberts, the PhD candidate.  
The manuscript text is presented as originally published by the journal. To maintain a 
consistent style between chapters in this thesis, abbreviations, placement of figures and 
tables within the text, as well as numbering of pages, figures and tables has been 
adjusted. The references have been collated in the section, ‘Bibliography’, with others 
contained in this thesis. 
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5.2.1 Abstract 
Background: Prostate cancer diagnosis requires improvement with the aid of more 
accurate biomarkers. PEUW could be a physiological equivalent to urine obtained 
following rectal prostatic massage, the current basis for the PCA3 test. The aim of this 
study was to investigate if PEUW contained prostate-based material, evidenced by 
presence of PSA, and to evaluate the diagnostic performance of PEUW-based 
biomarkers. 
Methods: Male patients referred for elevated serum PSA or abnormal digital rectal 
examination provided ejaculate and PEUW samples. PSA, PCA3 and β2M were quantified 
in ejaculate and PEUW and compared with absolute and clinically significant (according to 
D’Amico criteria) CaP presence, as determined by biopsies. Diagnostic performance was 
determined and compared with serum PSA using ROC analysis. 
Results: From 83 who provided PEUW samples, paired analysis with ejaculate samples 
was possible for 38 patients, while analysis in an unpaired, extended cohort was possible 
for 62 patients. PSA and PCA3 were detected in PEUW, normalized to β2M, and 
PCA3:PSA was calculated. In predicting absolute CaP status, PCA3:β2M in ejaculate 
(AUC 0.717) and PEUW (AUC 0.569) were insignificantly better than PCA3:PSA (AUC 
0.668 and 0.431, respectively) and comparable with serum PSA (AUC 0.617) with similar 
trends observed for the extended cohort.  When considering clinically significant CaP 
presence, serum PSA in the comparison (AUC 0.640) and extended cohorts (AUC 0.665) 
was comparable with PCA3: β2M (AUC 0.667) and PCA3:PSA (AUC 0.605) in ejaculate, 
with lower estimates for PEUW in the comparison (PCA3: β2M AUC 0.496; PCA3:PSA 
AUC 0.342) and extended (PCA3: β2M AUC 0.497; PCA3:PSA AUC 0.469) cohorts. The 
statistical analysis was limited by sample size. 
Conclusion: PEUW contains prostatic material, but has limited diagnostic accuracy when 
considering cell-derived DNA analysis. PCA3-based markers in ejaculate are comparable 
to serum PSA and DRE-urine markers.  
 
Keywords: biomarker, ejaculate, mRNA, PCA3, prostate cancer, PSA  
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5.2.2 Introduction 
The detection of CaP is fraught with difficulties that include limitations of currently available 
biomarkers, access to imaging and tissue sampling. Total serum PSA is currently the 
single most widely used marker clinically for identifying men at risk of CaP, but it is a non-
specific indicator of prostatic pathology that includes CaP among others so that population 
and opportunistic screening is discouraged due to over-investigation and over-detection 
resulting in overtreatment5. Contemporary CaP detection approaches have included, 
amongst others, advocacy for a biomarker panel, phi and the 4-kallikrein protein test193,359.  
Although imaging modalities, such as multiparametric MRI and even PSMA-PET, are 
being integrated into the detection strategy for triaging patients with an elevated PSA and 
may improve detection of clinically significant CaP360, there are limitations that detract from 
their widespread use. The false negative rate (approximately 15-20%) for multiparametric 
MRI suggests a significant proportion of clinically significant tumours may be missed360, 
which is also observed with PSMA-PET imaging of tumours that do not express PSMA361. 
That imaging is establishing a niche in detection strategies is undeniable however it is the 
cost of such imaging methods that really limits application to mainstream clinical practice. 
Improved patient selection for imaging with accurate biomarkers is likely to optimize their 
practical application clinically. 
Prostate-specific biofluids are an ongoing source for investigation using new analytical 
platforms12. PCA3, a long non-coding RNA, collected in the first void of urine following a 
vigorous DRE or prostatic massage, has been examined over the past 20 years362, with 
studies reporting to improve detection in men undergoing repeat biopsy 363, but its role 
clinically remains uncertain. Modifications of PCA3364, as well as a combination with 
TMPRSS2-ERG fusion gene have been described to improve detection365 but have not 
been accepted as a useful addition in routine patient testing366. Other approaches utilizing 
exosomes, proteomics and metabolomics have the potential to improve early diagnosis of 
localized disease20,21,367. Indeed molecular and metabolomic markers in ejaculate have 
been reported to improve diagnosis compared to serum PSA15,16,335. Paralleling the post-
massage urine concept, collection of urine following ejaculation, or PEUW potentially 
represents a new source of prostate-specific biomarkers for CaP detection and 
characterization, providing a physiologically produced alternative to serum or digital 
prostatic massage effluent for further biomarker discovery and development.  
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The aim of this study was to investigate the diagnostic potential of selected molecular 
markers in PEUW in detecting CaP and comparing diagnostic accuracy with the same 
markers in ejaculate, as well as serum PSA. The hypothesis tested was that the diagnostic 
performance of molecular markers in post-ejaculate urine would be comparable with those 
in ejaculate or serum PSA. 
5.2.3 Subjects and Methods 
5.2.3.1 – Patients  
A clinical cohort of men (n = 83) being investigated for CaP on the basis of an abnormal 
DRE and/or elevated serum PSA provided specimens of ejaculate and PEUW into sterile 
micro-urine jars, containing 20 ml Hanks Balanced Salt Solution (Gibco) and empty urine 
jars, respectively, between January 2007 and December 2009. As previously reported15, 
all specimens were processed within 2 h of production after being delivered to the hospital 
campus without cooling. All specimens were collected prior to or at least one month 
following TRUSBx or TPBx.   
Ethical approval to conduct this study was obtained from the University of Queensland 
Medical Research Ethics Committee (Project no. 2006000262) and the RBWH Human 
Research Ethics Committee (HREC/09/QRBW/320, HREC/09/QRBW/305 together with 
1995/088B). 
5.2.3.2 – Clinical data 
All patient data was prospectively collected following recruitment and included clinical 
details such as age, family history and serum PSA. Initial and updated TRUSbx/TPBx/RP 
histology specimens were reviewed by DP, JP-K and MLTHS and reported according to 
the 2005 ISUP classification350, including standard biopsy (number of cores taken, number 
and percentage of positive cores, Gleason score) and RP (gland size, Gleason score, 
pathological stage, extracapsular status and margin status) parameters.  
In order to identify the patients for whom active treatment would be recommended, risk 
stratification for biopsies in determining clinically significant CaP presence was performed 
using the D’Amico criteria recommended in the American Urological Association 
Guidelines337. The clinically significant CaP category included patients defined as 
intermediate- and high-risk according to the D’Amico criteria, while the absence of 
clinically significant CaP was defined as negative/low risk patients according to the 
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D’Amico criteria or those without CaP337. The most accurate classification of clinically 
significant CaP, based on histopathology from TRUSbx, TPBx and/or RP, was used given 
established disparity between TRUSbx and RP histopathology. As previously reported, 
patients were subsequently placed in one of two clinical groups based on classification 
scheme used. Because of the imprecise nature of TRUSbx especially, patient follow-up 
was pursued for up to 7 years to ensure that those designated as negative for prostate 
cancer really were negative. 
5.2.3.3 – Specimen processing and cellular isolation 
Ejaculate specimens combined with 20 ml Hanks Balanced Salt Solution were layered 
over 10 ml isotonic Percoll (GE Healthcare-Pharmacia) and centrifuged at 974×g for 30-60 
min at 4°C, with supernatants subsequently collected in 1 ml aliquots, snap-frozen on dry 
ice and stored at -80°C. The epithelial cell layer at the Percoll interface, present as a 
discrete band suspended between supernatant above and sperm and non-cellular 
components below, was then pipetted, washed with 25 ml PBS or Hanks and centrifuged 
at 1258×g for 10 min at 4°C.  
5.2.3.4 – RNA preparation  
Total RNA from collected cells was isolated using TRIzol reagent (Invitrogen) then 
subjected to on-column DNase treatment and clean-up with the RNeasy kit (Qiagen). Low 
yield samples were amplified using the SenseAmp kit (Gensisphere).  
5.2.3.5 – cDNA synthesis and quantitative reverse transcription PCR 
Quantitative reverse transcription PCR (qPCR) was undertaken using the QIAGEN 
Quantitect SYBR green qPCR Mastermix (QIAGEN, Germany) on a Corbett Rotorgene 
machine 3000/6000 (Corbett Research, Australia). cDNA synthesis was performed with 
200-500 ng of total RNA reverse transcribed using Superscript III (Invitrogen) and random 
hexamer primers (Promega). The synthesized cDNA was diluted 10-fold and 5 l was 
used for the assay in the presence of 7.5 µl Quantitect SYBR green mastermix (Qiagen) 
and 5 pmol gene specific forward and reverse primers. Each reaction was performed in 
triplicate for both patient samples and calibrator. Reaction conditions were 95°C for 15 min 
followed by 45 cycles of 20 s at 95°C, 20 s at 58°C and 20 s at 72°C. Data for each cycle 
was acquired at the 72°C for 20 s step.  
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The genes that were characterized were β2M, PCA3 and PSA using the following primers 
(Sigma-Aldrich, Australia) for qPCR: β2M (Fwd: 5’-AGCAGAGAATGGAAAGTCAAA-3’, 
Rev:5’-TGCTGCTTACATGTCTCG-3’); PCA3 (Fwd: 5’-
GGAAGGACCTGATGATACAGAGGTGAG-3’, Rev: 5’-CACAGGGCGAGGCTCATCG-3’; 
PSA (Fwd: 5’-GCATCAGGAACAAAAGCGTG-3’, Rev:5’-CCTGAGGAATCGATTCTTCA-
3’) 
Standardized processing (including standard curve fitting, dynamic tube, slope correct) 
was performed for all runs using Rotor-Gene 6000 Series Software Version 1.7 (Corbett 
Research, Australia). To maintain quality control, specimens with atypical melt curves or 
quantitation curves below threshold for any single target (with normal melt curves) were 
excluded. A standard threshold value was manually set for each individual gene across all 
samples and used to calculate Ct values, which were exported to Excel (Microsoft 
Corporation, Redmond, CA). Based on CtAv and CtSD values of triplicates observed 
across all genes (see Figure A3.1), cut off points defined for exclusion were CtAv > 35 and 
CtSD > 1.5 for PEUW and ejaculate, as previously described15. Analysis of PSA, PCA3 
and β2M in ejaculate and PEUW specimens was possible for 38 patients, with these 
markers detected in PEUW only from 62 patients.  
5.2.3.6 – Relative gene expression determination 
Relative gene expression was calculated using the method previously described by Pfaffl 
316, which uses the following equation: 
Expression (R) = EGOI∆Ct(Calibrator-sample)/ERG∆Ct(Calibrator-sample) 
“∆Ct (Calibrator - sample)” estimates the amplification (Ct values) difference between the 
calibrator reaction (uniform template quantity to standardize all runs) and the target gene 
transcription of the sample reaction (unknown)316. The reaction efficiency (E) of the GOI 
and endogenous RG are considered without the required use of a standard curve in every 
run, based on the assumption that reaction efficiency between different runs was 
consistent and normalized by the calibrator used.  
5.2.3.7 – RG variation 
β2M, a known housekeeping gene241,362, was used as the endogenous RG with 
subsequent relative gene expression calculated for PSA and PCA3. The commercial use 
of PCA3, which unlike PSA is highly overexpressed in prostate cancer209, requires PSA to 
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be used as the RG on the basis of reports that PSA expression is relatively constant and 
considers only cells of prostatic origin so the expression of PCA3 relative to PSA was also 
calculated362. 
5.2.3.8 – Data analysis 
Relative gene expression results were analysed considering two clinical classifications, 
absolute CaP status (cancer versus no cancer) and clinically significant (present versus 
absent) CaP status, as determined using the D’Amico classification337. Univariate analysis 
was conducted with the non-parametric Mann-Whitney U test.  
Receiver Operating Characteristic (ROC) analysis was performed for each marker and 
compared to each other and serum PSA, with binomial exact Confidence Interval and 
optimal cut points for each marker calculated in Stata Statistical Software 13 (StataCorp. 
College Station, Texas USA) using the Liu method368. Significance thresholds were 
Bonferroni corrected (<0.05/4 = <0.0125) to adjust for multiple comparisons (n = 4), and all 
reported p-values < 0.0125 were considered statistically significant. 
5.2.4 Results 
5.2.4.1 – Clinical characteristics  
From 83 potential patients with adequate clinical data who donated PEUW samples 
between January 2007 and December 2009, relative gene expression determination for 
PSA, PCA3 and β2M was performed. Strict exclusion criteria (see Figure A3.2) were 
applied, resulting in sample exclusion due to unsatisfactory q-PCR analyses (atypical melt 
or quantitation curves, n = 1), insufficient cDNA to reach detection threshold (n = 5), CtAv 
or CtSD outside determined cutoffs (n = 14) or coupled with an ejaculate sample excluded 
for a similar reason (n = 25). Of the remaining 38 patients, the relationships observed for 
the entire cohort with respect to median (interquartile range) age [62 (57 – 68) years] and 
serum PSA [6.7 (4.75 – 9.15) ng/ml] were preserved in this group, with a median age 62 
(57 – 69) years (p = NS) and serum PSA 6.3 (4.9 – 8.9) ng/ml (p = NS). Within the 
included 38 patients were 25 participants having a prostate biopsy positive for cancer with 
21 deemed to have clinically significant CaP. 
The demographic information of the cohort including median (IQR) age, serum PSA and 
relative expression ratios of RNA markers for each group, absolute and clinically 
significant CaP presence, are presented in Table 5.1A and 5.1B, respectively. Men were of 
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comparable ages in each classification group. Serum PSA was similar for men diagnosed 
with CaP compared with men in the no CaP group. This relationship was preserved for 
serum PSA when comparing men with clinically significant CaP against those without 
clinically significant CaP. Similar trends were observed in the expanded cohort, which 
comprised 62 patients with 36 participants with a positive prostate biopsy and 30 deemed 
to have clinically significant CaP (Table 5.1A, 1B). 
5.2.4.2 – Biomarker performance  
5.2.4.2.1 – Absolute CaP status 
When considering absolute CaP status (Table 5.1A) and compared to a chance AUC of 
0.500, serum PSA (AUC 0.617; p=0.217) and PSA:β2M (AUC = 0.600; p =  0.353) in 
PEUW samples provided similar diagnostic performance. PCA3:β2M (AUC = 0.569; p =  
0.522) and. PCA3:PSA (AUC = 0.431; p = 0.528) in PEUW demonstrated inferior 
predictive ability. Similar results were not observed in the expanded cohort, with serum 
PSA (AUC = 0.610, p = 0.128) performing better than PSA:β2M (AUC = 0.506; p = 0.935), 
PCA3:β2M (AUC = 0.550; p = 0.531) and PCA3:PSA (AUC = 0.529; p = 728) .  
In ejaculate, best diagnostic performance was observed for PCA3:β2M (AUC = 0.717; p = 
0.033), followed by PCA3:PSA (AUC = 0.668; p = 0.078) followed by less impressive 
performance for serum PSA (AUC 0.617; p=0.217) and poor performance of PSA:β2M 
(AUC = 0.486; p = 0.895). 
5.2.4.2.2 – Clinically significant CaP 
When considering clinically significant CaP (Table 5.1B), similar performance was 
observed for serum PSA (AUC = 0.640; p = 0.124), PSA:β2M (AUC = 0.608; p = 0.269) 
and PCA3:PSA (AUC = 0.342; p = 0.093).   The performance of PCA3:β2M (AUC = 0.496; 
p = 0.966)  was poorer and less predictive of clinically significant CaP . Within the 
expanded cohort, only serum PSA (AUC = 0.665; p = 0.018) performed as well with poorer 
performance for the PEUW-based PSA:β2M (AUC = 0.525; p = 0.740), PCA3:β2M (AUC = 
0.503; p = 0.967) and PCA3:PSA (AUC = 0.469; p = 0.681).  
In ejaculate samples, PCA3:β2M (AUC = 0.667, p = 0.083) was similar to serum PSA, and 
PCA3:PSA (AUC = 0.605, p = 0.263). The performance of PSA:β2M (AUC = 0.521, p = 
0.828) was less impressive. For graphical purposes, comparison ROC curves are 
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A 
 
Absolute Cancer status 
Comparison cohort 
noCaP (n = 13); CaP (n = 25) 
Extended PEUW Cohort 
noCaP (n = 26); CaP (n = 36) 
Demographic information ROC analysis Demographic information ROC analysis 
noCaP 
[median (IQR)] 
CaP 
[median (IQR)] 
AUC (95% CI) Cutpoint Sn Sp noCaP 
[median (IQR)] 
CaP 
[median(IQR)] 
AUC (95% CI) 
Age 65 (58.5 – 71) 63 (57 – 68.25) - - - - 64.5 (60 – 69) 63.5 (58 – 69) - 
Serum PSA 6.20 
(4.13 – 7.30) 
6.50 
(5.13 – 10.4) 
0.617 
(0.445 to 0.770) 
9.05 36 100 6.30 
(4.70 – 8.2) 
7.00 
(5.25 – 11.00) 
0.610 
(0.477 to 0.731) 
PEUW PSA:β2M 0.07 
(0.003 – 0.36) 
0.10 
(0.02 – 1.24) 
0.600 
(0.429 to 0.755) 
0.006 84 46 0.32 
(0.005 – 1.18) 
0.15 
(0.14 – 0.97) 
0.506 
(0.376 to 0.636) 
PCA3:β2M 0.23 
(0.01 – 0.60) 
0.21 
(0.06 – 1.24) 
0.569 
(0.399 to 0.728) 
0.652 44 77 0.19 
(0.02 – 0.48) 
0.18 
(0.07 – 0.99) 
0.550 
(0.419 to 0.677) 
PCA3:PSA 2.72 
(0.52 – 61.97) 
1.45 
(0.51 – 9.66) 
0.431 
(0.272 to 0.601) 
0.764 72 38 1.24 
(0.14 – 20.80) 
1.19 
(0.55 – 9.32) 
0.529 
(0.398 to 0.657) 
Ejaculate PSA:β2M 0.07 
(0.003 – 0.36) 
0.03 
(0.003 – 0.19) 
0.514 
(0.347 to 0.679) 
0.003 80 38 - - - 
PCA3:β2M 0.01 
(0.004 – 0.10) 
0.04 
(0.02 – 0.28)* 
0.717 
(0.548 to 0.851) 
0.023 72 77 - - - 
PCA3:PSA 1.55 
(0.12 – 2.80) 
4.62 
(0.77 – 11.84) 
0.668 
(0.496 to 0.812) 
1.77 64 77 - - - 
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B 
Clinically significant 
CaP 
Comparison cohort 
Absent (n = 17); Present (n = 21) 
Extended PEUW Cohort 
Absent (n = 32); Present (n = 30) 
Demographic information ROC Analysis Demographic information ROC Analysis 
Absent 
[median (IQR)] 
Present 
[median(IQR)] 
AUC 
(95% CI) 
Cutpoint Sn Sp 
Absent 
[median 
(IQR)] 
Present 
[median (IQR)] 
AUC 
(95% CI) 
Age 
61 
(56.25 – 69.5) 
63 
(57.75 – 69.25) 
    
63.5 
(58.5 – 68) 
64 
(58 – 70) 
 
Serum PSA 
5.80 
(4.38 – 7.30) 
6.50 
(5.28 – 13.43) 
0.640 
(0.468 to 0.789) 
6.500 57 65 
6.00 
(4.55 – 8.20) 
7.60 
(5.50 – 11.90) 
0.665 
(0.534 to 0.780)* 
PEUW 
PSA:β2M 
0.04 
(0.002 – 0.94) 
0.10 
(0.01 – 1.24) 
0.608 
(0.436 to 0.762) 
0.006 86 41 
0.21 
(0.006 – 1.17) 
0.18 
(0.01 – 1.17) 
0.525 
(0.394 to 0.653) 
PCA3:β2M 
0.23 
(0.02– 1.13) 
0.17 
(0.04 – 1.08) 
0.496 
(0.330 to 0.662) 
0.652 43 71 
0.20 
(0.02 – 0.72) 
0.16 
(0.04 – 0.93) 
0.497 
(0.367 to 0.627) 
PCA3:PSA 
2.77 
(0.71 – 61.97) 
1.11 
(0.29 – 7.79) 
0.342 
(0.196 to 0.513) 
0.764 67 29 
1.58 
(0.18 – 16.02) 
1.03 
(0.52 – 7.30) 
0.469 
(0.341 to 0.600) 
Ejaculate 
PSA:β2M 
0.03 
(0.003 – 0.23) 
0.03 
(0.003 – 0.31) 
0.521 
(0.353 to 0.685) 
0.014 67 47    
PCA3:β2M 
0.02 
(0.004 – 0.25) 
0.04 
(0.02 – 0.28) 
0.667 
(0.495 to 0.811) 
0.023 71 65    
PCA3:PSA 
1.56 
(0.44 – 6.58) 
3.42 
(0.66 – 16.1) 
0.605 
(0.434 to 0.759) 
1.77 62 65    
Table 5.1: Demographic information for patients based on absolute cancer status (positive vs. negative biopsy; A) and clinically significant CaP 
classification (B). Median and interquartile range are shown for age and each marker in post-ejaculate urethral washing and ejaculate samples. All 
comparisons using the Mann-Whitney U-test (two-tailed; using a Bonferroni corrected threshold) were non-significant (p > 0.0125). * p < 0.05 for Area 
under curve with 95% confidence interval (AUC 95% CI) comparisons of markers with chance (AUC 0.5) as determined by the DeLong method. All 
comparisons between AUC estimates were non-significant (p > 0.0125). Abbreviations: β2M, β2-microglobulin; IQR, interquartile range; PEUW, post-
ejaculate urethral washings; PSA, prostate specific antigen; PCA3, prostate cancer antigen 3; Sn, Sensitivity; Sp, Specificity.  
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available in Figures A3.3 and A3.4 including the comparison P-values against the serum 
PSA AUC. 
5.2.5 Discussion 
PEUW could potentially be a new source of prostate-specific biomarkers for CaP detection 
and characterization, providing an alternative to serum and urine for further biomarker 
discovery and development. Thus, we investigated in this study the utility of prostatic cells 
in PEUW as a physiological source of CaP biomarkers. We have shown that the diagnostic 
performance of the mRNA-based marker PCA3, normalised to PSA or β2M, in PEUW is 
likely to be inferior to these markers in ejaculate, which were comparable to serum PSA. 
Overall, the performance is similar to PCA3 in post-massage urine in isolation (AUC 
0.62)369, as well as in ejaculate in an expanded cohort (AUC 0.625)15. PCA3 performed 
best in this cohort in detecting absolute CaP status compared with clinically significant 
CaP, in accordance with previous reports365. This preliminary investigation helps to build 
on current CaP biomarker research literature.  
The use of PEUW as a prostate-based biofluid is advantageous for a number of reasons. 
First, it contains prostatic effluent following ejaculation, indicated here by the presence of 
PSA. In addition, there is no requirement for patient discomfort in contrast to prostatic 
massage. Furthermore, there is the potential for tumour disruption and dissemination of 
malignant cells370, given known elevations in serum PSA after TRUSBx and DRE371. 
Reports regarding serum PSA elevation after ejaculation are mixed, with levels reported to 
return to normal after 48 hours372, thus PEUW following global contraction of the prostate 
gland with ejaculation can be considered a physiological equivalent of non-physiological 
post-massage urine. PEUW sampling enables post-coital donation, which may be more 
acceptable for some men and has been used to investigate infertility. The combination of 
urine and ejaculatory components in PEUW allows for assessment of markers reflecting 
local (ejaculate) and systemic (urine) pathology. While this enables use in clinical 
scenarios where systemic biological alterations are important to monitor, such as active 
surveillance and metastatic disease, it is also a potential drawback of PEUW, because the 
local pathology markers in the ejaculate component can be confounded by the systemic 
contributions from the urine component. These may contribute to the lower diagnostic 
performance of PEUW compared to ejaculate described here.  
The benefits that we have previously outlined for the use of ejaculate as a prostate-based 
biofluid also apply to PEUW. Specifically, ejaculate contains malignant prostatic epithelial 
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cells14, with cell-derived molecular markers PCA3 and Hepsin shown to be comparable 
diagnostically with PCA3 in post-massage urine15. Analysis of microRNAs in cell-derived 
mRNA in ejaculate has been reported to improve CaP detection, with miR-200b combined 
with serum PSA (AUC = 0.751) significantly better than serum PSA alone (AUC = 0.555)16. 
We have previously reported the use of a composite score, created using contributions 
from serum PSA, ejaculatory miR-125b and miR-200c, to significantly improve CaP 
detection (AUC = 0.869) compared with serum PSA alone (AUC = 0.672; p < 0.05)15. The 
ability to provide an ejaculate sample may also indicate a favourable “performance” status 
and consequent survival benefit, with a high and significantly better overall and CaP-
specific survival benefit observed for these patients at 10, 15 and 20 years17. Incorporation 
of exosome and metabolome analysis may improve predictive accuracy using these non-
invasively obtained biofluids20,373, reducing anxiety and uncertainty for clinicians and 
patients managed by active surveillance, in addition to assisting with CaP testing. Use of 
PEUW may be more favourable than ejaculate as PEUW samples can be provided in the 
comfort of the home environment and post-intercourse, a strategy more likely to be used 
by men than the sterile surrounds of the clinic setting. Similar to urine cytology, the sample 
could be stored overnight in the fridge and brought to the clinic the morning after, 
assuming RNA integrity is maintained. 
The aim of this comparative study was to investigate the diagnostic potential of selected 
molecular markers in PEUWs in detecting CaP on the basis of the D’Amico classification 
benchmark337, widely used to stratify in the past. However, the goal posts are in the 
process of being changed as it is being realized increasingly that intermediate risk CaP is 
not one condition but a spectrum of conditions.  Recently, the management strategy of 
active surveillance has been extended to include some Gleason 3+4 (ISUP 2) tumours 
regarded as ‘favourable’ by the National Comprehensive Cancer Network for men with a 
life-expectancy <10 yrs374, with this change supported by the American Society of Clinical 
Oncology375. By inference, this means not all intermediate-risk tumours can be considered 
as clinically significant. However, for the purpose of comparison, risk classifications such 
as that proposed by D’Amico remain relevant until the entity of clinically significant can be 
defined better. 
The limitations of this preliminary, exploratory study include the small sample size resulting 
in large confidence intervals and low statistical power. Biologically, the potential for low 
ejaculatory contribution or dilution reducing the prostate-specific RNA yield may impair 
results. PCA3:PSA levels in PEUW were lower in men with CaP, both in the comparison 
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and expanded cohorts, resulting in ROC estimates below 0.5, which was the inverse of 
that observed for ejaculate samples and other published reports.  Although the sample 
drop-out rates were similar for PEUW and ejaculate, with positive PSA signals suggesting 
the presence of prostatic material in both sample sets, these results suggest malignant 
cells may dominate in the ejaculate. A potential explanation for this are changes in cell 
adhesion molecules, which have been recognized for quite some time in CaP376, with most 
attention focused on E-cadherin. Loss of E-cadherin is particularly evident in more 
aggressive tumours with cadherin switching also recently described377. Thus, 
disaggregated cells or cell clusters from aggressive tumours first appear in ejaculate as a 
result of global contraction of prostatic smooth muscle following accumulation in acini prior 
to ejaculation. This in turn may cause relatively fewer cancerous cells to be present in the 
urethra from the latter part of the ejaculate, which would be dislodged with subsequent 
voiding. As a result, PEUW may contain less cancerous cells but does contain prostate 
epithelial cells, evidenced here by the presence of PSA.  Thus, in patients suspected to 
harbor non-aggressive CaP, the presence of prostatic cells in PEUW with low expression 
of PCA3 may help determine which patients have non-aggressive CaP amenable to active 
surveillance or watchful waiting. 
In conclusion, we introduced and investigated PEUW as a physiological source of CaP 
biomarkers. We found that PEUW contains prostatic cells, as evidenced by PSA signal. 
However, significantly upregulated PCA3 levels, consistent with those reported for 
malignant tissue, were only observed in ejaculate specimens.  PEUW may yet prove to be 
a useful source of cell-free secreted markers, as opposed to cell-derived markers. Further 
biomarker development using these prostate-specific biofluids may result in improved 
diagnosis and monitoring of CaP, reducing anxiety and doubt for the benefit of clinicians 
and patients. 
  
134 
 
5.3 NMR-based metabolomics of post-ejaculate urethral washings to 
predict and characterise prostate cancer using local and systemic 
metabolite changes. 
The contributions of the co-authors to this chapter section were as follows: Experiment 
design, experiment execution, data processing and statistical analysis and drafting of this 
chapter section was performed by Matthew Roberts, the PhD candidate, under the 
supervision of Dr Horst Schirra and Prof RA “Frank” Gardiner. Renee Richards, Clement 
Chow and Marion Buck assisted with sample collection. Jake Hattwell assisted with 
experiment execution, data processing and statistical analysis. John Yaxley provided 
advice on histological and clinical interpretation and Prof Martin Lavin provided critical 
manuscript revisions. Preparation of the manuscript and associated figures was performed 
by Matthew Roberts, the PhD candidate.  
The references have been collated in the section, ‘Bibliography’, with others contained in 
this thesis. 
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5.3.1 Introduction 
Early diagnosis of CaP to facilitate curative treatment requires an accurate biomarker 
superior to serum PSA, which is limited in detecting csCaP. Genetic markers in excreted 
prostatic fluids, such as non-coding RNA PCA3, in combination with the TMPRSS2:ERG 
fusion gene, improve CaP diagnosis but are used uncommonly as adjunctive tests10. 
Prostatic fluid excreted in ejaculate contains biomarkers predictive of csCaP, with the 
PCA3 and Hepsin mRNA and miRNAs detected in the epithelial cell component providing 
a diagnostic improvement compared to serum PSA alone15. Biomarkers contained in the 
plasma component, or ejaculate, also improve diagnostic accuracy, such as the 
metabolites citrate, spermine and myo-inositol and proteins12,23.     
Difficulties in collecting ejaculate due to erectile dysfunction, performance anxiety or 
individual reservations have driven investigation of other prostatic fluids12. PEUW, being 
the first urine sample following ejaculation, contains PSA RNA indicating a prostatic 
contribution to this biofluid and opportunity for biomarker discovery321. PEUW has the 
potential to provide information regarding local pathology from the prostatic contribution, 
as well as systemic disturbances due to CaP, from the renal contribution. While the 
diagnostic performance of PEUW prostatic RNA did not improve when compared to serum 
PSA, this may be due to a dominance of normal prostatic cells over malignant cells and 
help identify patients without csCaP. 
Profiling of metabolites, or metabolomics, applied to urine has provided biomarker panels 
reported to significantly improve diagnostic accuracy293. Furthermore, local and systemic 
metabolic disturbances have been suggested, with fatty acid synthesis most commonly 
implicated294. Thus, metabolite profiling of PEUW is expected to demonstrate locally and 
systemically deranged metabolite levels and potentially link these to altered metabolic 
pathways. 
The aims of this study were to: 
1. Investigate the feasibility of PEUW NMR-based metabolomics and if PEUW 
contains metabolites from ejaculate that are different to normal MSU metabolites 
(Feasibility cohort). 
2. Test whether the PAP-mediated hydrolysis of phosphocholine to choline happens in 
PEUW similar as in ejaculate (as described in Chapter 3.2) (Kinetics),  
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3. Determine the diagnostic performance of PEUW metabolite profiles to predict and 
characterise CaP in a high-risk clinical cohort compared to diagnosis obtained via 
prostate biopsy and RP histology (Clinical cohort). 
5.3.2 Materials and Methods 
This study received ethical approval from the RBWH Human Research Ethics Committee 
(HREC/09/QRBW/320, HREC/09/QRBW/305 together with 1995/088B) and University of 
Queensland Medical Research Ethics Committee (Project no. 2006000262).  
5.3.2.1 – Participants and Samples  
5.3.2.1.1 – Feasibility  
Firstly, to investigate the feasibility of PEUW NMR-based metabolomics and if PEUW 
contains metabolites from ejaculate, PEUW samples were first collected into sterile micro 
urine jars from eight men attending the RBWH for investigation of an elevated PSA or 
abnormal digital rectal examination (Pilot cohort). Following standard sample processing, 
as described in Chapter 5.2, supernatants were snap-frozen on dry ice in 1 ml aliquots and 
stored at –80°C.  
Then to compare PEUW profiles with normal mid-stream urine metabolite profiles, male 
patients (n = 4) younger than 30 years old and with no significant family history of CaP 
provided urine, ejaculate and PEUW specimens either on site or at home (Young cohort).  
All samples were delivered to the laboratory without cooling as soon as logistically 
possible and processed within 2 h of production. Subjects provided 10 sample sets, with 
control MSU sample collections interspersed between collection of ejaculate/PEUW 
samples per the collection regime outlined in Table 5.2.  
5.3.2.1.2 – Kinetics 
Secondly, to determine the kinetic behaviour of ejaculate-based metabolites within PEUW 
and compare with those observed in ejaculate only, a PEUW sample was collected into a 
sterile micro urine jar from a healthy male (aged 26) for immediate processing and NMR 
spectroscopy.  
5.3.2.1.3 – Clinical cohort 
Finally, to determine if PEUW provided accurate discrimination for the diagnosis and 
characterisation of csCaP, PEUW samples were also collected from the population  
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Sample Number Label Sample 
1 A MSU 
2 1 E/U E, PEUW 
3 2 E/U E, PEUW 
4 B MSU 
5 3 E/U E, PEUW 
6 4 E/U E, PEUW 
7 C MSU 
8 5 E/U E, PEUW 
9 6 E/U E, PEUW 
10 D MSU 
Table 5.2: Sample collection regime for Young cohort biofluid samples. Mid-stream urine (MSU; 
A-D) sample collections are interspersed between collections of ejaculate (E) and post-ejaculate 
urethral washing (PEUW) samples.  
described in Chapter 4.3, comprising 151 patients. PEUW samples were provided 
following ejaculation either on site or at home prior to or at least one month after prostate 
biopsy. Clinical data collection, histology interpretation and reporting as well as risk 
stratification were performed per that described in Chapter 4.3. 
5.3.2.2 – Sample preparation 
PEUW samples were thawed on wet ice (Feasibility, Young, Clinical cohorts) or taken 
fresh (Kinetics sample) and distributed as aliquots comprising 80% NMR tube volume 
(500 μl for 5mm tube, 200 μl for 3mm tube), 10% 0.1 M sodium phosphate with borate and 
combined with D2O as lock substance that contained DSS as internal chemical shift 
standard and DFTMP as internal pH indicator leading to final concentrations of DSS and 
DFTMP of 100 µM to contribute the remaining 10% NMR tube volume. Samples were 
transferred to sterile 5 mm (Clinical cohort) and 3 mm (Feasibility, Young cohorts, Kinetics 
sample) NMR tubes (Bruker Biospin, Rheinstetten, Germany). 
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Ejaculate samples for the Young cohort were collected and prepared as described in 
Chapter 4.3.  
5.3.2.3 – NMR spectroscopy 
NMR spectra of PEUW samples were measured on Bruker Avance spectrometers 
equipped with a 5 mm self-shielded z-gradient triple resonance cryoprobe and sample 
changer operating at a 1H frequency of 900.13 MHz (Bruker Biospin; Feasibility, Young, 
updated Clinical cohorts, Kinetics sample) and 500 MHz (initial Clinical cohort).  
For the Feasibility, Young and Clinical cohorts, 1D NOESY spectra were acquired at 298 K 
with the “noesypr1d” pulse sequence, accumulating 200 (Feasibility, Young) and 128 
(Clinical) transients (following 8 dummy scans) at 32k data points with a spectral width of 
14 ppm 150,264. The transmitter frequency was set to the water resonance, which was 
suppressed by continuous wave irradiation during the NOESY mixing time of 0.15 s and 
relaxation delay of 2.3 s. Tuning/matching, shimming, and data acquisition were performed 
automatically with the ICON-NMR interface for high-throughput automation.  
For the Kinetics sample, a pseudo-2D NMR spectrum was acquired, processed and 
subject to linear curve fitting as described in Chapter 3.2.  
5.3.2.4 – Spectral Processing 
NMR spectra were processed in TopSpin 3.2 (Bruker Biospin). The free induction decays 
were baseline corrected by a Gaussian function (0.1 ppm filter width) for post-acquisition 
water deconvolution315, followed by multiplication with an exponential window function (0.1 
Hz line broadening), and Fourier transformation to 64k points. Subsequently, the spectra 
were manually phased, baseline corrected and referenced to DSS at 0.0 ppm. For all 
further data manipulation, the spectra were truncated to δ=10.0–0.25 ppm, exported into 
MATLAB 2015b (The Mathworks Inc., Natick, Massachusetts, United States). 
5.3.2.5 – Spectral alignment and data reduction  
Spectra were exported either in full resolution from TopSpin or as spectral bins, or 
buckets, of 0.0005 ppm width using AMIX (version 3.6.6, Bruker Biospin, Rheinsetten, 
Germany) and subsequently imported into MATLAB 2015b (The Mathworks Inc., Natick, 
Massachusetts, United States). Automatic peak alignment was performed using “icoshift” 
131  based on manually defined segments and data reduced to buckets of 0.01 ppm width 
over the range 10.0–6.5 and 4.5-0.25 ppm using an in-house MATLAB script. 
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5.3.2.6 – Multivariate statistical analysis  
MVSA was performed using methodology described in Chapter 4.3, except the 
exploratory, preliminary Clinical cohort analysis of 106 samples which used integral 
normalisation.  
5.3.3 Results 
5.3.3.1 – Feasibility cohort 
1D NOESY spectra of PEUW samples demonstrated the presence of metabolites from 
both ejaculate (e.g. choline, phosphocholine) and urine (e.g. creatinine), which are not 
reciprocally observed in the other biofluid. Metabolites contained in both ejaculate and 
urine, such as citrate, were also observed (Figure 5.1). 
 
Figure 5.1: 1D NOESY NMR Spectrum of PEUW, demonstrating the presence of metabolites 
known to be present in ejaculate (*choline), urine (creatinine, Cre; Urea; hippurate, Hip; 
trimethylamine N-oxide, TMAO; sarcosine, Sar ) and in both (citrate, Cit).   
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5.3.3.2 – Young cohort 
Three subjects provided samples totalling 14 MSU and 22 paired PEUW and ejaculate 
samples (Table 5.3).  
Subject 
Cycles 
completed 
Samples provided 
MSU PEUW E 
1 1 4 6 6 
2 0.6 2 4 4 
3 2 8 12 12 
Total 14 22 22 
Table 5.3: Collection totals for mid-stream urine (MSU), post-ejaculate urethral washing 
(PEUW) and ejaculate (E) samples.   
To date, 1D NOESY spectra have been acquired for MSU and PEUW samples, which 
predominantly demonstrate the presence of the choline peak at 3.195 ppm in PEUW 
samples compared with MSU samples (Figure 5.2).  
 
Figure 5.2: 1D NOESY segment (3.15 – 3.23 ppm) spectral overlay of a urine-based sample 
set from the Young cohort. A sample collection cycle shows mid-stream urine (MSU) spectra 
relative to post-ejaculate urethral washings (PEUW) spectra, with the choline peak (dotted line) 
predominantly observed in PEUW but not MSU spectra.  
Spectral alignment, with potential deconvolution and subsequent MVSA will be performed. 
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5.3.3.3 – Kinetics 
To test whether the PAP-mediated hydrolysis of phosphocholine to choline happens in 
PEUW similar as in ejaculate (as described in Chapter 3.2), we measured pseudo-2D 
NOESY spectrum of PEUW (Figure 5.3a). Hydrolysis of phosphocholine to choline was 
observed (Figure 5.3b). The apparent rate constant for this reaction in PEUW was (0.033 - 
0.038 hr-1; R2 = 0.991) in PEUW. This is considerably slower than in ejaculate at room 
temperature (0.6761 hr-1) and is between that seen for 5mM (0.044 – 0.055 hr-1; Figure 
3.3) and 10mM tartrate in ejaculate (0.011 – 0.024 hr-1; Figure 3.3) at 298 K. 
 
Figure 5.3: Pseudo-2D spectral overlay of serial measurements of PEUW at 298K over time in 
the region of choline/phosphocholine (A). Hydrolysis and subsequent decrease of 
phosphocholine results in an increase in choline (B), as demonstrated by the reaction curves, at 
a rate similar to inhibition of the reaction when 5 - 10mM tartrate is added to ejaculate at 298 K 
(Figure 3.3). 
5.3.3.3 – Clinical cohort – Preliminary analysis 
The demographics of the entire clinical cohort are as presented in Chapter 4.3.  
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A preliminary metabolomics analysis was undertaken on 106 samples, which underwent 
standard preparation, NMR spectral acquisition at 500 MHz with standard processing and 
data reduction at full resolution. Following integral normalisation, MVSA was performed in 
SIMCA using the clinical classifiers most reflective of available tumour grade. Buckets 
containing ethanol were excluded and the bucket table recalculated. 
Principal components analysis yielded a model (n=106, k=765, R2X=0.251; Q2=0.075) with 
2 principal components (PCs), with outlying samples present due to the presence of 
hippurate (PC1), creatinine (PC2) and unknown compounds (UC1, UC2; Figure 5.4a-c). 
As no discrimination was apparent for csCaP and risk groups and following exclusion of 
samples containing the UC1 (n = 3) and abnormal spectra (n = 2), supervised PLS using 
csCaP as the dependent variable (n=106, k=765, A=2 [forced], R2Y=0.413; Q2Y=-0.113) 
showed trimethylamine N-oxide (TMAO), glycine and choline to be significant metabolites 
(Figure 5.4d-e). PLS analysis that incorporated risk groups as the dependent variable 
(n=106, k=765, A=2 [forced], R2Y=0.159; Q2Y=-0.077) showed choline, creatinine, glycine 
and TMAO to be associated with high, intermediate, low and benign risk groups, 
respectively (Figure 5.4f-g). 
With no discrimination according to csCaP, risk subgroup analysis was performed as 
described in Chapter 4.3. Similar findings were observed, with group separation among 
low and intermediate samples (n=20, k=765, A=1 [auto], R2Y=0.51; Q2Y=0.164) and 
negative/low risk and benign samples (n=45, k=765, A=1 [auto], R2Y=0.369; Q2Y=0.124). 
Despite comparison with intermediate risk and benign samples, with creatinine and TMAO 
observed to be lower in negative/low risk samples, while glycine and an unknown 
compound were elevated (Figure 5.5). The remainder of subgroup analyses were invalid, 
while the metabolite patterns observed with supervised analyses were inconsistently 
observed in unsupervised analyses with the same spectra (data not shown). 
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Figure 5.4: Preliminary analysis of 106 PEUW spectra from patients being investigated for CaP. 
Panels a-c: Principal Components Analysis suggested influential metabolites to include 
hippurate (Hip), creatinine (Cre) and unknown compounds (UC1, UC2) without discrimination 
between csCaP groups (blue = negative/low risk; red = high risk). Panels d-e: Supervised, 
partial least squares analysis for csCaP demonstrated trimethylamine N-oxide (TMAO), glycine 
(Gly) and choline (Cho) to be significant metabolites in an invalid model.  Panels f-g: PLS 
analysis for CaP risk (Y variable) groups demonstrated choline, creatinine, glycine and TMAO to 
be associated with high (red), intermediate (gold), low (green) and benign (blue) risk groups, 
respectively.  
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Figure 5.5: Preliminary sub-group analysis of PEUW spectra classified as negative,low risk 
(green) compared with intermediate risk (gold) and benign (blue). Despite comparison with 
intermediate risk and benign samples, creatinine (Cre) and TMAO were observed to be lower in 
negative/low risk samples, while glycine (Gly) and an unknown compound (UC2) were elevated.  
When citrate, a metabolite consistently implicated in CaP biofluid studies, was not 
observed to be significant, as seen in the ejaculate metabolomics analysis in Chapter 4.3, 
inspection of the spectral overlay showed that the citrate signals were distorted due to the 
formation of borate adducts from the preservative buffer (Figure 5.6)378. In order to 
optimize information recovery and reduce artefacts from citrate adducts, all samples were 
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re-measured using sodium azide as preservative on a Bruker 900MHz spectrometer (with 
cryoprobe and SampleJet sample changer) with similar parameters to previous to acquire 
1D NOESY spectra. 
 
Figure 5.6: 1D NOESY PEUW spectral overlay showing sarcosine and citrate in the region 2.74 
– 2.5 ppm. Samples initially measured using borate preservative demonstrate citrate adducts, 
despite interval alignment with icoshift (a). Samples were re-measured using azide preservative 
to eliminate citrate adducts (b), which after optimal peak alignment (c), no peak overlap or 
adducts were observed. 
5.3.4 Discussion 
In this chapter section, it has been shown that PEUW contains both prostatic and systemic 
metabolites that require further investigation. Ejaculate-sourced metabolites in PEUW 
were present in the feasibility cohort and shown to behave similarly to that observed in 
ejaculate in the kinetics experiment. Ejaculate metabolites in PEUW were observed when 
compared to MSU and will be substantiated in further analyses comparing PEUW and 
MSU spectra to ejaculate spectra using MVSA methods. This study will serve to establish 
the reliability of PEUW as a biofluid that has the ability to provide information of local 
prostatic pathology, provided by the ejaculate component, as well as systemic changes 
present in conjunction with or as a result of prostatic pathology. 
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The reduced hydrolysis of phosphocholine to choline observed in PEUW, where ejaculate 
metabolites are contained within a urine media, is likely to be multifactorial. Indeed, 
reduced hydrolysis could be accounted for by differences in pH between ejaculate (pH 6.9) 
and PEUW (pH 5.14) based on studies in prostate extract where a 50% reduction in PAP 
activity is observed between these pH levels314. Varied inhibition has also been described 
due to presence of ions, such as calcium and zinc, which are commonly present in urine 
and thus PEUW314. 
When preliminary analysis was conducted in 106 patients being investigated for CaP, 
group separation was most pronounced when comparing negative/low risk with benign and 
intermediate risk samples. This relationship was observed for ejaculate samples in 
Chapter 4.3 and supported by other investigators, where it has been shown that metabolite 
changes are greatest early in the malignant transformation process279,280. With ejaculate-
metabolites minimally affected by PAP-related hydrolysis, the association of choline with 
high risk samples may be consistent with that observed in vivo, while creatinine has been 
implicated with CaP based on epidemiological data. Glycine has been associated with 
CaP tumorigenesis and altered methionine and other amino acid metabolism 283. The 
association of TMAO with benign and intermediate risk samples is likely an artefact of 
misclassification of the benign samples, as discussed at length in Chapter 4.3. TMAO has 
been reported in other studies to be associated with aggressive CaP in serum289. 
This preliminary, exploratory study is limited by incomplete analysis of the Young cohort 
experiment and Clinical cohort measured with sodium azide at 900 MHz. Additionally, the 
results are speculative due to the few low risk tumours included and limited statistical 
certainty, as these were the result of opportunistic sample collection for this proof-of-
concept study. Thus, this study was hypothesis-generating and statistical power 
considerations were reserved for future, larger validation studies on the basis of estimates 
presented here. Furthermore, potentially low ejaculate metabolite contributions from 
dilution with urine or reduced ejaculate volume may be addressed by normalisation to a 
consistently expressed compound unique to ejaculate, which is currently being 
investigated. As observed for RNA and discussed in Chapter 5.2, low ejaculate-based 
metabolites may also be a surrogate indicator of reduced malignant cell excretion in 
PEUW, however use of PEUW supernatants may serve to overcome this cell-based 
limitation, as observed in preliminary analyses. 
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5.3.5 Conclusions 
Following proof-of-concept for PEUW use and initially promising clinical results, it is 
expected that the multivariate model based on the metabolite profiles in PEUW will 
improve the prediction of CaP in this clinical cohort. These results can then be applied to 
other cohorts prospectively. The metabolites contained within this unique, non-invasive 
biofluid are likely to represent CaP-induced local and systemic metabolic disturbances.  
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Chapter 6 – From bench to bedside: clinical implementation of 
prostatic fluid biomarkers 
6.1 Synopsis 
The aim of this chapter is to describe how, based on the previously presented methods 
and results demonstrating the feasibility and potential to predict and characterise CaP, 
prostatic fluid biomarker performance can be confirmed in a phase 2 “window” clinical trial. 
Section 6.2 contains a published peer-reviewed published clinical trial protocol that 
outlines the implementation of a novel methodology developed within this thesis where 
serum PSA, combined with prostatic fluid biomarkers may be used to characterise and 
monitor CaP. The use of MRSI is described to demonstrate how in vivo metabolite profiling 
may assist in monitoring of disease progression or treatment effects. 
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6.2 “Can atorvastatin with metformin change the natural history of 
prostate cancer as characterized by molecular, metabolomic, imaging 
and pathological variables? A randomized controlled trial protocol.”  
(published manuscript) 
The manuscript entitled, “Can atorvastatin with metformin change the natural history of 
prostate cancer as characterized by molecular, metabolomic, imaging and pathological 
variables? A randomized controlled trial protocol.” has been published by Contemporary 
Clinical Trials (2016; 50:16-20) 
The contributions of the co-authors to this manuscript were as follows: Trial co-ordination 
and recruitment, experiment design, data processing and statistical analysis drafting was 
performed by Matthew Roberts, the PhD candidate, under the supervision of Dr Horst 
Schirra and Prof RA “Frank” Gardiner. John Yaxley, Geoff Coughlin, Troy Gianduzzo, 
Rachel Esler and Nigel Dunglison will contribute to trial recruitment. Suzanne Chambers 
will provide psychosocial advice and oversight. Robyn Medcraft will assist with trial co-
ordination. Renee Richards, Clement Chow, Marion Buck and Luke Selth will continue to 
assist with sample collection, experiment design and execution with data processing. 
Nicholas Kienzle, Macy Lu and Ian Brereton will assist with imaging co-ordination and 
interpretation. Hema Samaratunga, Joanna Perry-Keene and Diane Payton will provide 
advice on histological interpretation. Chikara Oyama will assist with laboratory 
experimental design. Suhail Doi provided guidance for sample size calculation and will 
assist with statistical analysis and data interpretation. Prof Martin Lavin provided critical 
manuscript revisions. Preparation of the manuscript and associated figures was performed 
by Matthew Roberts, the PhD candidate.  
The manuscript text is presented as originally published by the journal. To maintain a 
consistent style between chapters in this thesis, abbreviations, placement of figures and 
tables within the text, as well as numbering of pages, figures and tables has been 
adjusted. The references have been collated in the section, ‘Bibliography’, with others 
contained in this thesis. 
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6.2.1 Abstract 
Background: Atorvastatin and metformin are known energy restricting mimetic agents 
that act synergistically to produce molecular and metabolic changes in advanced prostate 
cancer. This trial seeks to determine whether these drugs favourably alter selected 
parameters in men with clinically-localized, aggressive CaP. 
Methods/design: This prospective phase II randomized, controlled window trial is 
recruiting men with clinically significant CaP, confirmed by biopsy following multiparametric 
MRI and intending to undergo RP.  Ethical approval was granted by the Royal Brisbane 
and Women’s Hospital Human and The University of Queensland Medical Research 
Ethics Committees.  
Participants are being randomized into four groups: metformin with placebo; atorvastatin 
with placebo; metformin with atorvastatin; or placebo alone. Capsules are consumed for 8 
weeks, a duration selected as the most appropriate period in which histological and 
biochemical changes may be observed while allowing prompt treatment with curative 
intent of clinically significant CaP. At recruitment and prior to RP, participants provide 
blood, urine and ejaculate. A subset of participants will undergo 7Tesla magnetic 
resonance spectroscopy to compare metabolites in-vivo with those in ejaculate and 
biopsied tissue.  
The primary end point is biochemical progression, defined using biomarkers (serum PSA; 
PCA3 and citrate in ejaculate and prostatic tissue). Standard pathological assessment will 
be undertaken alongside quality of life and psychosocial outcome assessments.  
Discussion: This study is designed to assess the potential synergistic action of metformin 
and atorvastatin on CaP tumour biology. The results may determine simple methods of 
tumour modulation to reduce disease progression. 
 
Keywords: Prostate cancer; atorvastatin; metformin; clinical trial; biomarkers; 
metabolomics 
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6.2.2 Introduction  
Aggressive CaP cells increase glucose uptake and glycolysis under normoxic 
conditions (the Warburg effect 179) producing glycolytic intermediates that also feed 
biosynthesis and CaP proliferation379,380. Metformin reduces glucose oxidation to 
increase glutamine metabolism and cell death while inhibiting metastatic behaviour. 
Epidemiological evidence suggests metformin use is associated with reduced risks of 
many cancers, including CaP381,382 with reduced hyperinsulinaemia by metformin in 
advanced CaP potentially improving ADT response383. When statins are combined with 
metformin, further reduction in CaP progression and improved clinical outcomes have 
been reported, indicating a potential additive or synergistic effect to this medication 
combination384-386.  Statins reduce cholesterol and mevalonic acid biosynthesis, with in 
vitro evidence that statins slow testosterone synthesis by inhibiting pre-cursor molecule 
transport, improving ADT response387. Hypercholesterolaemia is associated with high 
risk CaP 388 and androgen-independent CaP metastasis389 with statin use associated 
with lower PSA levels, percentage positive biopsies and fewer cases of advanced and 
fatal disease385. Lipophilic statins such as atorvastatin also inhibit CaP cell migration to 
bone marrow stroma390, however benefit in reducing biochemical recurrence, remains 
uncertain391.  
Medication safety profiles of metformin and atorvastatin are favourable, with significant 
side effects rarely observed. Concern for metformin regarding lactic acidosis is 
reserved for patients with significant comorbidities (chronic renal failure, congestive 
cardiac failure)392. Large cohorts consuming statins report rhabdomyolysis in up to 11 
per 100,000 person-years393. The use of metformin as a neoadjuvant agent for 4-12 
weeks by Joshua and colleagues was well tolerated and demonstrated a 10% 
reduction in PSA, 6.5% reduction in IGF-1 and 5% reduction in BMI394. Such ideal drug 
tolerability and favourable clinical effects supports their adjunctive use in localized 
prostate cancer without need for a phase I controlled trial in this context. 
Metformin and atorvastatin may influence malignant metabolic transformation in the 
prostate, known to favour ATP production and fatty acid synthesis, by shifting citrate, 
detectable in ejaculate12,20,289. Markers, such as PCA3, improve CaP detection and 
disease monitoring but may vary with epigenetic and exogenous stimuli15,321.  
Initially promising findings by Joshua and colleagues demonstrated significant changes 
in molecular markers following neoadjuvant metformin therapy prior to RP394. These 
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medications are also being explored in Metformin Active Surveillance Trial Study 
(NCT01864096) in delaying pathologic disease progression. Thus, exploring the role of 
energy restriction mimetic agents represents an exciting development in managing 
men with CaP. However, before atorvastatin and metformin can be entertained for use 
in patients with early CaP, their potential demonstrable beneficial effects with respect 
to tumour parameters need to be evaluated objectively.  
The primary aim of this study is to determine whether these drugs by themselves and 
together, favourably alter selected parameters in a group of clinically-localized, 
aggressive tumours.  
6.2.3 Materials and Methods 
6.2.3.1 – Study design 
This is a prospective randomized, double-blinded controlled phase II window trial designed 
to determine the efficacy on biochemical progression of atorvastatin and metformin, in 
isolation and together, in a population of men with early, clinically significant CaP. In 
addition, the effect of these drugs on CaP biology will be assessed in a population not 
previously studied in this respect whilst these men await definitive treatment by RP, in 
accordance with a phase II window trial design395. Men with an elevated PSA who have a 
mpMRI examination that demonstrates a PI-RADS 4 or 5 lesion and who, at consultation, 
express an intention to proceed to RP should biopsy confirm the suspicion of high-risk 
CaP, will be approached to enter the study. Our current practice includes in depth 
counselling prior to biopsy in order to ascertain the benefits to the patient in investigating 
for CaP. This includes outlining the biopsy and treatment process, with treatment options 
of surgery, radiotherapy, active surveillance or watchful waiting all discussed. Following 
written informed consent and randomisation by the manufacturing pharmacy (QPharm) to 
ensure clinician and participant blinding, four study groups are being examined, as outlined 
in Figure 6.1.   
The protocol is designed and reported according to the SPIRIT guidelines396. Participants 
will provide blood, urine and ejaculate after 48hrs abstinence of sexual activity. Blood and 
ejaculate samples will be used to determine biomarkers of interest as defined by the 
primary and secondary endpoints. Further exploratory analyses will be conducted as 
outlined in order to determine biochemical effects of these medications in this patient 
cohort. Prior to giving specimens, a subset of participants, selected by a sub-  
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Figure 6.1: Flow chart of study design, incorporating timing of specimen collection, imaging and 
capsule distribution. 
randomisation process, will opportunistically undergo a further mpMRI with MRS using a 
7Tesla machine at the University of Queensland Centre for Advanced Imaging. Here, we 
will assess the metabolic profile of participants prostates in-vivo, for comparison with those 
seen in ejaculate in vitro, and ascertain if superior imaging is provided by this machine. 
Participants will then undergo transperineal prostate biopsy targeting lesions of interest 
(cognitive biopsies) detected by pre-trial mpMRI, in addition to systematic whole gland 
biopsies using a template as per the local department protocol. Biopsy samples from index 
lesions and from non-index lesion areas will be taken for research purposes and stored for 
subsequent molecular and NMR analysis.  
Participants will undergo 8 weeks of capsule consumption, as this duration was determined 
to be most appropriate in which histological and biochemical changes may be observed 
while allowing prompt treatment with curative intent of clinically significant CaP. Non-
invasively obtained participant samples will be collected again and mpMRI with MRS will 
be repeated (for those previously randomized to have these investigations). The reason for 
allocating only a limited number of participants for mpMRI and MRS with the 7 Tesla 
machine is cost. The biomarker kinetic changes following biopsy are poorly described, 
however we expect these will be minimally affected by biopsy artefacts with 8 weeks of 
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treatment and healing. Latifoltojar and colleagues examined changes in mpMRI 
parameters following biopsy and described a return to baseline apparent diffusion 
coefficient parameters 1 month post biopsy397. The effects of biopsy on MRS parameters 
are currently unknown and will be examined in this study.  
Ethical approval has been obtained from the RBWH Human Research Ethics Committee 
(Approval no. HREC/14/QRBW/153 together with HREC/09/QRBW/320, 
HREC/09/QRBW/305 and 1995/088B) and The University of Queensland Medical 
Research Ethics Committee (Approval no. 2014000944 together with 2006000262) using 
the National Ethical Application Form. Specialist clinicians are overseeing all aspects of 
management through our established team. This trial has been registered in the Australian 
New Zealand Clinical Trials Registry (Registration number: ACTRN12615000571572). 
Consent to participate in the trial is being obtained from treating urologists or the Trial 
Coordinator (RM). This process also includes provision for storage and future use of 
clinical data and biological specimens. Database access is password-protected and limited 
to the Trial Coordinator (RM) who will then provide information as necessary to the other 
investigators. The database will be stored on a secure internal (UQ) server. At the 
conclusion of the trial, data access will be limited to the Trial Coordinator (RM) and 
relevant Principal Investigators (MJR, RAG). 
Adverse events are being monitored by the Trial Coordinator (RM), who contacts 
participants by telephone on two occasions during the trial to ensure satisfaction and 
determine the presence of any medication side-effects, or other difficulties. In addition, 
participants are instructed to contact the trial coordinator should they have any concerns or 
difficulties at other times during the trial. Further reports to the participants treating 
urologists and general practitioners, as well as relevant hospitals will be included and 
promptly assessed in detail.  
Untoward events are being determined by participant experiences of new symptoms 
during the study period, as well as routine monitoring using pathology tests, and the 
results of any other investigations prompted by other health professionals (e.g. general 
practitioners, emergency department clinicians) during the study period. The Clavien 
system is being used to document any adverse effects reported, while study 
questionnaires are also being monitored for participant satisfaction. Adverse outcomes 
and trial conduct are regularly audited and discussed with the relevant ethics 
representatives. 
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The funding source had no involvement in study design; in the collection, analysis and 
interpretation of data; in the writing of the report; and in the decision to submit the article 
for publication. 
6.2.3.2 – Study population and Recruitment 
Participants are being recruited from the RBWH Urology Outpatient clinic and specialist 
private practices in Brisbane, Queensland. Clinicians identify men as having clinically 
significant CaP on the basis of prostate imaging with mpMRI and who intend to proceed to 
RP. Following informed consent, those fulfilling all inclusion criteria and no exclusion 
criteria are entered into the randomization process. Recruitment is promoted by treating 
urologists discussing the study with eligible participants. 
6.2.3.2.1 – Inclusion criteria  
• suspected of having high-risk CaP on the basis of mpMRI (PIRADS 4/5 lesions), 
with clinically-localized CaP and who intend to proceed to RP following confirmation 
of their disease as high-risk following biopsies;  
• able to provide informed consent (written and verbal) in English;  
• considered by their urologist that involvement in the research programme/ 
involvement in the study is considered to be their best interests, for appropriate 
selection of patients who are likely to benefit from treatment;  
• prepared and able to provide a specimen of ejaculate for monitoring before biopsy 
and at the completion of treatment, just before RP;  
• willing to provide urine and serum samples prior to biopsy and again before RP  
• able to lie flat and willing to undergo mpMRI/MRS scanning on two occasions 
during the trial period with no previous or current history of claustrophobia; 
• normal fasting blood glucose, kidney and liver function tests; 
6.2.3.2.2 – Exclusion criteria 
• previous history of head injury, dementia, psychiatric illness or concurrent cancer;  
• regular administration of any lipid-lowering medication or blood-glucose lowering 
drugs 
• prior experience of any adverse effects with lipid or glucose-lowering drugs;  
• currently taking drugs known or thought to have an interaction with metformin and 
atorvastatin; 
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• previous ingestion of a 5-alpha reductase inhibitor drug; 
• known co-morbidities that would contraindicate commencement of metformin or 
atorvastatin, such as chronic kidney disease, congestive heart failure, liver disease.  
6.2.3.3 – Randomisation and allocation concealment 
Following enrolment, participants are randomized using a centralized database by an 
external research pharmaceutical organisation (QPharm Pty Ltd), which is experienced in 
participation and formulation of drugs for its own and other clinical trials. The 
randomization is stored and concealed by QPharm, resulting in blinding of clinicians and 
participants to study medications. Unblinding will be permissible in the event of an adverse 
event resulting in cessation of medication use, with liaison between the investigators, 
QPharm and the participant. All medications are identical in appearance to maintain 
blinding during medication ingestion. 
6.2.3.4 – Intervention 
Participants are randomized into one of the four study groups:  
1) metformin 500 mg twice a day with placebo once a day;  
2) atorvastatin 20 mg once a day with placebo twice a day;  
3) metformin 500 mg twice a day with atorvastatin 20 mg once a day;  
4) placebo three times a day.  
All capsules have been formulated by QPharm Pty Ltd to appear identical in order to 
comply with blinding for participants and investigators.  
6.2.3.5 – Outcome measures 
6.2.3.5.1 – Primary endpoint 
The primary end point is serum PSA “biochemical evolution” (bEvo), defined as an increase 
in Serum PSA prior to surgery and following 8 weeks of treatment from baseline 
measurement of 20% (based on values of reported studies394,398,399). These studies were 
used instead of those from larger observational studies400,401 as the observational studies 
had a low (25 – 30%) proportion of clinically significant CaP. The term “biochemical 
progression” is intended for this specific definition and different from “biochemical 
recurrence” commonly used in the post-treatment scenario. 
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6.2.3.5.2 - Secondary endpoints  
Secondary endpoints that are being assessed opportunistically are biochemical progression 
for ejaculate-based biomarkers PCA3:PSA and citrate, defined for each biomarkers as 
follows:  
a) PCA3:PSA measured in ejaculate: Increase from baseline measurement by 20% 
(based on improved all-cause and cancer-specific survival estimates402). 
b) Citrate measured in ejaculate and prostatic biopsies at the time of transperineal 
biopsies and the prostate ex-vivo after RP as well as MRS: Increase from baseline 
measurement of 30% (based on serum citrate association with aggressive prostate 
cancer289). 
These biochemical markers are being preferentially assessed ahead of tissue histological 
markers on the basis that biochemical effects precede histological change, known as the 
‘field effect’ in cancer biology172, and are thus more likely to be detected in vitro using 
ejaculate and in vivo using MRSI.  
6.2.3.5.3 – Clinical Data Collection 
Clinical data will be obtained by participating urologists and the Trial Coordinator (RM), 
who contacts participants by telephone on at least two occasions during the trial to ensure 
participant satisfaction and determine the presence of any side-effects or other difficulties. 
The Trial Coordinator is experienced in the data collection tools being used. Data will be 
collected onto a CAISIS database, used in our randomized, controlled study of open and 
robotic prostatectomy403,404 and with which we are familiar.  
6.2.3.5.4 – Assessment and Follow-up 
Participants are being assessed for inclusion upon enrolment for prostate biopsy. Those 
whose biopsies do not include any Gleason 4 or 5 tumour do not receive drug and do not 
take any further part in the study. Participants continuing receive medication, as per 
randomization protocol, and are placed on the waiting list for surgery which is planned for 
8 weeks after their biopsies. 
Serum investigations used clinically include total PSA (Abbott Architect® assay) and free-
total PSA estimations as well as serum testosterone and metabolic screening (serum 
biochemical and lipoprotein profiles). Blood tests will all be performed according to 
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standard assays by Sullivan & Nicolaides Pathology in addition to glycoslylated PSA 
quantified as previously described405.  
The intended duration from diagnosis and treatment is 8 weeks, with assessments 
performed prior to biopsies and again just before RP. mpMRI and MRS will be assessed 
by IB, NK and ML. Biopsy and RP slides will be reviewed by specialized uropathologists 
(JP-K, JDP, MLTHS) with reference to the 2014 ISUP classification406 for continuity and 
expert interpretation. Standard parameters for biopsies (total number of cores, number and 
percentage of positive cores, Gleason/ISUP score) and RP specimens (gland size, margin 
status, extracapsular status, pathological stage, Gleason score) are being reported. 
Surgical follow-up is being determined by the treating urologist with follow-up assessments 
performed at these appointments until 24 months post-operatively.  
Technical details regarding biological sampling and storage as well as molecular and 
metabolomic investigations are outlined in Chapters 4 and 5. 
6.2.3.6 – Sample size and statistical analysis  
Sample sizes were based on a randomized selection design with the aim of achieving a 
80% probability that the best schedule produced the highest observed response rate407-409. 
We took the expected baseline freedom from biochemical progression rate for the placebo 
schedule to be 80% based on results reported for the serum PSA biomarker399. We 
estimate that we need to study 20 participants per schedule, to have a 80% probability of 
selecting the schedule that has a true freedom from biochemical progression rate that is at 
least 15% higher assuming this is the minimal practically significant difference. This 
calculation can be verified through the online calculator from the Centre for Clinical 
Research and Biostatistics of the Chinese University of Hong Kong 
(https://www2.ccrb.cuhk.edu.hk/stat/phase2/Randomized.htm). We were unable to suitably 
estimate the proportion of men who would be enrolled with a negative biopsy result and so 
are continuing to recruit until the sample size is achieved. 
Differences in categorical variables between groups will be tested using chi squared 
analysis while continuous variables will be compared using two-sample t tests. Univariate 
analysis will be performed using the binary bEvo variable as the outcome and intervention 
schedule category as the predictor using a GLM with a Poisson family, log link and robust 
error variances in order to generate the relative risk. Multivariable analysis will also be 
performed using a similar GLM to determine the independence of the schedule of 
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treatment from other relevant explanatory variables. The latter will be included in the 
multivariable model if they are found to be associated with outcome (P<0.2) on univariate 
analysis. Link specification will be tested using the squared linear predictor while the 
goodness of fit of the model will be evaluated by the ability of the linear predictor from the 
model to classify participants into progressors and non-progressors (i.e., its predictive 
performance) will be evaluated using the C statistic, a term equivalent to the area under a 
receiver operating characteristic curve for the dichotomous outcome (bEvo). All analysis 
will be done using Stata (StataCorp, College Station, TX) and P<0.05 will be the threshold 
for significance.  
6.2.4 Discussion 
Since commencing the study in March 2015, 9 participants have been recruited and 2 
have completed the treatment and assessment protocols. One man with a mpMRI PI-
RADS 4 lesion did not have CaP detected with his biopsies. As a consequence his 
participation in the trial was terminated. Compared with recruitment for altruistic ejaculate 
donation by patients without likelihood of personal benefit, recruitment for this study, which 
includes ejaculate donation as an essential requisite, has been much easier but 
considerable greater difficulty is being experienced identifying men who have not been 
consuming a statin regularly.  
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Part 4 – Conclusions   
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Chapter 7 – Summary and discussion  
7.1 Summary 
The early detection CaP is limited by an absence of biomarkers that accurately reflect 
clinically significant disease. Currently implemented PSA-based CaP detection method 
have limitations that, despite use of adjunctive biomarkers such as phi, PCA3 and 
TMPRSS2:ERG, require new biomarkers to accurately diagnose localised CaP. Prostatic 
fluid in ejaculate or as PEUW contains CaP-specific biomarkers and provides a surrogate 
marker for patients with CaP who may survive long enough to benefit from curative 
treatment, based on improved overall survival of ejaculate donors relative to age-matched 
patients with CaP. Biomarkers in prostatic fluid have been reported to improve diagnosis in 
small proof-of-concept studies with minimal validation performed to date.  
This thesis investigated prostatic fluid derived from ejaculate and PEUW collected from a 
“high risk”, clinically applicable cohort to improve CaP diagnosis and characterisation using 
molecular and metabolomic detection methods. Specifically, this Thesis also sought to 
optimise ejaculate sample processing for metabolomics studies and evaluate the 
diagnostic performance of mRNA, microRNA and metabolomic markers in ejaculate and 
PEUW to complement serum PSA in detecting clinically significant CaP.  
To optimise ejaculate sample processing for metabolomics studies, the addition of tartrate 
and cooling of ejaculate samples improved the stability of choline and phosphorylcholine 
levels reflected by NMR-based metabolite kinetics. Clinical sample collection into a sterile 
urine jar containing 5 mM (on-site) or 10 mM (off-site) tartrate in 20 ml PBS solution cooled 
to 277 K and cooled during transport until processing would result in at most a 2-3% 
change in choline and phosphorylcholine to facilitate sample collection off-site without 
significant effect on choline-based metabolites.  
To evaluate the diagnostic performance of mRNA and microRNA markers in 66 ejaculate 
samples to complement serum PSA in detecting clinically significant CaP, a Hepsin:PCA3 
ratio together with serum PSA best predicted absolute and clinically significant CaP. For 
20 patients with matched mRNA and microRNA expression, serum PSA combined with 
miR-200c and miR-125b improved prediction of absolute CaP (AUC=0.869 vs 0.672; 
p<0.05), improving specificity (67%) at 90% sensitivity compared with PSA alone (11%).  
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Following adjustment for variable glucose concentration attributable to the initial buffer 
used and unbalanced metabolite (choline/phosphocholine) regulation, metabolomic 
analysis of ejaculate supernatants showed that metabolites best predicted low and 
intermediate risk CaP with grouping observed between these groups and benign and 
intermediate risk samples. Lipoproteins dominated spectra of high grade samples with less 
metabolite contributions. Overall CaP prediction using metabolites described in previous 
studies was not validated.  
To establish that PEUW contains prostatic-specific biomarkers, prostatic cell RNA 
isolation, amplification and qPCR for β2M, PSA, PCA3 and Hepsin was possible for 38 
PEUW samples, with corresponding ejaculate markers. PCA3:PSA in ejaculate 
(AUC=0.668) and PEU (AUC=0.569) were comparable with serum PSA (AUC=0.617) in 
predicting absolute CaP status, which may be due to a dominance of normal prostatic cells 
over malignant cells and help identify patients without csCaP. To corroborate these 
findings, NMR-based metabolomics analysis of PEUW demonstrated that PEUW contains 
prostate-specific biomarkers attributable to the presence of ejaculate, both in young 
healthy volunteers and at-risk patients. Kinetics methodology confirmed these metabolites 
to behave kinetically similar to those observed in ejaculate. Initial metabolomic analysis of 
PEUW demonstrated best discrimination between low and intermediate risk groups as well 
as benign samples, but was complicated by the presence of borate-citrate adducts. 
Following adjusted sample preparation and data acquisition, spectral alignment and 
statistical analysis is ongoing. 
A published study protocol for a phase II “window” randomised controlled clinical trial that 
commenced in March 2015 described how these in vitro NMR-based metabolomic findings 
may translate to in vivo metabolite quantification using MRSI. These combined NMR-
based approaches may serve to better triage patients for biopsy or in active surveillance 
cohorts and monitor altered tumorigenesis by metabolically restricting drugs, such as 
metformin and atorvastatin.  
 
  
164 
 
7.2 Future directions 
The promising methods and early performance of prostatic fluid biomarkers presented 
within this Thesis provide a strong platform from which to expand future research. Suitable 
research topics include: 
1. Completion of the PEUW metabolomics analysis following measurement using 
sodium azide. With improved sample preservation and measurement at 900 MHz 
for improved sensitivity and spectral resolution, metabolites and/or relationships not 
previously described may be used to improve diagnosis and characterisation of 
CaP. 
2. Confirmation of the reproducibility, feasibility and diagnostic performance of 
biomarkers contained in prostatic cells in ejaculate and PEUW as well as 
metabolomic markers in ejaculate and PEUW supernatants in independent cohorts.  
3. Once diagnostic performance reliability is established, sample collection protocols 
can be tailored for practical use as a screening test with incorporated optimization 
methods (such as that presented in Section 3.2). This research would encourage 
use of these methods by other researchers to advance this novel approach. 
4. Evaluation of genetic markers in the cell-free fraction of ejaculate, predominantly 
contained in exosomes, or prostasomes, which have been shown by other 
investigators to contain durable RNA species for biomarker quantification in other 
biofluids. Accurate description of these RNA species may provide more accurate 
biomarkers and insight into the underlying pathogenesis of CaP. 
5. Matched analysis of ejaculate and PEUW to provide a “one stop shop” for CaP 
characterisation of low and high risk tumours, given both biofluids contain valuable, 
independent markers for assessing both disease states. A streamlined method for 
accurate non-invasive CaP diagnosis would be invaluable to clinicians in patients. 
6. Matched ejaculate, prostate tissue and prostate MRSI analysis of metabolites 
contained in tumour foci with adjacent non-cancerous tissue to determine which 
metabolic changes may be monitored in vitro or in vivo to predict CaP prior to 
histological transformation. Prediction and/or observation of pre-malignant changes 
using non-invasive methods would allow for more accurate diagnosis at an early 
state to facilitate successful curative treatment. 
7. Metabolic pathway analysis to determine the aetiology of initial prostatic malignant 
transformation and identify targets for imaging or therapeutics for early treatment 
and possible prevention of CaP in young men.    
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Subject Temperature (K) [Tartrate] (mM) Metabolite a Standard Error b Standard error c Standard error R2 
1 279 0 P-Cho 38103858.4230 304721.3457 0.1352 0.0059 1317449.2016 164916.5174 0.9996 
1 279 1 P-Cho 53747867.2310 1183268.5773 0.0183 0.0009 - - 0.9842 
1 279 3 P-Cho 48264917.8107 8906090.8846 0.0078 0.0018 3928866.5773 9024694.5405 0.9978 
1 279 5 P-Cho 53801463.6366 115913.7570 0.0042 6.2466E-005 - - 0.9983 
1 279 10 P-Cho 52460768.9812 235701.9838 0.0019 0.0001 - - 0.9676 
1 279 20 P-Cho 55062996.4100 335650.4872 0.0011 0.0002 - - 0.8442 
1 279 0 Cho 40294692.2026 850908.5798 0.1366 0.0160 33301468.6564 735503.2491 0.9969 
1 279 1 Cho 69451615.9273 21770972.9779 0.0139 0.0067 18501941.1790 2008376.6902 0.9700 
1 279 3 Cho 51577287.9334 8475533.1906 0.0080 0.0017 15402977.9459 253286.7039 0.9981 
1 279 5 Cho 62074627.6958 16849787.7718 0.0041 0.0013 15641323.1738 131248.0263 0.9972 
1 279 10 Cho 1576151530.4223 40592399458.7058 7.9614E-005 0.0021 14631253.4209 118322.0284 0.9970# 
1 279 20 Cho 1737122804.2224 182001860194.8281 4.2918E-005 0.0045 15204230.9720 154147.3216 0.9857# 
2 279 0 P-Cho 2402151.0406 34405.3437 0.2313 0.0570 466311.7839 17375.6995 0.9985 
2 279 1 P-Cho 10351138.8972 60594.8648 0.0413 0.0006 912672.9738 57676.6990 0.9999 
2 279 3 P-Cho 9799443.1905 330835.4009 0.0169 0.0009 2112304.5491 346770.0885 0.9994 
2 279 5 P-Cho 7630811.2090 1059172.4069 0.0103 0.0019 3915456.4594 1083182.2525 0.9975 
2 279 10 P-Cho 12242928.4153 61285.9509 0.0034 0.0001 - - 0.9855 
2 279 20 P-Cho 11882917.6267 90290.2163 0.0010 0.0002 0.02241 -204.7, 204.7 0.7485 
2 279 0 Cho 3547237.5526 183893.5199 0.0927 0.0145 17503996.6498 150393.4192 0.9824 
2 279 1 Cho 12156586.0058 133578.7990 0.0277 0.0006 10644222.9645 42896.4762 0.9998 
2 279 3 Cho 20717430.0584 2934789.6702 0.0073 0.0013 8208371.8203 68898.6172 0.9989 
2 279 5 Cho 23076839.1354 8205266.2361 0.0039 0.0015 7390693.3729 52808.9642 0.9985 
2 279 10 Cho 8566587.4940 1857210.3462 0.0082 0.0023 7443275.9106 54665.4962 0.9966 
2 279 20 Cho 4231653.7028 944654.6186 0.0128 0.0042 7019873.1039 69115.5093 0.9886 
3 279 0 Pho 647152.9466 3592.2321 0.1344 0.0013 12506.0315 775.2215 0.9985 
3 279 1 Pho 857404.2570 4823.9129 0.0226 0.0003 17987.6467 5737.3078 0.9994 
3 279 3 Pho 799722.6348 59567.6846 0.0097 0.0011 74182.6003 62065.2167 0.9927 
3 279 5 Pho 625938.9961 39313.7092 0.0081 0.0007 218060.6912 40449.7390 0.9968 
3 279 10 Pho 514495.2618 82413.6554 0.0060 0.0012 319664.5811 83737.4398 0.9904 
3 279 10(2) Pho 409699.9401 23208.0808 0.0105 0.0009 476917.3685 24347.0687 0.9947 
202 
 
3 279 0 Cho 685343.2148 5964.4212  0.1265 0.0019 369913.1895 6084.7792 0.9963 
3 279 1 Cho 940721.7920 7230.4875 0.0200 0.0003 201526.9689 2253.9355 0.9993 
3 279 3 Cho 1201927.7331 115571.6732 0.0065 0.0008 168570.1818 3117.8211 0.9958 
3 279 5 Cho 1339537.5833 226968.1645 0.0034 0.0006 158887.9521 1601.7431 0.9972 
3 279 10 Cho 150800.4529 1504.3530 0.0023 0.0008 150800.4529 1504.3530 0.9956 
3 279 10(2) Cho 5547542.1445 8420879.2608 0.0006 0.0009 167662.7321 1655.9938 0.9948 
1 298 0 P-Cho 22209489.7905 181326.6944 0.6761 0.0141 1332439.2205 47634.7365 0.9995 
1 298 3 P-Cho 45101043.6580 183461.0530 0.0764 0.0005 - - 0.9998 
1 298 5 P-Cho 52394228.0472 265866.5087 0.0511 0.0005 - - 0.9994 
1 298 10 P-Cho 50545590.4709 268682.6090 0.0250 0.0004 - - 0.9982 
1 298 20 P-Cho 48454768.5224 274597.5368 0.0113 0.0004 - - 0.9909 
1 298 0 Cho 22643267.4205 435491.3116 0.5228 0.0240 36225005.6536 426319.4110 0.9975 
1 298 3 Cho 43345377.2891 348251.7688 0.0829 0.0018 14807784.4947 218052.9035 0.9997 
1 298 5 Cho 47537726.3565 356051.3724 0.0551 0.0010 14492313.5208 134309.0014 0.9999 
1 298 10 Cho 49788381.6239 1278681.0883 0.0249 0.0009 12383644.0943 74272.1601 0.9999 
1 298 20 Cho 36091259.8225 3927866.1897 0.0180 0.0025 11103210.8580 102377.3865 0.9995 
2 298 0 P-Cho 1452898.6810 Infinity 53.4403 Infinity 406988.7864 Infinity 0.9414 
2 298 3 P-Cho 9693784.3910 100662.8214 0.1588 0.0041 761092.0954 63548.3961 0.9992 
2 298 10 P-Cho 11614260.4769 123931.4720 0.0399 0.0009 - - 0.9965 
2 298 20 P-Cho 11393037.0701 87152.9838 0.0192 0.0006 - - 0.9941 
2 298 0 Cho 2505535.8946 103763.4229 0.3087 0.0343 14911955.3622 98451.2428 0.9899 
2 298 3 Cho 9345535.5600 82844.1713 0.1767 0.0038 8574215.7630 80045.7208 0.9995 
2 298 10 Cho 10459737.4442 260422.9935 0.0563 0.0029 6053031.7447 75816.5546 0.9993 
2 298 20 Cho 10670687.8822 727400.8455 0.0266 0.0026 5698269.4567 44069.8900 0.9994 
3 298 0 Pho 647152.9466 3592.2321 0.1344 0.0013 12506.0315 775.2215 0.9985 
3 298 1 Pho 857404.2570 4823.9129 0.0226 0.0003 17987.6467 5737.3078 0.9994 
3 298 3 Pho 4920809.8736 6499.5874 0.0360 7.1377E-005 - - 0.9998 
3 298 5 Pho 4983259.1449 6071.7653 0.0269 5.3128E-005 - - 0.9998 
3 298 10 Pho 514495.2618 82413.6554 0.0060 0.0012 319664.5811 83737.4398 0.9904 
3 298 10(2) Pho 4969305.5641 6859.0618 0.0148 4.4646E-005 - - 0.9994 
3 298 0 Cho 3823184.8682 42122.8310 0.3538 0.0062 1421822.1890 42264.4416 0.9945 
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3 298 1 Cho 4435188.8130 17698.2542 0.0900 0.0007 951199.7732 18364.5560 0.9991 
3 298 3 Cho 4839361.1861 15420.9763 0.0335 0.0003 763969.1487 13116.1839 0.9994 
3 298 5 Cho 4992300.0244 25038.6922 0.0242 0.0003 778759.5921 11795.1999 0.9994 
3 298 10 Cho 5193269.4087 64792.7117 0.0131 0.0003 811892.5964 7873.1410 0.9995 
3 298 10(2) Cho 5376125.0250 67547.8058 0.0124 0.0003 754768.7830 7198.1964 0.9996 
Table A1.1: Calculated apparent first-order kinetics exponential fit parameters for spectral intensities for phosphorylcholyne-choline hydrolysis. The 
equation used to model the decay of phosphorylcholine was: 𝑓 (𝑡) = 𝑎 ∙  𝑒(−𝑏∙𝑡) + 𝑐. A # symbol after the R2 value denotes a model that would not 
converge as a 3 or 2 parameter model. The equation used to model the production of choline was: 𝑓 (𝑡) = 𝑎 ∙  (1 − 𝑒(−𝑏∙𝑡)) + 𝑐    
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Metabolite  
Chemical shift range 
(ppm) 
Number of Protons 
per signal 
Absolute Molar Concentration (mM) 
Subject 1 
(Mean  ± StDev) 
Subject 2 
(Mean ± StDev) 
Subject 3  
(Mean ± StDev) 
298 K 
n=6 
279 K 
 n=6 
298 K  
n=6 
279 K  
n=6 
298 K  
n=5 
279 K  
n=4 
Choline 
CHEBI:15354 
3.186 – 3.206 9 
0.53 ± 
0.33 
0.25 ± 
0.02 
0.31 ± 
0.15 
0.13 ± 
0.01 
0.09 ± 
0.05 
0.06 ± 
0.01 
Phosphorylcholine 
CHEBI:18132 
3.206 – 3.216 9 
0.82 ± 
0.31 
0.73 ± 
0.01 
0.21 ± 
0.10 
0.17 ± 
0.005 
0.26 ± 
0.06 
0.21 ± 
0.01 
Glycerophosphorylcholine 
CHEBI:16870 
3.216 – 3.226 9 
0.26 ± 
0.04 
0.19 ± 
0.005 
0.10 ± 
0.04 
0.04 ± 
0.002 
0.06 ± 
0.002 
0.04 ± 
0.001 
Citrate 
CHEBI:30769 
2.486 – 2.706 4 (sum) 
1.58 ± 
0.15 
1.08 ± 0.02 
2.25 ± 
0.18 
1.37 ± 0.04 0.58 ± 0.02 
0.42 ± 
0.01 
Lactate 
CHEBI:24996 
1.306 – 1.336 3 
0.51 ± 
0.20  
0.25 ± 0.02  
0.45 ± 
0.31  
0.16 ± 0.01  0.13 ± 0.02  
0.06 ± 
0.004  
Spermine  
CHEBI:15746 
1.776 – 1.816 4 
0.31 ± 
0.03  
0.20 ± 
0.008  
0.44 ± 
0.03  
0.28 ± 0.01  
0.10 ± 
0.003  
0.07 ± 
0.003  
Fructose 
CHEBI: 28645 
3.976 – 4.036  1.45 
1.63 ± 
0.46  
1.14 ± 0.04  
0.56 ± 
0.10  
0.40 ± 0.03  0.39 ± 0.03  
0.31 ± 
0.02  
Tartrate (reference) 
CHEBI:15671 
4.296 – 4.346 2 10 10 10 
 
Table A1.2: Descriptive statistics for calculated concentrations of key metabolites identified in the multivariate statistical analysis (Figure 3.6) using 
tartrate as a concentration standard. The number of spectra included (n) for each subject at each temperature are provided. CHEBI – Chemical Entities 
of Biological Interest. 
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Figure A1.1: Representative 1D NOESY spectra of human ejaculate (Subject 3). Panel a – 
Single 1D NOESY spectrum (range -2 – 12 ppm) containing 1 mM tartrate acquired at t=0, with 
the segment to the left of the excluded water signal (5.1 – 4.5 ppm) up scaled by a factor of 
eight to improve metabolite visualisation. Panel b – Stacked plot showing 1D NOESY spectra 
containing 10 mM tartrate, acquired at 2 hour intervals across a 60-hour period. The figure 
shows the stability of the metabolite signals provided by the addition of tartrate. 
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Figure A1.2: Time-dependent phosphorylcholine (PCho) hydrolysis to choline (Cho) in ejaculate 
at 277 K with 1 mM tartrate characterised by NMR spectroscopy. Panel a – Stacked plot 
showing 1D NOESY spectra in the range 2.3 – 4.4 ppm with major metabolites labelled, 
acquired at various times (7.2, 11.4 and 23.5 h) after initial acquisition (0 h) demonstrating 
changes in peak intensities of phosphorylcholine (decrease) and choline (increase) over time. 
Panel b – Section of a pseudo-2D NOESY spectrum demonstrating changes in choline (Cho – 
increase), phosphorylcholine (PCho – decrease) and glycerophosphorylcholine (G-P-Cho – no 
change) metabolite peaks over time.  
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Figure A1.3: Panel a - Overlay of initial (t=0) 1D NOESY NMR spectra acquired from ejaculate 
samples at 298 K with varying tartrate concentrations (yellow = 0 mM, blue = 1 mM, red = 
3 mM, green = 5 mM, purple = 10mM, orange = 20 mM) over the region 2.4 – 4.4 ppm, 
demonstrating changes in initial choline (Cho) and phosphorylcholine (PCho) peak heights. The 
remaining metabolites, glycerophosphorylcholine (G-P-Cho), fructose, citrate and spermine, 
demonstrate constant peak heights. Panel b – Relative intensity change in phosphorylcholine 
peak at 3.21 ppm at different temperatures (298 K = squares; 279 K = triangles) after 24 hours 
for three subjects (blue, red, gold).  
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Figure A1.4: Relative expression of RNA biomarkers (PCA3, PSA and Hepsin normalized to 
β2M) in LNCaP cell culture and phosphate buffered saline (PBS - black). Expression levels are 
unchanged in the presence of 20 mM tartrate (dark grey), 0.05% sodium azide (antimicrobial 
sample preservative – light grey) and a combination of tartrate and sodium azide (white). * p > 
0.05.  
 
 
Figure A1.5: Apparent activation energies (EA) (right panel) calculated from linear fits of 
apparent rate constants of phosphorylcholine hydrolysis (measured in s-1) for each subject at 
277 K, 279 K and 298 K in an Arrhenius plot (left panel). Data for all volunteers yield similar 
slopes in the Arrhenius plot and thus also similar apparent activation energies for PAP. Black 
circles: Subject 1, open circles: Subject 2, black triangles: Subject 3. 
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A) 
Variable Odds Ratio Standard Error P>z 95% Confidence Interval 
Serum PSA 1.284 0.134 0.017 1.046 1.575 
Hepsin:PCA3 0.888 0.069 0.128 0.762 1.035 
 
 
B) 
Variable Odds Ratio Standard Error P>z 95% Confidence Interval 
Serum PSA 1.239 0.194 0.172 0.911 1.684 
miR-200c 3.219 2.119 0.076 0.886 11.695 
miR-125b 0.616 0.242 0.216 0.285 1.328 
 
Table A2.1: Stepwise logistic regression results incorporating serum PSA, Hepsin, PCA3 and 
Hepsin:PCA3 (n = 66; A) and additional analysis incorporating miRNAs (n = 20; B). All markers 
available for entry in the model; p to enter 0.3; p to remove 0.35; Univariate composite scores 
based on MLR modelling were created as follows: Composite1 = (Serum PSA) – (Hepsin:PCA3 
/ 2), Composite2 = (Serum PSA) + ( miR-200c*5.5) - ( miR-125b*2). 
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Figure A2.1 – Comparison plot of CtAv vs. CtSD plots for qPCR of PSA, Hepsin and PCA3. 
This plot was used to determine a suitable cut off at which sample numbers and quantification 
were optimized, specifically CtAv > 35 and CtSD > 1.5.  
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Figure A2.2 – Flowchart demonstrating loss of samples for consideration in final analysis from 
initial cohort. These exclusions were the result of rigorous consideration based on experimental 
and statistical factors.  
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Figure A2.3 – Predictive probability plots illustrating the relationship between the composite 
scores (Composite1 – A; Composite2 – B; x-axis) and the prediction of the binary variable 
based on the multivariate logistic regression (y-axis). The formulae used to calculate the 
composite scores, based on the regression coefficients, are indicated in the x-axis label for each 
figure. 
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Figure A2.4– Supervised partial least squares multivariate statistical analysis of ejaculate 
samples with different predictive classifiers against benign samples. Analysis of high risk (red 
triangles) versus benign (blue squares) samples (M7; Panels a, b), intermediate risk (yellow 
diamonds) versus benign samples (M8, Panels c, d), negative/low risk (green circles) versus 
benign samples (M9, Panels e, f), and of samples with presence (filled squares) and absence 
(empty squares) of primary Gleason pattern 4 or 5 on radical prostatectomy histology (M10, 
Panels g,h) did not show significant group separation among the invalid models. Scores plots 
(panels a, c, e, g) show sample groupings, and the loadings plots (b, d, f, h) show responsible 
metabolite signals. Metabolite abbreviations: Ac = acetate; Cit = citrate; Cre = creatine; Lac = 
lactate; Gly = glycine; Lip = lipids/lipoproteins; Lys = lysine; PG = propylene glycol; Pyr = 
pyruvate; Spe = spermine; Uri = uridine; UC1 = unknown compound 1.  
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Figure A2.5– Supervised partial least squares multivariate statistical analysis of ejaculate 
samples containing only PBS buffer, with different predictive sample classifiers compared with 
benign samples. Analysis of csCaP versus benign samples (M12; Panels a,b), low versus 
intermediate risk (M13; Panels c,d), intermediate risk versus benign (M14; Panels e,f), high risk 
versus benign (M15; Panels g,h), and all risk groups (M16; Panels i,j) were similar to those seen 
in the main cohort. Scores plots (panels a, c, e, g, i) show sample groupings, and loadings plots 
(b, d, f, h, j) show the responsible metabolite peaks. Blue squares = benign; Green circles = 
negative/low risk; Yellow diamonds = intermediate risk; Red triangles = high risk/cancer present. 
Metabolite abbreviations: Cit = citrate; Cre = creatine; Fru = fructose; Glut = glutamine; Lac = 
lactrate; Lip = lipids/lipoproteins; Lys = lysine; PG = propylene glycol; Pyr = pyruvate; Spe = 
spermine; Uri = uridine.   
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Figure A2.6 – Unsupervised multivariate statistical analysis (principal components analysis) of valid 
supervised models to test validity of the supervised models. Comparison of intermediate (yellow 
diamonds) and low (green circles) risk based on RP histology (panels a, b) and on best available 
histology in samples collected in PBS (panels c, d) are shown. Comparison of low-risk and benign 
(blue squares) samples are shown in panels e, f. Scores plots (panels a, c, e) show sample groupings, 
and loadings plots (b, d, f) show the responsible metabolite peaks. Metabolite abbreviations: Cit = 
citrate; Fru = fructose; Glut = glutamine; Lac = lactate; Leu = leucine; Lip = lipids/lipoproteins; Lys = 
lysine; Pyr = pyruvate; Spe = spermine; UC2 = unknown compound 2. 
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Figure A2.7 – Box plots comparing lactate bucket intensity (following quantile normalisation) 
against risk categories (0 = benign, 1 = low, 2 = intermediate, 3 = high) for all samples (a) and 
samples collected in PBS only (b).  
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Figure A2.8 – Supervised multivariate statistical analysis (partial least squares) of samples 
according to presence or absence of the TMPRSS2:ERG fusion gene (M11). The scores plot (a) 
shows sample grouping, and the loadings plot (b) the responsible metabolite peaks. Empty 
boxes = negative; Filled boxes = positive.  Metabolite abbreviations: Cit = citrate; Glu = 
glutamine; Lac = lactate; Lip = lipids/lipoproteins; Lys = lysine. 
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Model  Type Group 1 Group 2 Scaling na kb Ac R2X d R2Y d Q2 d 
M1 PCA All samples (exclude 2 outliers) Par 149 907 6 0.757 -- 0.624 
M2 PCA M1 after Add-to-Subtract Par 151 914 16 0.885 -- 0.5 
M3 PCA M2 after excluding Cho, PCho, GPCho Par 151 884 15 0.874 -- 0.643 
M4 PLS Benign CaP Par 151 884 2 0.413 0.114 -0.128 
M5 PLS Low (RP) Intermed (RP) Par 11 884 2 0.479 0.868 0.449 
M6 PLS Low (Bx/RP) Intermed (Bx/RP) Par 27 884 2 0.449 0.507 -0.193 
M7 PLS Benign Intermed Par 69 884 2 0.333 0.209 -0.21 
M8 PLS Benign High Par 123 884 2 0.418 0.157 -0.076 
M9 PLS Benign Low Par 63 884 2 0.398 0.339 -0.011 
M10 PLS Primary Gleason ≥4 Primary Gleason <4 Par 61 884 2 0.275 0.263 -0.21 
M11 PLS PBS benign PBS csCaP Par 38 884 2 0.368 0.278 -0.21 
M12 PLS PBS Low (RP) PBS Intermed (RP) Par 6 884 2 0.555 0.907 0.165 
M13 PLS PBS Benign PBS Low Par 12 884 2 0.491 0.867 0.292 
M14 PLS PBS Benign PBS High Par 32 884 2 0.435 0.305 -0.21 
M15 PCA Low (RP) Intermed (RP) Par 11 884 2 0.584 -- 0.296 
M16 PCA PBS Low (RP) PBS Intermed (RP) Par 6 884 2 0.69 -- 0.143 
M17 PCA PBS Benign PBS Low Par 12 884 3 0.724 -- 0.416 
M18 PLS TMPRSS2:ERG positive TMPRSS2:ERG negative Par 73 884 2 0.44 0.175 -0.21 
Table A2.2: Figures of Merits of all MVSA models.  Abbreviations: Bx = biopsy-based histology (RP histology used where available); CaP = prostate 
cancer; Cho = choline; csCaP = clinically significant prostate cancer;GPCho = glycerophosphocholine; Intermed = intermediate risk CaP; Par = Pareto 
scaling; PBS = phosphate buffered saline; PCA = principal components analysis; PCho = phosphocholine; PLS = partial least squares; RP = radical 
prostatectomy only histology; aNumber of samples b Number of X variables c Number of principal/latent components 
d R2X and R2Y are the fraction of the sum of squares for the selected component representing the variance of X and Y variables, and Q2 is the 
predictive ability parameter of the model, which is estimated by cross-validation. Negative Q2 values in the table denote weak statistical models.
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 Log base 10 of 
Mean (± Std. 
Error) (mM) 
Logistic Regression ROC analysis 
P-
value 
Coefficient 
Std. 
Error 
AUC 
Std. 
Error 
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a
n
c
e
r 
s
ta
tu
s
 
alanine 0.1734 (0.0208) 0.7998 0.5211 2.0552 0.555 0.0498 
choline 1.3326 (0.1392) 0.0291 2.0211 0.9263 0.556 0.0495 
citrate 2.9243 (0.2643) 0.1490 -1.2433 0.8616 0.542 0.0490 
creatine 0.1156 (0.0114) 0.8786 -0.1850 1.2113 0.565 0.0492 
fructose 1.0591 (0.1004) 0.9631 -0.0413 0.8938 0.603 0.0510 
glucose 3.2694 (0.2118) 0.9144 -0.0262 0.2439 0.629 0.0487 
glutamine 0.5802 (0.0604) 0.8559 -0.3076 1.6943 0.541 0.0509 
glycerophosphocholine 0.2259 (0.0236) 0.0951 -1.0546 0.6318 0.603 0.0485 
lactate 0.8520 (0.0645) 0.5879 -0.5962 1.1003 0.579 0.0484 
leucine 0.4067 (0.0416) 0.0008 -12.3505 3.6772 0.572 0.0499 
myo-inositol 0.3251 (0.0238) 0.9287 -0.1095 1.2238 0.592 0.0472 
phosphocholine 0.1810 (0.0459) 0.1042 0.6905 0.4250 0.543 0.0499 
serum PSA 8.0867 (0.6075)* 0.0601 1.5605 0.8299 0.593 0.0472 
pyruvate 0.3709 (0.0373) 0.9736 -0.0286 0.8672 0.546 0.0493 
uridine 0.1793 (0.0167) 0.7146 0.1528 0.4180 0.568 0.0495 
valine 0.3206 (0.0392) 0.0013 1.4923 1.6868 0.534 0.0503 
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alanine 0.1734 (0.0208) 0.1629 -2.2913 1.64212 0.592 0.0466 
choline 1.3326 (0.1392) 0.1595 1.1536 0.82009 0.584 0.0467 
citrate 2.9243 (0.2643) 0.1147 -1.4430 0.91479 0.580 0.0466 
creatine 0.1156 (0.0114) 0.8808 -0.1703 1.13641 0.603 0.0465 
fructose 1.0591 (0.1004) 0.5227 -0.5368 0.83976 0.611 0.0470 
glucose 3.2694 (0.2118) 0.3728 0.1970 0.22114 0.584 0.0475 
glutamine 0.5802 (0.0604) 0.4141 1.1168 1.36745 0.572 0.0473 
glycerophosphocholine 0.2259 (0.0236) 0.4243 -0.4494 0.56244 0.599 0.0463 
lactate 0.8520 (0.0645) 0.8719 -0.1501 0.93131 0.582 0.0467 
leucine 0.4067 (0.0416) 0.0025 -9.2502 3.05625 0.597 0.0466 
myo-inositol 0.3251 (0.0238) 0.4242 0.9335 1.16819 0.609 0.0459 
phosphocholine 0.1810 (0.0459) 0.2600 0.4343 0.38565 0.506 0.0477 
serum PSA 8.0867 (0.6075)* 0.0228 1.7942 0.78808 0.617 0.0456 
pyruvate 0.3709 (0.0373) 0.6820 -0.3337 0.81464 0.569 0.0472 
uridine 0.1793 (0.0167) 0.2795 0.4318 0.39939 0.568 0.0473 
valine 0.3206 (0.0392) 0.0030 9.7952 3.29686 0.571 0.0471 
 
Table A2.3: Logistic regression weightings following targeted metabolite quantification using 
Chenomx, similar to that reported by18. Among 151 patients, CaP status (positive 98, negative 
53) and D’Amico risk (high = 82, low = 69) were used as dependent variables (Enter, p enter 
0.05, p exclude >0.1). *units = ng/ml  
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Metabolitesa Moieties: δ 1H in ppm (multiplicity) 
acetate CH3: 1.91 (s) 
alanine βCH3: 1.47(d), αCH: 3.78(q) 
asparagine βyCH2: 2.84(m), βxCH2: 2.94(m), αCH: 3.99(m)  
choline N-CH3: 3.19(s), 2-CH2: 3.51(dd) 1-CH2: 4.06(ddd) 
citrate CHyHx: 2.53(d), 2.66(d)  
creatine γCH3: 3.03(s), αCH2: 3.92(s)  
formate CH: 8.4 (s) 
fructose 3.59(m), 3.70(m), 3.82(m), 3.89(dd), 3.99(m), 4.02(dd), 4.12(m) 
α-glucose 5-CH: 3.41(t), 3-CH: 3.53(dd), 4-CH: 3.71(t), CHyHx: 3.77(m), 3.84(m), 6-CH: 3.83(ddd), 2-CH: 5.23(d) 
β-glucose 3-CH: 3.24(dd), 5-CH: 3.40(t), 6-CH: 3.46(ddd), 4-CH: 3.49(t), CHyHx: 3.73(m), 3.90(dd), 2-CH: 4.64(d) 
glutamate 2.04(m), βCH2: 2.12 (m), βCH2: 2.34(m), αCH: 3.75(m) 
glutamine βCH2: 2.13(m), γCH2: 2.45(m), αCH: 3.77(t) 
glycerophosphocholine N-(CH3)3: 3.22(s), 2-CH2: 3.61(m), glycerol-CH/CH2: 3.90(m), 1-CH2: 4.30(m) 
glycine CH2: 3.55 (s) 
isobutyrate βCH3: 1.06(d), αCH: 2.38(m) 
isoleucine δCH3: 0.93(t), γ2CH3: 1.00(d), γCH2: 1.25 (m), γ1CH2: 1.46(m), βCH: 1.97(m)c, αCH: 3.65(d) 
lactate βCH3: 1.32(d)b, αCH: 4.11(q)b 
leucine δyCH3: 0.95(d), δxCH3: 0.96(d), βCH2: 1.71(m), γCH: 1.71(m), αCH: 3.73(m) 
lipids/lipoproteins 0.84 (b), 0.9(b), 1.45(b), 1.66 (b), 2.02(b) , 2.25(b), 2.35(b) , 3.01(b), 3.10(b) 
lysine γCH2: 1.43(m), δCH2: 1.72(m), βCH2: 1.90(m), εCH2: 3.02(m), αCH: 3.75(m) 
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myo-inositol H5: 3.27(t), H1, H3: 3.53 (dd), H4, H6: 3.62 (t), H2: 4.06(t)  
phenylalanine CH2: 3.12(m), βCH2: 3.28 (dd), αCH: 3.99(dd), δCH: 7.32(d), ξCH: 7.36(m), ε CH: 7.42(m)  
phosphocholine N-CH3: 3.21(s), 2-CH2: 3.59(dd) 1-CH2: 4.16(ddd) 
propylene glycol 1.13 (d), 3.44 (dd), 3.54 (dd), 3.88 (m) 
pyruvate βCH3: 2.36(s) 
serine αCH: 3.84(dd), βCH2: 3.96(m) 
spermine NH2CH2(CH2)26/7-CH2: 1.80(b), NH2CH2(CH2)2CH2NH2/11-CH2: 2.1(m), 3.1(m) 
tyrosine βyCH2: 3.04(dd), βxCH2: 3.19(dd), αCH: 3.93(dd), εCH: 6.89(m), δCH: 7.18(m) 
threonine γCH3:1.32 (d), αCH: 3.58 (d), βCH: 4.25 (m) 
Trimethylamine-N-
oxide (TMAO) 
N(CH3)3: 3.25 (s) 
UC1  1.22 (b) 
UC2 1.23 (s) 
uridine 3.80(dd), 3.91(dd), 4.12(m), 4.22(dd), 4.34(dd), cyclic H5: 5.88(d), ribose H1: 5.90(d), cyclic H6: 7.86(d) 
valine γyCH3: 0.98(d), γxCH3: 1.03(d), βCH: 2.26(m), αCH: 3.61(d) 
 
Table A2.4: Assignments of metabolites identified in 1D NOESY ejaculate spectra. The resonance assignment of metabolites was based on Chenomx 
NMR Suite 8.2 as well as reported by Lynch et al. (1994). Key to multiplicities: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, 
multiplet; b, broad; TMAO, trimethylamine-N-oxide; UC, unknown compound. 
a The assignments of most metabolites are equivalent to Metabolomics Standard Initiative level 2 (putatively annotated compounds, i.e. assignments 
based upon physicochemical properties and/or spectral similarity with public/commercial spectral libraries but no internal standard used) except for UC1 
& UC2 which are Metabolomics Standard Initiative level 4 (unidentified metabolites). 
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Figure A2.9 – Principal components multivariate statistical analysis of samples following sum of 
choline-containing buckets (Cho_all; choline, phosphocholine, glycerophosphocholine) and 
citrate (cit_all), coloured according to CaP presence (red = CaP; blue = benign).  
Lipids/lipoproteins (2.02, 0.90, 0.84) were also influential as seen in Chapter 4.3.  
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Appendix 3 – Chapter 5 
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Figure A3.1 – Comparison plot of average Ct (CtAv) vs. Ct standard deviation (CtSD) plots for 
qPCR of PSA, PCA3 and β2M in PEUW. This plot was used to determine a suitable cutoff at 
which sample numbers and quantification were optimized, specifically CtAv > 35 and CtSD > 
1.5 (indicated by the red dashed line).  
 
227 
 
 
Figure A3.2 – Flowchart demonstrating sample loss during workflow towards final analysis from 
initial cohort. Experimental and statistical factors were rigorously considered, resulting in these 
exclusions. 
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Figure A3.3 – ROC comparison figures for each analysis, comprising PEUW (paired cohort) 
and Ejaculate (paired cohort) for absolute CaP. The p-values in the table (“Pr>chi2”) are for the 
difference between each biomarker area vs the reference (serum PSA). Std. Err. = standard 
error, chi2 = 2, df = degrees of freedom. 
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Figure A3.4 – ROC comparison figures for each analysis, comprising PEUW (paired cohort) 
and Ejaculate (paired cohort) for clinically significant CaP. The p-values in the table (“Pr>chi2”) 
are for the difference between each biomarker area vs the reference (serum PSA). Std. Err. = 
standard error, chi2 = 2, df = degrees of freedom. 
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Appendix 4 – Publication links 
 
Chapter 2.2 - http://espace.library.uq.edu.au/view/UQ:319160  
Chapter 3.2 - http://espace.library.uq.edu.au/view/UQ:408512   
Chapter 4.2 - http://espace.library.uq.edu.au/view/UQ:354600  
Chapter 4.3 - http://www.sciencedirect.com/science/article/pii/S2287888217300387  
Chapter 5.2 - http://espace.library.uq.edu.au/view/UQ:410590  
Chapter 6.2 - http://espace.library.uq.edu.au/view/UQ:408799  
 
 
 
